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Summary Report 
As the 21st century progresses, the U.S. economy is facing a time of great change that severely impacts 
the ability of states to maintain their normal economic modus operandi. In this nation, where states are 
free to chart their own courses through the free market economy, the pace of change is likely to produce 
winners and losers. In winning states, the private sector—with catalytic support from the public sector—is 
making the proactive decisions and investments that will spur future growth; in other states, they are 
hampered by a lack of vision and are failing to act at all. 
Increasingly, it is technology-based economic development, driven by innovation, talent, and investment 
capital, that is shaping the future of successful U.S. state economies.  An area of science and technology 
in which rapid advancements are driving development opportunities is that of bioscience.  Human, 
animal, and plant biosciences are driving business opportunities in a broad range of areas such as drugs 
and pharmaceuticals, research and testing, medical devices, biorenewable chemicals, biomaterials, and 
biofuels.  States, such as Iowa, with core strengths in each of these areas have the opportunity to position 
themselves to build their bioscience-based economies. 
Aware of this potential economic opportunity, the Iowa Department of Economic Development (IDED) 
retained the services of Battelle’s Technology Partnership Practice (TPP) to assess Iowa’s core bioscience 
competencies and to produce a formal strategy and roadmap to drive bioscience growth in the state.  The 
biosciences are complex and diverse; key challenges for any state are to determine which areas of 
bioscience to pursue and how to allocate resources to accomplish their efficient development.  Battelle’s 
analysis provides this guidance. 
This strategic roadmap or pathway outlines a comprehensive approach to bioscience-based economic 
development that requires a long-term commitment from the state, its institutions, and the commercial 
bioscience sector.  Leading technology states have accomplished their growth usually over a decade or 
more, using a sustained commitment to strategies and actions that build critical mass in research and 
commercial biosciences—Iowa will need to do no less. 
Iowa comes to this path with considerable strengths.  It is home to two major bioscience research 
universities (Iowa State University and the University of Iowa), with supplemental expertise provided by 
the University of Northern Iowa.  In addition to its academic strengths, Iowa is home to a diverse range of 
bioscience industry, incorporating agbiosciences, traditional biotechnology, pharmaceuticals, medical 
devices, and various additional sectors.  Also, a recent study for BIO, the national biotechnology trade 
association, compared Iowa’s bioscience industry base with the rest of the nation.  The report pointed to 
Iowa’s national leadership role in bioenergy, biofuels, and related biomass initiatives.  Iowa is one of only 
six states in the nation that have both a large employment base and a significant specialization in 
agricultural feedstock and chemicals, which includes organic and agricultural chemicals and agricultural 
processing and is focused on industrial applications geared toward production agriculture, energy, 
industrial commodities, and specialty health products.1  
A significant portion of these advances in Iowa’s bioscience-based economy can be directly attributed to 
the initiatives of the state’s leaders.  In 2001, Governor Vilsack launched a statewide technology cluster 
                                                 
1 Battelle Technology Partnership Practice and SSTI.  Laboratories of Innovation: State Bioscience Initiatives 2004, 
www.bio.org, June 2004. 
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initiative that identified three areas of focus:  biosciences, advanced manufacturing, and information 
solutions.  Furthering this effort, in 2003 the Iowa Legislature approved the Iowa Values Fund, a 7-year, 
$503 million state investment in the three cluster areas.  The goals of this fund are to help move and grow 
Iowa’s economy, create jobs, and help generate wealth for Iowans.  The Iowa Values Fund is composed 
of four main components: 
• Business development and assistance 
• University research and development 
• Workforce training 
• Quality of life. 
Iowa also has focused significant programmatic investments to develop tax incentives for research and 
development, to help universities turn research into business opportunities, and to create venture capital 
funding to aid business start-ups.  For instance, during the 2002 session, Governor Vilsack and the Iowa 
Legislature enacted an economic stimulus measure designed to encourage private venture capital 
investment in emerging, expanding, and restructuring business enterprises in communities throughout 
Iowa. To facilitate the goals set forth in the Act, Governor Vilsack and the Legislature authorized the 
formation of the Iowa Capital Investment Corporation (ICIC) for the purpose of mobilizing tax credits to 
incentivize private venture capital investments.  ICIC’s primary purpose is to organize and manage the 
Iowa Fund of Funds (Fund of Funds). The Fund of Funds is a private, for-profit limited partnership 
authorized to make investments in private venture capital funds.  To facilitate private investment in the 
Fund of Funds and minimize the need for public appropriations, the Legislature also authorized the 
issuance of contingent tax credits to guarantee, at least partially, investments in the Fund of Funds.  The 
Iowa Capital Investment Board (ICIB) oversees the issuance of the tax credits contingent on certain ICIB-
developed criteria.  
Therefore, while Iowa may not yet have reached a critical mass of bioscience activity that places it among 
the leading states in all areas of the biosciences, as it now has in agricultural feedstock and chemicals, 
Iowa has the potential to build on its existing assets and increase its economic and research bases in other 
segments of the biosciences as well.  To that end, this roadmap identifies specific strategies and actions 
that will serve, if acted upon, to help realize a bioscience-driven economy through leveraging existing 
organizations and programs and developing new initiatives.  In other words, this strategy aims to provide 
guidance for building a strong Iowa economy for the future. 
IOWA’S BIOSCIENCE VISION 
With strong public and private leadership and long-term commitment on the part of Iowa’s research 
institutions, business community, nonprofit community, and state and local governments, it is reasonable 
to expect that Iowa can achieve the following vision by 2014: 
Iowa is a leading Midwestern state with a comprehensive set of strengths in the plant, animal, 
and human sciences.  Iowa is a leader in the application of biorenewable resources to create 
value-added products and has become a significant player in the production of advanced food 
products, drugs, biologics, and related biomedical technologies.  The Iowa biosciences are 
characterized by strong public-private and industry-university relationships, resulting in a strong 
base of bioscience companies operating in Iowa in the development and production of plant, 
animal and human bioscience products.   
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MISSION 
To achieve this vision, Iowa must make the following efforts to approach its future in the biosciences: 
• Invest in the further development of key R&D platforms at Iowa’s regent universities2, 
including facilities, equipment, scientific resources, and the attraction and retention of Eminent 
Scholars and their research teams to generate commercializable innovations from these investments. 
• Put in place incentives, programs, and organizations that will facilitate and encourage the 
translation of bioscience innovation into products, processes, and other mechanisms of 
economic value and wealth creation for Iowa. 
• Secure capital funding sources that will provide the financial resources necessary to move 
innovative technology from the research bench to commercialization and into full-fledged 
entrepreneurial businesses growing, expanding, and succeeding from their base in Iowa. 
• Apply itself to the creation of an educational, economic, and social environment conducive to 
the creation, attraction, and retention of human talent at all key bioscience business skill levels—
from R&D scientists to experienced management and production personnel. 
Iowa has the potential to develop and sustain leadership in key focused bioscience platforms, but realizing 
that potential will require Iowa to adopt the best practices proven as drivers of technology-based 
economic development in other states, including 
• Engaged universities taking an active leadership role; 
• Intensive networking across sectors and with industry; 
• Available capital covering all stages of the business cycle; 
• Discretionary federal or other R&D funding support; 
• Workforce and talent pool on which to build and sustain efforts; 
• Access to specialized facilities and equipment; 
• Stable and supportive business, tax, regulatory, and incentive policies; and 
• Patience and a long-term perspective.  
METHODOLOGY 
To facilitate an in-depth understanding of core bioscience opportunities and to develop a strategy for 
building the Iowa bioscience economy, the IDED engaged TPP to develop a state bioscience strategy and 
pathway in a two-phase effort: 
• Economic and core competency analyses of the biosciences in Iowa.  This Phase I work was 
released March 2004 in the report entitled, The State of Iowa Biosciences Path for Development: 
Economic and Core Competency Analyses.  In this report, Battelle examined the current quantitative 
position of Iowa in commercial bioscience sectors and in academic bioscience R&D and produced a 
formal assessment of core competencies and fundamental strength platforms upon which Iowa’s 
bioscience economy may be built. 
                                                 
2 Iowa’s regent universities include Iowa State University, The University of Iowa, and the University of Northern 
Iowa. 
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• A strategy and actions roadmap or pathway.  This Phase II report, embodied herein, provides a 
summary of the Phase I findings and completes the Iowa Bioscience Pathway by providing specific 
guidance in bioscience-based economic development. 
To complete both Phases I and II assignments, Battelle used both quantitative and qualitative techniques, 
including more than 500 face-to-face interviews with representatives of industry, academe, government, 
and other stakeholder organizations in Iowa.3  Meeting the key goals for the project required that Battelle 
• Conduct an economic analysis of Iowa’s existing bioscience industry, identifying trends, current 
strengths, emerging industries, and emerging clusters within the biosciences; 
• Assess Iowa’s position in bioscience research and provide a detailed understanding of the bioscience 
core competencies that form platforms for future bioscience development; 
• Identify key barriers and gaps in private and public investments, policies, programs, and activities that 
negatively impact Iowa’s ability to realize its development potential from the biosciences; 
• Outline a series of specific strategies and actions designed to fill in the gaps and maximize the 
economic advantage of Iowa’s core bioscience strengths; and 
• Provide an implementation plan, showing action priorities, estimated resource requirements, and an 
organizational structure for moving the roadmap forward. 
IOWA’S BIOSCIENCE BASE 
Iowa’s Bioscience Industry Sector 
This analysis addressed the diversity of the bioscience industry by dividing it into three sectors: 
agricultural, medical, and plant-life sciences. The agricultural sector consists of those industrial 
subsectors involved in developing, supporting, and manufacturing new farming and food production 
technologies for advancing health and nutrition. The medical sector consists of those industrial subsectors 
involved in manufacturing and developing clinical techniques aimed at and directed toward advancing 
human health care. The plant-life sciences sector consists of those industrial subsectors involved in 
research, testing, developing, and manufacturing clinical and agronomic techniques and products for 
improving the functions of living organisms.  
Eight major bioscience subsectors were included in the economic analysis (Figure SR-1). These 
subsectors encompass a wide variety of industrial activity upon which Iowa is well situated to further 
build and strengthen its overall bioscience base.  
 
                                                 
3 Many individuals were interviewed for both Phase I and Phase II of this analysis. 
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Figure SR-1: Broadly Defined Iowa “Bioscience” Industry 
 
Iowa’s Bioscience Cluster 
Recent employment trends since 2000 indicate a bioscience growth rate that is above the national 
average. In Iowa, the bioscience industry experienced above-average employment growth between 2000 
and 2002, growing by 5.3 percent and gaining 4,179 jobs. In 2002, the Iowa bioscience industry 
employed 82,849 individuals across 1,856 establishments. Even more promising is that this growth rate 
was above the national average. The bioscience industry across the United States grew at a rate of 
3.7 percent between 2000 and 2002.  
The bioscience industry also represents a sizable portion of Iowa’s economy. Bioscience employment 
concentrations over the same time period consistently accounted for a larger share of state private-sector 
employment than at the national level. In 2002, bioscience employment in Iowa accounted for 7.0 percent 
of total state private-sector employment. Nationally, the bioscience industry accounted for 5.6 percent of 
total private-sector employment. 
The current level of Iowa’s bioscience employment concentration is considered to be regionally 
specialized. The fact that bioscience employment in Iowa accounts for a larger share of private sector 
employment than the industry does at the national level results in an above-average location quotient for 
Iowa. Overall, the state possesses a regional specialization in the bioscience industry that is 24 percent 
more concentrated than the nation’s. 
Iowa’s Bioscience Cluster Subsectors 
Iowa’s bioscience subsectors can be categorized into four classes— stars, emerging potential, transitional, 
and divergent—based upon their growth relative to U.S. growth and their location quotients from 1998 to 
2002 (Figure SR-2).  Subsectors classified as stars are those that possess significant regional specializa-
tion and growth rates exceeding national levels. Emerging potential subsectors are those that are growing 
more rapidly than the industry at the national level and that present the opportunity to develop a 
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concentration if rapid growth continues. Subsectors classified as transitional or divergent are not keeping 
pace with national growth trends. Though the 4-year trend is not irreversible, these subsectors demon-
strate current characteristics that may threaten the long-term viability of the industry base in Iowa. 
 
Figure SR-2: Iowa Bioscience Subsector Performance, 1998–2002 
 
The bioscience industry is a strong driver for the U.S. and Iowa economies, diversifying the economic 
base; offering good, well-paying jobs; and contributing to overall economic productivity.  
Summary and Conclusions 
Key conclusions from the economic analysis of Iowa’s current economic base include the following: 
1. The bioscience industry is a significant contributor to the Iowa economy. In 2002, bioscience 
employment accounted for 7.0 percent of total employment in Iowa, exceeding the national average of 
5.6 percent of total private-sector employment.  
2. Iowa’s bioscience industry is diverse, with subsectors that are growing rapidly.  Iowa has a significant 
concentration in the organic and agricultural chemicals subsector that is growing rapidly.  The drugs and 
pharmaceuticals and medical equipment and devices subsectors also are growing rapidly.  Finally, Iowa 
has a mature base in the biosciences represented by the number of subsectors in which Iowa is considered 
to be specialized, including agricultural equipment and machinery, agricultural processing, and 
agricultural services.  
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3. The bioscience industry is a tremendous source of well-paying jobs. Compared with other major Iowa 
industries, the bioscience industry is one of the highest paying in the state. The average wage of a 
bioscience worker in 2002 exceeded the statewide average annual wage by more than $12,700 and 
surpassed wages in such sectors as manufacturing; information; construction; and finance, insurance, and 
real estate.  Because the bioscience industry is diversified, comprises a substantial share of state economic 
activity, and is a source of high-paying jobs, it is reasonable to support initiatives that focus on it.   
IOWA’S BIOSCIENCE R&D BASE 
Without a strong bioscience research foundation, it is difficult for any state or region to initiate or sustain 
major industry development related to the biosciences.  Universities are the primary leaders in basic and 
applied bioscience research.  Furthermore, research centers are not only essential to the basic research 
discoveries that generate product leads for bioscience companies, but also contribute to an environment in 
which these bioscience companies can flourish.  University research centers can be a key asset for the 
bioscience industry in bridging the gap between basic and applied research.   
In identifying core research focus areas in the biosciences, the objective is to identify those fields with a 
critical mass of ongoing activity and measures of excellence.  Core research focus areas are identified 
using both quantitative and qualitative methods, which for this study included extensive field interviews 
with more than 360 key administrators, scientists, and researchers across Iowa. 
With $439.8 million in research funds, Iowa ranks 24th in total university R&D funding (according to the 
National Science Foundation)—notably exceeding its population rank of 30th.  Within the academic R&D 
arena, the state is performing particularly well in the biosciences, with 66 percent of all academic research 
funds falling under this definition. This level of performance places Iowa 21st in the nation. Also, Iowa 
ranks better than its population base in the three major macro-categories of bioscience R&D, ranking 19th 
in medical sciences, 20th in agricultural sciences, and 22nd in biological sciences. However, given Iowa’s 
agricultural base, its ranking in agricultural sciences is a matter of some concern. 
OPPORTUNITIES FOR BIOSCIENCE DEVELOPMENT IN IOWA 
Core Platforms for Iowa’s Bioscience Development 
From analysis of peer-reviewed grant activity, publications activity, and interviews with university deans, 
faculty, and researchers, Battelle has identified six short- or near-term “platforms” that hold potential for 
the development of the biosciences in Iowa. These include the following:  
¾ BioEconomy Platform—Using plant and animal biomass and waste streams to generate chemicals, 
energy, fuels, and materials for industrial and commercial applications.  
¾ Integrated Drug Discovery, Development, Piloting, and Production Platform—Leveraging 
Iowa’s strengths in basic biomedical research, drug development, and Good Manufacturing 
Practice(s) production into an integrated pipeline of new drugs and therapeutics. 
¾ Advanced Food and Feed Platform—Using Iowa’s established strengths in plant and animal 
sciences, production agriculture, food science, nutrition, and processing technology to develop and 
produce functional foods and nutraceuticals. 
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¾ Integrated Post-Genomic Medicine Platform—Using Iowa’s genomics expertise and specific 
disease/disorder skills, in conjunction with epidemiologic data and Iowa’s stable population, to 
produce rapid advances in post-genomic medicine and associated discoveries. 
¾ Animal Systems Platform—Using Iowa’s bioscience and genomics expertise to establish a 
leadership position in the modeling of animal systems and in the development of technologies and 
applications for genes, genetic markers, transgenic animals, chimeric animals, and cloning. 
¾ Integrated Biosecurity Platform—Deploying the strengths of Iowa’s institutions in human, animal, 
and plant disease prevention, protection, and treatment to establish an integrated approach to securing 
the environment, food production systems, and human health and safety. 
These six areas represent broad platforms upon which a significant R&D base, business base, and 
bioscience economy may be built in Iowa in the near to short term. They each specifically draw upon 
Iowa’s institutional expertise in multiple fields, because multidisciplinary research increasingly is gaining 
importance in driving funding, new study areas, technologies, discoveries, and commercializable 
innovations. In each case, the analysis shows that these platforms match well with large and rapidly 
growing projected domestic and international markets. In most cases, the markets are characterized in 
terms of having expanding multibillion-dollar existing and emerging potential. 
In addition to the broad technology platforms, biomedical imaging is a niche platform offering an 
opportunity for development in the near term. Four emerging, longer-term opportunity areas representing 
potential for additional sector development include  
¾ Host-Parasite Biology and Systems; 
¾ Instrumentation, Devices, and Sensors; 
¾ Formation of a Cardiovascular Research Institute; and 
¾ Formation of a Free Radical Research Institute. 
It should be noted that the list of near-term competencies will need to be nurtured and developed over the 
long term as well.  In addition, other cross-cutting, enabling technologies (such as bioinformatics) will 
affect the potential for these platforms, and investments will need to be considered. 
IOWA’S COMPETITIVE POSITION IN THE BIOSCIENCES 
Further investigation of Iowa’s position in the biosciences and bioscience-based economic development 
was accomplished through the use of a SWOT (strengths, weaknesses, opportunities, and threats) 
analysis.  This analysis was accomplished through one-on-one interviews, small group discussions, and 
focus groups involving leaders throughout the state.   
STRATEGIES AND ACTIONS 
Gap Analysis 
Conclusions from the SWOT analysis drove the identification of key issues that need to be addressed for 
Iowa to achieve its mission and accomplish its bioscience economic development vision. These issues 
represent gaps in creating an integrated, wealth-generating continuum that begins with R&D and 
culminates in full-scale and ongoing bioscience business operations.  Figure SR-3 summarizes the key 
gaps that must be addressed to realize Iowa’s bioscience development potential. 
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 Figure SR-3:  Iowa’s Key Gaps Along the Biosciences Development Continuum 
 
Strategies and Actions 
For biosciences to realize their potential as a major economic engine for Iowa, the state must 
simultaneously address both the strengthening of research drivers and the efficient development of 
commercial enterprise from research innovations.  Four strategies and 20 associated actions have been 
identified to further develop Iowa’s bioscience research base and build a critical mass of bioscience 
companies. 
• Strategy One:  Build Iowa’s bioscience research capacity around selected technology platforms 
focusing on investments in talent, facilities, and equipment. 
• Strategy Two:  Encourage and facilitate the commercialization of bioscience R&D to enhance 
opportunities for start-up, emerging, and existing Iowa firms. 
• Strategy Three:  Foster a business environment that supports, sustains, and encourages the growth 
and sustainability of bioscience firms in Iowa. 
• Strategy Four:  Invest in and develop Iowa’s bioscience talent pool. 
These strategies and associated actions are summarized in Table SR-1.  Implementation of these strategies 
and actions is anticipated as a 5-year period.  Immediate priorities should be undertaken in the next year 
to 18 months, short-term priorities should be undertaken in 18 months to 3 years, and mid-term priorities 
in 3 to 5 years.   
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government
• Need to increase
mentoring, support
and assistance for
entrepreneurs
• Need to increase
availability of skilled
managerial staff for
start-up enterprises
• Need to provide
access to seed funding
and early stage angel/
venture financing
rounds
• Need to increase
incubator and
accelerator space
proximate to main
university campuses
• Need to increase
networking and
advocacy capacity of
bioscience support
associations
• Need to increase the
visibility and voice
of the sector in Iowa
• Need to anchor
growing bioscience
businesses in Iowa
with access to
expansion capital and
targeted incentives and
favorable policies
• Need to build critical
mass of companies in
core platform-based
sectors
• Need to enhance
the connectivity of
post-secondary
education and workforce
development providers
to bioscience industry
• Need to facilitate key
supply-chain linkages
and development of
support sectors
Ke
y 
G
ap
s
Ke
y 
G
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Table SR-1:  Iowa Bioscience Pathway Strategies and Actions 
Strategy Actions Priority 
Strategy One: 
Build Iowa’s 
bioscience 
research capacity 
around selected 
technology 
platforms 
focusing on 
investments in 
talent, facilities, 
and equipment. 
 Undertake key recruitment, capacity building, 
and required investments to ensure rapid 
scientific progress in the core bioscience 
platforms.  
 Create an Endowed Chairs Program to attract 
world-class, entrepreneurial talent in the core 
bioscience platforms. 
 Form a Strategic Technology Platform 
Infrastructure Fund to strengthen and accelerate 
the scientific and commercialization work of the core 
bioscience platforms.  
 Engage Iowa’s Congressional Delegation in 
discussions pertaining to federal funding and 
specific project support. 
 Institute an industry-university matching grant 
program dedicated to the identified bioscience 
technology platforms to encourage relationships 
between academic researchers and industry. 
Short-term 
 
 
Short-term 
 
 
Short-term 
 
 
Immediate 
 
 
Immediate 
Strategy Two: 
Encourage and 
facilitate the 
commercialization 
of bioscience 
R&D to enhance 
opportunities for 
start-up, 
emerging, and 
existing Iowa 
firms. 
 
 Create and Fund an Economic Development 
Director position at the Iowa Board of Regents to 
provide catalytic support for regent university 
economic development initiatives.  
 Develop and implement policies and procedures that 
actively encourage faculty entrepreneurship and 
commercialization activities at the regent 
universities. 
 Increase funding to the regent universities to 
allow for sufficient staffing and resources for 
commercialization activities. 
 Establish and fund a University Entrepreneurs 
Center at each university. 
 Form a statewide commercialization 
intermediary for supporting, building, and 
sustaining development of new bioscience business 
enterprises in Iowa.   
Immediate 
 
 
Immediate 
 
 
Immediate 
 
 
Short-term 
 
Immediate 
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Table SR-1:  Iowa Bioscience Pathway Strategies and Actions (continued) 
Strategy Actions Priority 
Strategy Three:    
Foster a business 
environment that 
supports, 
sustains, and 
encourages the 
growth and 
sustainability of 
bioscience firms 
in Iowa. 
 
 Form the Iowa Bioscience Alliance to facilitate 
communications, foster joint approaches to issues, 
and develop a critical mass of support to stimulate 
actions required to realize Iowa’s bioscience vision. 
 Establish a State Bioscience Advocate position, 
reporting to the Director of IDED, to drive the 
implementation of this strategy. 
 Implement Iowa’s bioscience image and brand 
through aggressive marketing, public relations, and 
signature events. 
 Review and make necessary changes to state 
incentives (including the Iowa Values Fund), tax 
policies, and legal code to be responsive to the 
needs of growing bioscience firms. 
 Conduct an economic impact study to measure 
the projected returns to the state and its regions that 
are estimated to result from proposed bioscience 
investments.  The study should pay special attention 
to geographic equity and the diffusion of innovation 
benefits throughout the state. 
 Develop a training program for state and local 
economic development professionals that would 
include information on university bioscience 
technology platforms and technical capabilities, the 
specialized needs of bioscience companies, and 
programs and incentives that can be used to assist 
new bioscience ventures and expanding and/or 
relocating firms. 
Short-term 
 
 
Short-term 
 
 
Immediate 
 
 
Short-term 
 
 
 
Short-term 
 
 
 
 
Mid-term 
 
 
Strategy Four:  
Invest in and 
develop Iowa’s 
bioscience talent 
pool.  
 Improve K-12 scientific education by focusing on 
stimulating interest among Iowa’s children in 
science, thereby preparing them for careers in 
Iowa’s growing bioscience sectors. 
 Develop a bioscience vocational career education 
program and ensure seamless delivery between 
secondary and community college programs that 
serve Iowa’s growing concentration of bioscience 
employers. 
 Streamline bioscience articulation agreements 
within and between community colleges and Iowa’s 
regent universities to allow students to transfer 
credits between academic institutions.   
 Leverage alumni associations and the state’s 
Human Resources Recruitment Consortium to 
attract to Iowa bioscience professionals, including 
experienced bioscience managers.   
Mid-term 
 
 
Mid-term 
 
 
 
Short-term 
 
 
 
Immediate 
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IMPLEMENTATION PLAN 
Obviously, the biosciences already are an important part of the Iowa economy and show great potential 
for expanding their positive economic impacts for the state.  However, if Iowa is to achieve its vision for 
the biosciences, it must aggressively implement the strategies and actions outlined in this report.  Because 
the state does not have unlimited resources, it is, of course, important to set priorities.  The following 
section summarizes the critical actions that must be taken to develop Iowa’s bioscience sector. 
Critical Actions 
To realize the full bioscience economic potential that this roadmap lays out, Iowa must successfully 
implement certain critical actions.  Specifically, the ultimate success of the strategy hinges on the forward 
movement of six activities, in essence Iowa’s bioscience critical path.  In other words, it is these six 
critical actions that are most significant to, and the underlying foundation for, the eventual success of this 
strategy.  Therefore, when initial resource allocations are being determined, efforts must be made to 
ensure that the following critical actions receive funding priority:   
• Form a Strategic Technology Platform Infrastructure Fund to reinforce the core bioscience 
platforms by supporting faculty recruitment, entrepreneurial endowed chairs, and other key actions.  
The fund will be directed through academic consortia set up to develop the six bioscience platforms.  
Financed perhaps by bonds or other sources, the fund also would provide infrastructure and 
equipment funding to reinforce the platforms. 
• Develop and implement policies and procedures at the regent universities to ensure the highest 
level of encouragement and support for private-sector partnering, commercialization, and 
entrepreneurship.  
• Form a statewide commercialization intermediary for supporting, building, and sustaining 
development of new bioscience business enterprises in Iowa.  This organization will proactively 
assist Iowa’s bioscience entrepreneurs, and provide business development services to companies 
formed from university-based technology transfer and commercialization efforts and from other 
sources of intellectual capital. 
• Form the Iowa Bioscience Alliance to serve as a guiding force in engaging industry in the strategy 
implementation and stewardship.  Connect the Alliance to the proposed academic consortia to be 
formed around the bioscience platforms to ensure industry-university collaboration of platform R&D 
and commercialization of innovations. 
• Institute an industry-university matching grant program dedicated to the identified bioscience 
technology platforms to boost bioscience R&D collaborations between academia and industry in 
Iowa. 
• Increase funding to the regent universities to allow for sufficient staffing and resources for 
commercialization activities. 
The above actions will ensure the following: that the strengths of the current core bioscience platforms are 
leveraged and further built; that industry and academe work together on joint R&D initiatives to develop 
commercial innovations from each platform; that funding and support are available to develop bioscience 
entrepreneurs and their business ventures; and that the regent universities are optimally leveraged for the 
bioscience-based economic development of the state. 
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Immediate Priorities  
Immediate work plan priorities are those steps that should be undertaken in the first 12 months of 
strategy implementation, regardless of how critical they are to the overall strategy.  Several 
immediate priorities can be implemented right away, while others will need to be planned and allocated 
funds before they can become fully operational.  The following actions should be undertaken in the first 
year: 
• Create and fund an Economic Development Director position on the Iowa Board of Regents to 
provide catalytic support for regent university economic development initiatives. 
• Develop and implement policies and procedures that actively encourage faculty entrepreneurship and 
commercialization activities at the regent universities. 
• Engage Iowa’s Congressional Delegation in discussions pertaining to federal funding and specific 
project support. 
• Institute an industry-university matching grant program dedicated to the identified bioscience 
technology platforms to encourage relationships between academic researchers and industry.    
• Increase funding to the regent universities to allow for sufficient staffing and resources for 
commercialization activities. 
• Form a statewide commercialization intermediary for supporting, building, and sustaining 
development of new bioscience business enterprises in Iowa.  The commercialization organization 
will work to address technology, capital, and talent issues. 
• Implement Iowa’s bioscience image and brand through aggressive marketing, public relations, and 
signature events. 
• Leverage alumni associations and the state’s Human Resources Recruitment Consortium to attract to 
Iowa bioscience professionals.  An initial emphasis should be placed on attracting individuals with 
experience in bioscience management. 
Resource Requirements 
For each action, Table SR-2 indicates the priority of the action, breaks down state funding needs into 
two 5-year phases, and indicates the anticipated external leverage.  In addition to the Iowa Bioscience 
Pathway financial plan detailed in Table SR-2, the proposed revenue sources to be allocated from the 
state for this financial plan are broken down in Table SR-3.  Overall, total costs to the state government in 
two 5-year phases are $301.6 million, of which $169.8 million is bond financed and $131.8 million is 
financed through general fund appropriations.  State general fund and bond financing investments over a 
10-year period are estimated to generate external leverage of more than $1.5 billion, or $5 of outside 
funds for every $1 invested by the state. Bond financing support is focused on further building Iowa’s 
strengths in its technology platforms and the associated investments found in several actions primarily 
under Strategy One.  Phase I totals $144.2 million, including bond financing of $96.8 million for capacity 
building of infrastructure, recruitment, and matching support; and $47.4 million in general fund 
appropriations.  In Phase II (years 6 to 10), state funds of $157.3 million would be required, including 
$73 million in bond financing for further capacity building and $84.3 million in general fund 
appropriations.   
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Table SR-2:  Iowa Bioscience Pathway Financial Plan 
Action Priority 
Annual State Funding 
by Year: 
Years 1-5 
Annual State Funding 
by Year: 
Years 6-10 
Estimated One-
Time Costs 
Leverage 
Ratio of 
Private and 
Federal 
Funds 
Capacity 
building in 
the key 
platform 
areas  
Short-term 
 
Consortia:  $1.2 M 
increasing to $2.0 M by 
year 5  
 
Matching grants:  $1.7 M 
increasing to $3.8 M— 
this item covered under 
Infrastructure Fund 
Consortia:  $2 M per  
year rising to $5 M by 
year 10  
 
 
Matching grants:  $3.8 M 
staying constant 
years 6-10 
 
$10.188 M 
annually for first 
5 years for platform 
investments, or 
$50.94 M from the 
bond-financed 
Strategic 
Investment Fund 
(see below) 
9:1 federal 
funding 
leverage 
based on 
other state 
performance 
Entrepre-
neurial 
Endowed 
Chairs 
program  
Short-term 
 
$2 M per year for 3 years 
and $1M in year 4 
Second round of 
additional chairs:  $3 M 
for 3 years and $1.5 M in 
year 4 
 2:1 (match to 
state funds) 
Strategic 
Technology 
Platform 
Infrastructure 
Fund 
Short-term 
 
This Fund supports above 
actions in capacity 
building of platforms and 
endowed chairs as well as 
matching grants item 
below and one-time costs 
of these and prototype 
fund 
 $169.44 M 
capitalization via 
bonds with 
$96.76 M in 
Phase I 5-year 
period and $73 M 
in Phase II 5-year 
period 
 
Engage 
Iowa’s 
Congres-
sional 
Delegation 
for federal 
funding 
Immediate 
 
Existing resources    
Industry- 
university 
matching 
grant 
program  
Immediate Initial year funding at  
$1.5 M rising to $3.0 M  
by year 5  
Years 6 through 10 rise 
from $3.0 M  to $5.0 M 
 3:1 (match to 
state funds) 
Economic 
Development 
Director 
position on 
the Iowa 
Board of 
Regents  
Immediate 
 
$150,000 per year $175,000 per year   
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Table SR-2:  Iowa Bioscience Pathway Financial Plan (continued) 
Action Priority 
Annual State 
Funding by Year: 
Years 1-5 
Annual State 
Funding by Year: 
Years 6-10 
Estimated 
One-Time 
Costs 
Leverage 
Ratio of 
Private and 
Federal 
Funds 
Policies and 
procedures that 
actively 
encourage faculty 
entrepreneurship 
and 
commercialization 
Immediate 
 
$200,000 per year $240,000 per year   
Funding to the 
regent universities 
for 
commercialization 
activities/tech 
transfer 
Immediate 
 
$2.9 M in year 1 
increasing to $9.55 M 
in year 5 
Mining:  start at 
$300,000 and 
increase to $600,000 
by year 5  
TT:  start at $1.5 M 
and increase to 
$5.8 M by year 5  
Business develop-
ment : start at 
$300,000 and 
increase to $750,000 
by year 5  
Industry liaison:  start 
at $300,000 and 
increase to $1.2 M by 
year 5  
Marketing and 
communications:  start 
at $500,000 and 
increase to $1.2 M by 
year 5  
Increase by 10% per 
year or: 
Year 6:  $10.5 M 
Year 7: $11.55 M 
Year 8:  $12.71 M 
Year 9:  $13.98 M 
Year 10:  $15.38 M 
$1 M to be 
covered as 
infrastructure 
funds from 
Strategic Infra-
structure Fund 
6:1 leveraged 
return in 
increased 
sponsored 
research, 
licensing 
revenue, and 
equity in 
start-ups 
Establish a 
University 
Entrepreneurs 
Center 
Short-term $450,000 per year Years 6 and beyond 
increase to $600,000 
per year 
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Table SR-2:  Iowa Bioscience Pathway Financial Plan (continued) 
Action Priority 
Annual State 
Funding by Year: 
Years 1-5 
Annual State 
Funding by Year: 
Years 6-10 
Estimated 
One-Time 
Costs 
Leverage 
Ratio of 
Private and 
Federal 
Funds 
Form a statewide 
commercialization 
intermediary  
Immediate 
 
$1 M year 1 
$1.5 M year 2 
$2 M years 3, 4, and 5
Years 6 and beyond 
increase to $2.2 M per 
year 
$3 M to $5 M 
Prototype 
Development 
Fund over first 
5 years and 
similar amount 
for years 6-10 
financed by 
Infrastructure 
Fund 
$25 M to $50 M 
initial 
capitalization for 
BioSeed Fund 
as part of Fund 
of Funds 
(nondirect state) 
and privately 
financed 
thereafter 
Leveraged 6:1 
return in private 
funds, sales, 
and other 
income 
Form the Iowa 
Bioscience 
Alliance 
Short-term 
 
$400,000  in year 1 
decreasing in year 5 
to $100,000  
Ongoing support in 
years 6 and beyond of 
$100,000 per year 
 Leverage 3:1 
private, 
university, and 
other funds 
Establish a State 
Bioscience 
Advocate position 
Short-term 
 
$125,000 in year 1 
increasing to 
$175,000 in year 5  
$200,000 in year 6 
increasing to 
$300,000 in year 10  
  
Implement Iowa’s 
bioscience image 
and brand through 
aggressive 
marketing 
Immediate 
 
As currently budgeted 
IDED 
   
Review and make 
necessary 
changes to state 
incentives, tax 
policies, and legal 
code  
Short-term 
 
  $100,000 for 
study and 
review in year 2 
 
Conduct an 
economic impact 
study for 
bioscience 
strategy 
Short-term 
 
  $100,000 for 
study and 
review in year 1 
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Table SR-2:  Iowa Bioscience Pathway Financial Plan (continued) 
Action Priority 
Annual State 
Funding by Year: 
Years 1-5 
Annual State 
Funding by Year: 
Years 6-10 
Estimated 
One-Time 
Costs 
Leverage 
Ratio of 
Private and 
Federal 
Funds 
Develop a 
biosciences-
development 
training program 
for state and local 
economic 
development 
professionals  
Mid-term 
 
$470,000 for UNI’s 
IDM operations 
funded (currently they 
are at $280,000) 
beginning in years 2 
through 5  
Maintain funding at 
$470,000 per year in 
years 6 through 10 
  
Improve K-12 
scientific 
education 
Mid-term 
 
To be determined    
Provide 
articulation 
agreements 
between K-12 and 
community 
colleges in 
bioscience 
education 
Mid-term 
 
  $500,000 in 
year 3 
 
Streamline 
bioscience 
articulation 
agreements within 
and between 
community 
colleges and 
universities 
Short-term 
 
Existing resources    
Leverage alumni 
associations and 
the state’s Human 
Resources 
Recruitment 
Consortium 
Immediate Existing resources    
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Table SR-3:  Financial Plan by Year and Proposed Sources of Revenue  
(state funds only—dollars in millions) 
Year Total State Investments Bond Financed General Fund Support 
1  21.913  16.588  5.325 
2  30.193  22.633   7.530 
3  29.878  19.738  10.140 
4  30.158  18.813  11.345 
5  32.083  18.988  13.095 
Subtotal Year 1-5   $144.225   $96.76  $47.435 
6  26.685  12.200  14.485 
7     33.930  18.350   15.580 
8  31.265   14.500   16.765 
9     32.195   14.150   18.045 
10     33.265   13.800   19.465 
Subtotal Year 6-10    $157.340  $73.000   $84.340 
Grand Total  $301.565  $169.76  $131.775 
 
Organization and Structure 
State science and technology initiatives are most effective when they are executed on a bipartisan basis, 
with strong executive and legislative branch support, involvement, and cooperation.  States such as 
Pennsylvania, New York, Maine, Maryland, and North Carolina have been successful with their science 
and technology investments because their efforts have been broad based, they have mobilized private 
sector champions behind them, and their initiatives have become institutionalized into both economic 
development and higher education at state and regional levels. 
The following deficiencies indicate that Iowa is less than optimally organized to develop its bioscience-
based economy: 
• No Science and Technology Office, Science and Technology Advisor, or Bioscience Advocate at the 
state government level.  As a result, policies are more likely to be enacted in an ad hoc fashion, rather 
than following a formal strategic plan and pathway. 
• No economic development function coordinated at the level of the Iowa Board of Regents.  Thus, the 
individual universities hold sole responsibility for setting strategy and actions. 
• Declining funds to support regent university economic development, technology transfer, and 
commercialization activities.  With budget cuts of more than 60 percent in the past 3 years, the regent 
universities have seen their organizational capacity in these key functions drastically reduced. 
• Small and comparatively under-resourced bioscience-related industry organizations (such as the Iowa 
Biotechnology Association and BIOWA). Therefore, the services and bioscience development 
initiatives they can undertake are limited. 
• No clear organizational and assistance structures for would-be bioscience entrepreneurs to follow in 
terms of accessing business development assistance, prototype development and pre-seed/seed 
funding, management talent, expansion capital, etc. 
To help solve these organizational deficiencies, the Iowa Bioscience Pathway proposes a set of strategies 
and actions that involve multiple public and private organizations and entities.  These strategies and 
actions have been designed to build on the base of organizational capabilities that currently exist in Iowa 
and to provide resources and actions that create a structure for filling critical gaps. 
 Iowa’s Bioscience Pathway for Development 
 
 xxvii 
Directing and administrating the implementation of the Iowa Bioscience Pathway are critically important 
functions.  Given the important role that industry, academe, and government each must play, it is 
imperative that an organization be structured that will engage each of these groups in the process.  The 
logical convening entity would be the Iowa Bioscience Alliance (as shown in Figure SR-4).  The 
Alliance, staffed and financially supported by the Iowa Department of Economic Development, would be 
a formal collaboration between industry and academe.  Industry and academic consortia, established for 
each bioscience platform, would be the core constituent components of the Iowa Bioscience Alliance, 
working to advance applied bioscience R&D in the state.  In addition, it is proposed that the 
commercialization intermediary organization directly report to the Alliance. 
 
Figure SR-4:  Basic Organizing Structure of Iowa Bioscience Development  
 
Measures of Success and Accountability 
The following measures and performance goals, to be monitored on an ongoing basis by the Iowa 
Bioscience Alliance, should be used to determine the successful accomplishment of performance 
objectives: 
• There will be more than 130 new bioscience business start-ups in Iowa by 2014. 
• Iowa’s location quotient in all the biosciences will exceed 1.4 to 1.5 by 2008, compared with 1.24 in 
2002.  
• Iowa will increase its university R&D funding (primarily from federal sources) for bioscience-related 
research from $291 million in 2001 to $700 million by 2010 and more than $900 million by 2014. 
• The state will leverage at least $5 in federal and other dollars for every $1 of state support. 
• There will be substantial implementation progress on the actions outlined in this pathway – at least 
70 percent will have substantial action after 3 years and 90 percent within 5 years.  
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10-Year Economic Impact 
The state’s proposed investment of $302 million in bond financing and general fund support over the next 
10 years will leverage an estimated $1.5 billion in federal, industry, and other funds.  This level of 
investment is projected to translate into more than 5,100 private sector jobs through new and relocated 
firms, as well as an additional 10,950 private sector jobs from an indirect multiplier impact on other 
industries and businesses, for a total projected impact of 16,050 jobs by the year 2014.  These numbers 
likely will increase substantially in a 15- to 20-year period as the exponential impact multiplies again and 
again.  Total sales in year 10 are projected at nearly $1.4 billion.   
Although it takes considerable time for state and private investments to have measurable impacts on a 
state economy, it is important to note that the overall economic impacts surely will include some that 
cannot be projected such as additional increases in direct university employment and retained private 
sector jobs with higher skills and better pay.   
CONCLUSION 
Iowa has the opportunity to build its economy through the application of advanced biosciences. Indeed, 
given the state’s agricultural-bioscience expertise, its leading-edge work in biorenewables, and its distinct 
strengths in various areas of human and animal medicine, the biosciences represent the most logical path 
to a high-productivity, high-wage, 21st century economy.  Iowa already is beginning to see distinct 
progress around advanced areas of bioscience; but, a definite opportunity exists to accelerate the process 
and optimize the growth of the sector in the state. 
This pathway for development lays out a detailed approach to accomplishing bioscience-based economic 
development in Iowa.  The strategy puts forward a bioscience agenda that effectively integrates the 
private, public, and academic sectors in Iowa into a unified driving force for development centered on 
Iowa’s bioscience platform strengths.  In addition, the pathway seeks to leverage the significant 
momentum that already has been built through the state’s investments in programs such as the Iowa 
Values Fund. 
However, for Iowa to succeed in achieving its bioscience vision, the state must take a comprehensive 
approach that addresses each of the key recommendations in this strategy.  Strengthening Iowa’s 
bioscience research infrastructure will result in jobs and income for the citizens of Iowa only if research 
findings are commercialized and new companies created based on technological innovation.  Similarly, 
for commercialization to be successful, there must be a steady pipeline of discoveries.  To retain and grow 
bioscience firms, firms must feel that Iowa supports them in its policies and regulations.  And lastly, if 
Iowa’s economy is to benefit from innovation in the biosciences, the state must have a talent pool ready to 
fill the new jobs created in bioscience companies.  A comprehensive and integrated approach is needed 
for Iowa to become a significant player in the biosciences.   
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 1 
Introduction 
Iowa, like many Midwestern states, finds itself at a challenging time in its history.  A declining 
manufacturing base and an increasingly competitive worldwide agricultural market threaten the 
traditional economic prosperity and high standard of living that Iowans and others in the Midwest have 
come to expect.   
To sustain the comparatively high wages that Americans enjoy, the nation has to work to attain ever 
higher levels of productivity by adopting advanced technologies and educating a workforce skilled in 
deploying, operating, and leveraging that technology (whether in manufacturing, services, agricultural 
production, or other sectors of the economy).  The sustainability of this economic model depends upon a 
well-educated and skillful population and consistent progress through technological innovation.  As talent 
and technology increasingly drive the ability of states to create wealth, there are likely to be winners and 
losers among the states.  Multiple knowledge economy growth poles have emerged in the United States in 
places such as Silicon Valley, San Diego, Boston, Seattle, North Carolina, Maryland, and Austin.  These 
locations have brought together the critical mix of talent, technology and capital to facilitate an economy 
driven by innovation, an economy able to sustain high levels of economic performance in an increasingly 
competitive global market, a “new economy.” 
The U.S. economy always has been nourished by inventiveness and creativity, so the “innovation 
economy” per se is not new; rather, innovation has become the primary impetus of economic growth and 
competitiveness among regions and developed nations. Two fundamental forces are driving technology 
and knowledge advancement as determinants of economic success: 
• The rapidly accelerating pace of scientific discoveries and the technologies that are developed from 
these discoveries. For example, advances in genetics have accelerated dramatically the discovery 
process in the biosciences. The opportunity to accelerate the discovery and development processes, 
along with the ability to protect and profit from intellectual property, has led to an innovation race 
among competing countries, regions, and states. 
• Global world markets and increasing pressure on the United States to maintain its high-wage, high-
skill employment base through technology gains and productivity increases. 
To be secure and sustainable in its economic future, Iowa must join the ranks of states committed to 
leveraging their know-how and creativity to create economic platforms in technology-driven fields.  
Through research and development (R&D), innovation, and the commercialization of innovation, a 
positive economic future may be secured.  The biosciences represent one of those fields. 
In recent years, considerable attention has been paid in state economic development circles to the 
importance of the biosciences as an engine for innovation and technology growth in the 21st century. 
Many states have developed bioscience plans, mostly focused on applying bioscience to human 
biomedical products (primarily research and testing and, in rarer cases, pharmaceuticals and diagnostics, 
medical devices, instruments, and replacement tissue). While applying bioscience to human health holds 
significant economic potential, so too does applying bioscience to animal and plant sciences—including 
agricultural productivity, agricultural and food products, livestock and companion animal health, new 
engineering materials, and chemicals and biologics developed via biomass pathways. The plant and 
animal biosphere contains a huge repository of genes; the novel combination, mining, and use of which 
have the potential to stimulate change in a broad range of industries, from medicinal and food products to 
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advanced manufacturing industries such as materials and energy sources. Traditional bioscience and 
bioengineering disciplines also have a great deal to contribute in new production and processing 
technologies, improved products from agricultural commodities and biological materials, and the novel 
application of bioresources to as-yet undiscovered economic uses.   
Given the economic prospects contained within the rapidly advancing bioscience sector, it is not 
surprising that multiple states should seek to identify and leverage their core bioscience competencies.  
The presence and ongoing operation of bioscience research and development institutions in a state likely 
can provide a comparative advantage for growing and diversifying an economy along one of many paths.   
Iowa, as this report will detail, has the opportunity to become a significant player in the bioscience-
driven economy.  Iowa comes to this path with considerable strengths.  It is home to two major 
bioscience research universities (Iowa State University [ISU] and the University of Iowa [U of I]), with 
supplemental expertise provided by the University of Northern Iowa (UNI).  In addition to its academic 
strengths, Iowa is home to a diverse range of bioscience industry, incorporating agbiosciences, traditional 
biotechnology, pharmaceuticals, medical devices, and various additional sectors.  
A significant portion of these advances in Iowa’s bioscience-based economy can be directly attributed to 
the initiatives of the state’s leaders.  In 2001, Governor Vilsack launched a statewide technology cluster 
initiative that identified three areas of focus:  biosciences, advanced manufacturing, and information 
solutions.  Furthering this effort, in 2003 the Iowa Legislature approved the Iowa Values Fund, a 7-year, 
$503 million state investment in the three cluster areas.  The goals of this fund are to help move and grow 
Iowa’s economy, create jobs, and help generate wealth for Iowans.  The Iowa Values Fund is composed 
of four main components: 
• Business development and assistance 
• University research and development 
• Workforce training 
• Quality of life. 
Iowa also has focused significant programmatic investments to develop tax incentives for research and 
development, to help universities turn research into business opportunities, and to create venture capital 
funding to aid business start-ups.  For instance, during its 2002 session, the Iowa Legislature enacted an 
economic stimulus measure designed to encourage private venture capital investment in emerging, 
expanding, and restructuring business enterprises in communities throughout Iowa. To facilitate the goals 
set forth in the Act, the Legislature authorized the formation of the Iowa Capital Investment Corporation 
(ICIC) for the purpose of mobilizing tax credits to incentivize private venture capital investments.  ICIC’s 
primary purpose is to organize and manage the Iowa Fund of Funds (Fund of Funds). The Fund of Funds 
is a private, for-profit limited partnership authorized to make investments in private venture capital funds.  
To facilitate private investment in the Fund of Funds and minimize the need for public appropriations, the 
Legislature also authorized the issuance of contingent tax credits to guarantee, at least partially, invest-
ments in the Fund of Funds.  The Iowa Capital Investment Board (ICIB) oversees the issuance of the tax 
credits contingent on certain ICIB-developed criteria.  Tax credits totaling $982,000 of the total 
$10 million available have been issued to date related to the 20 percent credit for qualifying businesses 
and community-based seed funds.  Also, credits totaling $644,000 of the total $5 million available have 
been issued related to the 6 percent credit for qualifying venture capital funds. 
While these investments are sizeable, the race among states to establish leadership positions in bioscience 
fields has already started, and the window of opportunity for Iowa to invest the resources necessary to 
 Iowa’s Bioscience Pathway for Development 
 
 3 
leverage its strengths and become a significant player in the leading sector of the 21st Century economy 
will not remain open indefinitely.  The state has to understand its strengths, offset its weaknesses, and 
make highly strategic private and public investments to leverage its core bioscience competencies into a 
sustainable bioscience-driven economic sector. 
To facilitate an in-depth understanding of core bioscience opportunities and to develop a strategy for 
building the Iowa bioscience economy, the Iowa Department of Economic Development (IDED) engaged 
Battelle’s Technology Partnership Practice (TPP) to develop a state bioscience strategy and pathway in a 
two-phase effort: 
• Economic and core competency analyses of the biosciences in Iowa.  This Phase I work was 
released March 2004 in the report entitled, The State of Iowa Biosciences Path for Development: 
Economic and Core Competency Analyses.  In this report, Battelle examined the current quantitative 
position of Iowa in commercial bioscience sectors and in academic bioscience R&D and produced a 
formal assessment of core competencies and fundamental strength platforms upon which Iowa’s 
bioscience economy may be built. 
• A strategy and actions roadmap or pathway (Phase II) for the state that provides specific guidance 
in bioscience-based economic development. 
To complete both Phases I and II assignments, Battelle used both quantitative and qualitative techniques, 
including more than 500 face-to-face interviews with representatives of industry, academe, government, 
and other stakeholder organizations in Iowa.4  Meeting the key goals for the projects required that Battelle 
• Conduct an economic analysis of Iowa’s existing bioscience industry, identifying trends, current 
strengths, emerging industries, and emerging clusters within the biosciences; 
• Assess Iowa’s position in bioscience research and provide a detailed understanding of the bioscience 
core competencies that form platforms for future bioscience development; 
• Identify key barriers and gaps in private and public investments, policies, programs, and activities that 
negatively impact Iowa’s ability to realize its development potential from the biosciences; 
• Outline a series of specific strategies and actions designed to fill in the gaps and maximize the 
economic advantage of Iowa’s core bioscience strengths; and 
• Provide an implementation plan, showing action priorities, estimated resource requirements, and an 
organizational structure for moving the roadmap forward. 
The findings, conclusions, and recommendations of the strategy and actions roadmap are the subject of 
this report.  Pertinent aspects of the economic and core competency analyses from Phase I also are 
included so that this report can serve as a standalone document for the state.  In the process of completing 
the roadmap, further adjustments to the Phase I analyses were made; these have been incorporated into 
this document. 
This strategy begins with an analysis of Iowa’s bioscience base, examining the current state of its 
industrial core as well as the strength of its research activities.  This leads to a summary of the Phase I 
core competency findings. Key strengths, weaknesses, opportunities, and threats as they relate to 
bioscience-driven economic-development are summarized.  Further, this report puts forth a vision and 
mission for bioscience development in the state and provides a situational analysis in which challenges 
                                                 
4 Many individuals were interviewed for both Phase I and Phase II of this analysis. 
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and gaps related to the realization of this vision are examined.  Specific strategies and actions are then 
proposed that will serve, if acted upon, to facilitate realization of the vision through leveraging existing 
organizations and programs and developing new initiatives.  To the extent feasible, actions proposed in 
this Plan take advantage of and utilize existing institutions and organizations whenever possible.  An 
implementation plan is also put forward to provide critical guidance to the state and key stakeholder 
institutions in moving Iowa into a strong leadership position in bioscience development. 
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Iowa’s Bioscience Base 
In considering the base of a state or region’s bioscience activity, two dimensions are critical—the level of 
industrial development and the bioscience research base. A strong bioscience R&D base is critical to the 
development of a state’s or region’s bioscience sector given the close relationship between basic research 
discoveries and product development in this industry sector.  Major new products and innovations in the 
biosciences are frequently related to basic research discoveries; whereas, in other technology sectors, the 
links are less direct. To assess Iowa’s current competitive position and to identify those bioscience niches 
in which the state has strengths, Battelle examined the state’s existing bioscience industry sector and 
bioscience R&D base. 
IOWA’S BIOSCIENCE INDUSTRY SECTOR 
What Industries Constitute the Biosciences? 
Varying industrial classifications could be used to define the bioscience sector of the economy. Currently, 
there is no commonly accepted definition. Categorization is difficult because of the diversity of 
bioscience activity. The industry is dynamic and encompasses a wide variety of industrial applications. 
Continual innovation further complicates the industry definition. Bioscience advancements constantly are 
being applied in new and different ways, creating new industry segments, such as genetically improved 
foods, or alternate energy sources, such as agriculturally based fuels.  
This analysis addressed the diversity of the bioscience industry by dividing it into three sectors: 
agricultural, medical, and plant-life sciences. The agricultural sector consists of those industrial 
subsectors involved in developing, supporting, and manufacturing new farming and food production 
technologies for advancing health and nutrition. The medical sector consists of those industrial subsectors 
involved in manufacturing and developing clinical techniques aimed at and directed toward advancing 
human health care. The plant-life sciences sector consists of those industrial subsectors involved in 
research, testing, developing, and manufacturing clinical and agronomic techniques and products for 
improving the functions of living organisms.  
These three sectors can be further delineated into eight subsectors (Figure 1). Each subsector of 
bioscience activity encompasses a wide variety of industrial activity in which Iowa is well situated to 
further build and strengthen its overall bioscience base.  
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Figure 1: Broadly Defined Iowa “Bioscience” Industry  
 
 
Iowa’s Bioscience Cluster 
Recent employment trends since 2000 indicate a growth rate that is above the national average. In 
Iowa, the bioscience industry experienced above-average employment growth between 2000 and 2002, 
growing by 5.3 percent and gaining 4,179 jobs. In 2002, the Iowa bioscience industry employed 82,849 
individuals across 1,856 establishments. Overall, the industry has demonstrated above-average growth 
since 2000, despite the economic downturn that began in March 2001.5 
Even more promising is that this growth rate was above the national average. The bioscience industry 
across the United States grew at a rate of 3.7 percent between 2000 and 2002. Table 1 illustrates the 
bioscience industry’s overall performance in Iowa and the nation. 
The bioscience industry also represents a sizable portion of Iowa’s economy. Bioscience employment 
concentrations over the same time period consistently accounted for a larger share of state private-sector 
employment than at the national level. In 2002, bioscience employment in Iowa accounted for 7.0 percent 
of total state private-sector employment. Nationally, the bioscience industry accounted for 5.6 percent of 
total private-sector employment. 
 
                                                 
5 The National Bureau’s Business Cycle Dating Committee maintains a chronology of the U.S. business cycle. The 
chronology identifies the dates of peaks and troughs that frame economic recession or expansion. The period from a 
peak to a trough is a recession, and the period from a trough to a peak is an expansion. According to the chronology, 
the most recent peak occurred in March 2001, ending a record-long expansion that began in 1991. The most recent 
trough occurred in November 2001, inaugurating an expansion. 
http://www.nber.org/cycles/november2001/recessnov.html. 
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Table 1: State and National Bioscience Comparison, 1998–2002 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The current level of Iowa’s bioscience employment concentration is considered to be regionally 
specialized. The location quotient is a common measure of the concentration of an industry within an 
economic region. When the concentration is significantly above average, a location quotient above 1.20, 
the region is said to possess a specialization in the industry. The fact that bioscience employment in Iowa 
accounts for a larger share of private sector 
employment than the industry does at the 
national level results in an above average 
location quotient for Iowa. Applying the 
formula in Figure 2 indicates that Iowa 
possesses a regional specialization in the 
bioscience industry that in 2002 was 1.24, 
an increase from 1.20 in 2000.6 
                                                 
6 Location quotients are a common measure of the concentration of a particular industry in a region relative to the 
nation (reference area). The LQ consists of the ratio of the share of total regional employment that is in the particular 
industry and the share of total employment in the nation (reference area) that is in the particular industry. An LQ 
greater than 1.0 for a particular industry indicates that the region is relatively concentrated, whereas an LQ less than 
1.0 signifies a relative under-representation. A location quotient of above 1.20 denotes employment concentration 
well above the national average. Throughout this report, LQs are used to report regional industry concentrations 
relative to the United States as a whole. The minimum concentration threshold for declaring a regional specialization 
is a matter of judgment and varies somewhat in the relevant literature. In this analysis, regional specializations are 
defined by LQs of 1.2 or greater. 
LQRi = (Ri / RT) / (USi / UST)  
Where: 
  Ri = industry i employment for the region 
  RT = total employment for the region 
  USi = industry i employment for the nation 
  UST = total employment for the nation 
Figure 2: Location Quotient Formula 
Biosciences  Total Private Sector Biosciences
 Total Private 
Sector
Establishments
2000 1,951 98,845 81,772 7,697,470
2002 1,856 83,340 86,273 7,852,549
% Change  00-02 -4.9% -15.7% 5.5% 2.0%
Employment
2000 78,670 1,217,722 5,855,230 108,358,433
2002 82,849 1,185,668 6,072,130 107,618,787
% Change  00-02 5.3% -2.6% 3.7% -0.7%
Employees per Establishment
2000 40 12 72 14
2002 45 14 70 14
Location Quotient
2000 1.20                n.a n.a n.a
2002 1.24                n.a n.a n.a
Wages
2000 36,127 27,570 41,165 35,470
2002 39,253 29,158 44,199 36,517
% Change  00-02 8.7% 5.8% 7.4% 3.0%
Percent Share of Private Sector of Employment
2000 6.5% n.a 5.4% n.a
2002 7.0% n.a 5.6% n.a
Metric
IOWA UNITED STATES
p ,
Iowa Workforce Development, Employment Statistics Bureau
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Iowa’s Bioscience Cluster Subsectors 
Iowa’s bioscience cluster includes eight individual subsectors.  Each subsector specializes in distinct 
aspects of the biosciences and contains its own value chain and set of supply relationships.  Cross-cutting 
relationships also exist among and between the subsectors.  Accurately depicting Iowa’s bioscience 
industry requires examining each of these unique subsectors. Dissecting the industry also helps identify 
specific areas of strength and opportunity to create synergies and facilitate future development potential 
for the entire industry sector. 
Iowa’s bioscience subsectors can be categorized into four classes—stars, emerging potential, 
transitional, and divergent—based upon their performance from 1998 to 2002, as shown in Figure 3. The 
four categories are based on (1) the subsector’s growth relative to U.S. growth and (2) the subsector’s 
location quotient. Subsectors classified as stars are those that possess significant regional specialization 
and growth rates exceeding national levels.  Emerging potential subsectors are those that are growing 
more rapidly than the industry at the national level and that present the opportunity to develop a 
concentration if rapid growth continues. Subsectors classified as transitional or divergent are not keeping 
pace with national growth trends. Though not irreversible, these subsectors demonstrate current 
characteristics that may threaten the long-term viability of the industry in Iowa.  
 
Figure 3: Iowa Bioscience Cluster Subsector Performance, 1998–2002 
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Stars 
The organic and agricultural chemicals subsector is the fastest growing subsector in Iowa relative to 
the United States and is regionally specialized.  The subsector had an employment base of 4,416 in 2002 
across 56 establishments. This employment increase is substantial considering that, at the national level, 
the subsector experienced a 15.3 percent employment drop. The phenomenal growth in Iowa has 
positioned the subsector well above the national employment concentration level.  
The state’s employment concentration in organic and agricultural chemicals is 2.5 times greater than the 
national average. This level of employment makes organic and agricultural chemicals in Iowa signifi-
cantly specialized. In addition to the regional specialization, Iowa’s employment level represents an 
increasing concentration. The subsector’s fast-paced growth is a major reason for the state’s growing 
specialization.  
Emerging Potential 
The drugs and pharmaceuticals subsector is the second fastest-growing bioscience subsector and 
outpaced growth of this industry at the national level.  The growth that Iowa experienced in drugs and 
pharmaceuticals, bringing employment levels above 2,500 across 44 establishments, surpassed the U.S. 
growth rate of 11.3 percent. The ability of drugs and pharmaceuticals to remain ahead of national 
employment growth rates has contributed to a rising employment concentration.   
The medical equipment and supplies subsector experienced the second fastest employment growth rate 
in Iowa relative to the United States. Though growth was only half as much as the drugs and pharma-
ceuticals subsector, medical equipment and supplies was second only to organic and agricultural 
chemicals in terms of relative growth compared with the nation. Iowa’s employment base in the medical 
equipment and supplies subsector grew by 6.1 percent. Across the nation, subsector employment in 
medical equipment and supplies decreased by 0.6 percent.  Despite the encouraging growth trend over the 
past four years, the medical equipment and supplies subsector in Iowa remains small. In 2002, the 
subsector employed 1,847. 
The hospitals and laboratories subsector is Iowa’s largest bioscience subsector and is growing. The 
Iowa hospitals and laboratories subsector employed 41,882 in 2002. Although not often considered at the 
forefront in bioscience research or production, hospitals and laboratories are important contributors. In 
particular, health centers perform clinical trials and collaborate with companies on research and 
development.  
Transitional 
The agricultural machinery and equipment subsector is the most specialized bioscience subsector in 
Iowa. In 2002, the subsector employed more than 10,000 workers across the state. This level of employ-
ment is far above the national level. The agricultural machinery and equipment subsector in Iowa 
possesses a location quotient of 11.83. This concentration level represents an employment base in the 
state that is more than 10 times the national level.  
The agricultural processing subsector is the largest agriculture-related bioscience subsector in terms of 
employment size and the second most regionally specialized subsector in Iowa’s bioscience industry. In 
2002, the agricultural processing subsector employed 19,458 across 976 establishments within the state. 
The subsector’s size is demonstrated by examining the average establishment size. The typical 
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agricultural processing establishment in Iowa employs 22 individuals. Nationally, the average 
establishment employs 16 individuals.  
In Iowa, the agricultural processing subsector is more concentrated and is composed of larger firms. The 
state’s employment concentration in the agricultural processing subsector is more than seven times 
greater than the national average. The location quotient of 7.34 clearly represents a strong regional 
specialization. 
The agricultural services subsector also is regionally specialized. The agricultural services subsector is 
the smallest of all the bioscience subsectors, employing 1,187 in 2002. Although small in size, the 
subsector is significantly concentrated and is considered to be regionally specialized in Iowa. The 
subsector is more than twice as concentrated in Iowa as in the nation. 
Economic Analysis Summary 
Key conclusions from the economic analysis of Iowa’s current economic base include the following: 
1. The bioscience industry is a significant contributor to the Iowa economy. In 2002, bioscience 
employment accounted for 7.0 percent of total employment in Iowa, exceeding the national average of 
5.6 percent of total private-sector employment. The strength that Iowa demonstrates in this technologic-
ally advancing industry suggests that this sector of the economy is an asset for the state upon which to 
build. 
Another way to observe the impact of the bioscience industry on the state economy is by examining the 
gross state product (GSP) of Iowa. The health services, food and kindred products, and chemicals and 
allied product subsectors making up the bioscience sector account for large shares of Iowa’s GSP. In fact, 
compared with the United States, each subsector in Iowa has a larger share of the GSP (Table 2). 
 
Table 2: Bioscience Share of Gross State Product, 2001 
 
2. Iowa’s bioscience industry is diverse, with subsectors that are growing rapidly.  Iowa has a significant 
concentration in the organic and agricultural chemicals subsector that is growing rapidly. The drugs and 
pharmaceuticals and medical equipment and supplies subsectors also offer potential as they are growing 
rapidly.  Finally, Iowa has a mature base in the biosciences represented by the number of subsectors in 
which Iowa is considered to be specialized, including agricultural machinery and equipment, agricultural 
processing, and agricultural services.  
3. The bioscience industry is a tremendous source of well-paying jobs. Compared with other major Iowa 
industries, the bioscience industry is one of the highest paying in the state. The average wage of a 
2001 Gross State Product 
Industry
(millions of 
current dollars) 
Percent Share 
of Total GSP
(millions of 
current dollars) 
Percent Share 
of Total GSP
 Total Gross State Product 90,942 100.00% 10,137,190 100.00%
 Farms 2,831 3.11% 80,596 0.80%
 Ag. services, forestry, and fishing 623 0.69% 60,054 0.59%
 Food and kindred products 3,788 4.17% 123,683 1.22%
 Chemicals and allied products 2,880 3.17% 163,456 1.61%
 Health services 5,653 6.22% 589,788 5.82%
Source: U.S. Bureau of Economic Analysis, 2001 Gross State Product by Industry Category, Released April 2003
Iowa United States
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bioscience worker in 2002 exceeded the 
statewide average annual wage by more 
than $12,700 and surpassed wages in 
such sectors as manufacturing; 
information; construction; and finance, 
insurance, and real estate (FIRE) (Table 
3). Because the bioscience industry is 
diversified, comprises a substantial share 
of state economic activity, and is a 
source of high-paying jobs, it is 
reasonable to support initiatives that 
focus on it. 
Conclusions 
The economic analysis of the Iowa 
bioscience economy indicates that the 
industry is dominated by the agriculture-
related subsectors. In particular, three 
subsectors are well positioned to be the 
foundation of a comprehensive economic 
development strategy (Table 4). The organic and agricultural chemicals subsection is a sizable, growing 
regional specialization that is extremely well-positioned to benefit from increases in ethanol production 
(an organic chemical). Agricultural processing is the largest of the agriculturally based bioscience 
subsectors and represents a solid base that is significantly more specialized in Iowa than in the nation and 
possesses an average annual wage per 
employee that is higher than the 
national average. Similarly, agricultural 
machinery and equipment exhibits a 
solid employment base and high 
average annual wage. 
The better-than-average employment 
growth rate exhibited between 2000 
and 2002 suggests that the bioscience 
industry represents an economic 
development opportunity for Iowa. 
This opportunity can have even more 
impact if industrial and academic 
initiatives are linked and focused around similar priorities.  To create a more durable and vibrant 
bioscience industry, the State of Iowa must target initiatives to support existing strengths and encourage 
and stimulate emerging subsectors. While Iowa must tailor initiatives to target those niches with the 
greatest promise of economic growth, the state must not lose sight of the inherent diversity of bioscience 
activity. The challenge that state leaders face is the need to balance initiatives between solidifying core 
areas within the biosciences and promoting new innovative industrial technologies that promise continual 
economic growth. 
Organic and Ag Chemicals   $52,760 
Ag Machinery and Equipment   $51,672 
Ag Processing     $46,318 
FIRE      $40,471  
Biosciences     $39,253 
Wholesale Trade     $38,300  
Manufacturing       $38,230  
U.S. Total Private Sector    $36,517 
Transportation and Utilities    $35,708  
Information     $34,830  
Construction      $34,777  
Iowa Total Private Sector    $29,158  
Professional Business Services   $28,630  
Ag/Natural Resources and Mining   $25,364  
* Wages are based on 2002 ES-202 data from the Bureau of 
Labor Statistics (BLS) and the Iowa Workforce Develop-
ment’s Employment Statistics Bureau. 2002 Information for 
the U.S. was retrieved from the BLS and is considered 
preliminary according to the Department of Labor. 
Table 3: Average Iowa Annual Wages per Employee, 2002* 
Key Iowa Bioscience Subsectors 
   
  2002 Location
Subsector Employment Quotient
 
Organic & Agricultural Chemicals 4,416 3.51
Agricultural Processing 19,458 7.34
Agricultural Machinery & Equipment 10,115 11.83
Table 4: Key Iowa Bioscience Subsectors 
Source: Battelle calculations based on ES-202 data from the U.S. Department 
of Labor’s Bureau of Labor Statistics and Iowa Workforce Development’s 
Employment Statistics Bureau. 
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Battelle also conducted a recent study for BIO, the national biotechnology trade association, which 
compared Iowa with the other 49 states using a more narrow definition of agriculture than that used in this 
report.  Nevertheless, that report demonstrated Iowa’s national leadership role in bioenergy, biofuels, and 
related biomass initiatives.  Iowa is one of only six states in the nation that have both a large employment 
base and a significant specialization in agricultural feedstock and chemicals, which includes organic and 
agricultural chemicals and agricultural processing and is focused on industrial applications geared toward 
production agriculture, energy, industrial commodities, and specialty health products.7   
IOWA’S BIOSCIENCE R&D BASE 
Major university and nonprofit research institutions not only are the key to basic research discoveries that 
generate product leads for bioscience companies, but, more importantly, create an environment in which 
bioscience companies can flourish. Moreover, these institutions can be an asset for the bioscience industry 
in bridging the gap between basic and applied research.  
Key trends in life science research, particularly focused on university research activity, are examined in 
the following paragraphs. In assessing Iowa’s position in the biosciences, Battelle reviewed published 
statistics that allowed comparison of Iowa institutions to other leading bioscience institutions. Sources of 
information included 
• External, national research funding sources, including National Science Foundation (NSF), U.S. 
Department of Agriculture (USDA), and National Institutes of Health (NIH) grant funding; 
• Institute for Scientific Information (ISI) science publications citation index statistics; 
• Proprietary Battelle Starlight™ analysis tools for mining research and patent abstract information to 
identify clusters of research expertise and focus. 
Iowa’s Position in Bioscience R&D 
From the standpoint of academic funding for R&D, the State of Iowa is performing well for its size. With 
$439.8 million in research funds, Iowa ranks 24th in total university R&D funding (according to the 
NSF)—notably exceeding its population rank of 30th. 
Within the academic R&D arena, the state is performing particularly well in the biosciences, with 
66 percent of all academic research funds falling under this definition. This level of performance places 
Iowa 21st in the nation. Also, Iowa ranks well across the three major macro-categories of bioscience 
R&D (Table 5):  
• 19th in medical sciences ($138 million) 
• 20th in agricultural sciences ($50 million) 
• 22nd in biological sciences ($84 million). 
 
                                                 
7 Battelle Technology Partnership Practice and SSTI.  Laboratories of Innovation: State Bioscience Initiatives 2004, 
www.bio.org, June 2004. 
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Table 5: Iowa Bioscience-Related Funding 
R&D Funding at Iowa Universities 
(Rank of State of Iowa vs. Other States - For 7 Iowa Colleges & Universities) 
Field FY 2001 % U.S. Rank 
TOTAL OF ALL ACADEMIC DISCIPLINES  $ 439,810  1.3% 24 
LIFE SCIENCES TOTAL  $ 290,912  1.5% 21 
  Agricultural Sciences  $  49,993  2.2% 20 
  Biological Sciences  $  84,185  1.4% 22 
  Medical Sciences  $ 137,689  1.4% 19 
  Other Life Sciences  $  19,045  2.5% 15 
OTHER CRITICAL SCIENCES     
  Chemical Engineering  $   3,558  0.9% 32 
  Chemistry  $   9,625  1.0% 30 
Source: National Science Foundation, Survey of Research and Development Expenditures at Universities and 
Colleges, and Battelle calculations, FY 2001. 
 
As the pie charts in Figure 4 illustrate, the percent of each type of bioscience and associated sciences 
R&D in Iowa is quite similar to that in the nation as a whole, except that Iowa has a significantly higher-
than-average concentration in agricultural sciences (16 percent versus 11 percent nationally). 
Finally, Iowa ranks 25th in total NIH awards, considered one of the “gold standards” of bioscience 
funding (Figure 5). Once again, this performance exceeds the state’s population ranking. 
Iowa’s comparatively strong performance in bioscience R&D cannot, however, be taken for granted. The 
biosciences are a key target for growth in many states; and, in recent years, Iowa’s total growth in 
bioscience funding has not kept pace with that of the nation—resulting in a slightly declining bioscience 
R&D market share of total academic R&D (Figure 6). 
Key data relating to Iowa’s recent performance in the biosciences are highlighted in Table 6 and further 
explain how Iowa has not kept pace with national bioscience research funding trends. The data show that 
Iowa has a greater concentration of total academic R&D in the biosciences than the national average and 
also that bioscience academic R&D spending per capita is considerably above the U.S. average. This 
comparative concentration in the biosciences is declining somewhat as Iowa’s growth in bioscience 
R&D funding has not kept pace with the growth rate of U.S. bioscience research. To put it another way, 
if Iowa’s bioscience R&D increase from 1997 to 2001 had kept pace with the overall U.S. growth rate, 
Iowa would have received approximately $8 million more in bioscience R&D funding in FY 2001. 
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Figure 4: Share of Bioscience-Related R&D for Iowa and the United States 
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Figure 5: Total NIH Funding and Number of Awards, FY 2002 
 
Figure 6: Academic R&D in Iowa as a Percentage of U.S. Academic R&D 
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Table 6: Recent Bioscience Performance in Iowa and the United States 
Metric Iowa United States 
Total Academic R&D, FY 2001 $439,810,000 $32,652,261,000 
Total Bioscience R&D, FY 2001 $290,912,000 $19,145,970,000 
Bioscience as a % of All Academic R&D 66.1% 58.6% 
Annual Academic Bioscience R&D Per Capita, FY 2001 $99.22 $67.10 
% Increase in Academic Bioscience R&D, FY '97–01 37.7% 41.5% 
Source: National Science Foundation, Survey of Research and Development Expenditures at Universities and 
Colleges, and Battelle calculations, FY 2001. 
 
Iowa’s Bioscience R&D Strengths 
The previous section highlighted basic trends in academic bioscience R&D activity within Iowa. In this 
section, the analysis is extended to examine the specific areas of bioscience and bioscience-related 
activities that are receiving extramural funding.  It is important to note that, as mentioned earlier, the 
biosciences are broad and no state has core strengths in every aspect of them. In Iowa, quantitative data 
on funding by discipline, publications citations, and numbers of grants serves to highlight some of the 
fields in which Iowa has a specialization. 
NIH data show that the University of Iowa College of Medicine performs particularly well in funding for 
• Orthopedics (where it ranks third in the nation); 
• Public health and preventative medicine (fifth); 
• Otolaryngology—ear, nose and throat (fifth); 
• Pediatrics (eighth); 
• Anesthesiology (10th); and 
• Biostatistics and related math sciences (11th). 
Iowa State University also received NIH awards, but performs particularly well in accessing NSF and 
USDA awards. Iowa State performs well in multiple disciplines, including biological infrastructure, 
environmental biology, integrative biology and neuroscience, and molecular and cellular biosciences. 
Iowa State’s USDA funding highlights its work in veterinary medicine and animal sciences. 
The ISI publishes statistics on the publications frequency and impact of academic institutions. Within 
Iowa, several university disciplines are strong performers on ISI metrics. The data show that Iowa is 
particularly powerful in 
• Clinical immunology and infectious diseases; 
• Agriculture and agronomy; 
• Anesthesia and intensive care; 
• Otolaryngology; 
• Entomology and pest control; and 
• Ophthalmology. 
Other disciplines that are strong in terms of citations include agricultural chemistry, dentistry, oral surgery 
and medicine, microbiology, veterinary medicine, and animal health. 
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Both the grants funding and ISI data serve to highlight several factors: 
• There is significant institutional depth in a broad range of bioscience, biomedical, and related 
disciplines. Both Iowa State University and the University of Iowa contribute to this depth. 
• Iowa has strengths in the three primary components of bioscience— plant sciences/agricultural 
science, veterinary medicine/animal health, and human medicine. 
• The University of Iowa is particularly strong and productive in clinical immunology and infectious 
diseases, immunology, otolaryngology, ophthalmology, anesthesia and intensive care, and clinical 
psychology and psychiatry. 
• Iowa State University has demonstrable impact in agriculture/agronomy and entomology and pest 
control. The University also has a strong concentration in agricultural chemistry, animal and plant 
sciences, veterinary medicine and animal health, and food sciences and nutrition. 
• Both the University of Iowa and Iowa State University have strengths in environment/ecology 
research. 
A quantitative analysis was completed, using Battelle’s own proprietary Starlight™ cluster analysis 
software system. Starlight™ uses pattern recognition algorithms on text data (grant abstracts) to find 
areas in which a critical mass of research is occurring. This analysis identified six “meta clusters” of 
research in Iowa comprising 
• Cell and molecular studies 
• Crop and soil analysis 
• Disease and infection studies (both human and animal/agricultural) 
• Genetics 
• Neural studies 
• Vascular analytics. 
Iowa’s performance in the cell/molecular studies and genetics fields (with 510 grants and 259 grants, 
respectively) is particularly noteworthy given the importance of these disciplines to modern bioscience 
progress. Strengths in these disciplines are provided by both the University of Iowa and Iowa State 
University. 
Taking all of the quantitative data into account, Tables 7 and 8 list Iowa’s broadly based and human 
medicine/health core focus areas, respectively. 
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Table 7: Iowa’s Broadly Based Core Focus Areas Suggested by Quantitative Data 
Federal Research Grants Starlight Cluster Analysis 
Core Focus Areas 
NIH NSF USDA 
Publication & 
Citation Strength  
(ISI Data) Grants Patents 
Academic 
Reputation (U.S. 
News & World 
Report Rankings) 
Plant Breeding and 
Genetics  9 9  9 9  
Biotechnology and 
Applied Microbiology 9 9 9 9 9 9  
Immunology and 
Infectious Disease 9  9 9 9   
Agricultural 
Equipment 
Engineering 
  9   9 9 
Food Safety and 
Nutrition 9  9 9    
Materials Science      9  
Agricultural 
Chemicals   9 9    
Entomology and Pest 
Control  9 9 9    
Veterinary Medicine 
and Animal Health  9 9 9   9 
 
Table 8: Iowa’s Human Medicine/Health Core Focus Areas Suggested by Quantitative Data 
Federal Research Grants 
Starlight 
Cluster 
Analysis Core Focus Areas 
NIH NSF USDA 
Publication & 
Citation 
Strength  
(ISI Data) Grants 
Academic 
Reputation (U.S. 
News & World 
Report Rankings) 
Best Hospitals  
(U.S. News & 
World Report 
2003 Rankings) 
Anesthesiology 9   9  9  
Audiology 9     9  
Biostatistics 9       
Cardiovascular 9    9   
Neurosciences, Neurology 
& Neurosurgery 9 9   9  9 
Nursing      9  
Oncology    9 9   
Ophthalmology    9   9 
Orthopedics 9      9 
Otolaryngology 9   9   9 
Pediatrics 9       
Public Health & 
Preventative Medicine 9     9  
Radiology & Radiation 
Diagnostics 9       
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Conclusions 
Iowa is strong and diversified in its bioscience R&D base and has a small but growing commercial base in 
certain related disciplines. The R&D basics are in place across agricultural bioscience, animal science, 
and human/medical bioscience, and the leading universities are already working on collaborations to help 
advance their bioscience work. 
The next section examines Iowa’s specific bioscience core competencies based on the convergence of its 
industrial and academic research bases, both established and emerging, in order to identify specific areas 
of opportunity for bioscience development in Iowa.  For more in-depth detail on both the methodology for 
and analyses of the quantitative and qualitative data collected on Iowa’s bioscience R&D base and core 
competencies, please see the Phase I report, The State of Iowa: Biosciences Path for Development: 
Economic and Core Competency Analyses. 
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Opportunities for Bioscience Development in Iowa 
Understanding Iowa’s research core competencies requires identifying the key research strengths and 
drivers for bioscience development in the state. But, realizing economic impact from these strengths 
requires identifying and developing key technology platforms around which this research can be 
commercialized in products, processes, and market-driven niches. Identifying core competencies also 
helps focus on the state’s specific possibilities for becoming a bioscience growth center around major 
niches and opportunities. Of particular importance is the ability of a state to have specific areas for near-
term development (within the next 2 to 5 years) that takes advantage of core research strengths that will 
contribute to economic growth. It is these near-term development areas that can launch a state on its way 
to becoming a thriving center for the biosciences and provide the foundation for longer-term investments 
needed to establish broader core competencies for growth. 
Because research and industry development in the biosciences are closely linked, with industry relying on 
research to generate new bioscience products, it is helpful to focus on areas of primary research for near-
term development. But, research alone is insufficient to ensure bioscience development. The most likely 
areas for bioscience development can be found where research intersects with a state’s industry base, 
competitive advantages, and market opportunities. 
The criteria for selecting opportunities for technology development include areas in which there are 
• Existing research focus strengths; 
• Bases of commercial activity emerging or established within the state, or a genuine opportunity to 
create a base in the near future; 
• Distinct opportunities to leverage the state’s comparative advantages to create competitive 
marketplace advantages; 
• Significant product market potential; and 
• Links to, or reinforcements of, other bioscience strengths and core research competencies, thereby 
helping to enhance other fields as it expands. 
IOWA’S BIOSCIENCE CORE COMPETENCIES 
The previous analysis of quantitative data sets a context for understanding where Iowa’s core 
competencies in bioscience research are focused. To further investigate these fields and understand the 
core bioscience focus areas in Iowa, extensive qualitative interviews were conducted with university 
administrators, faculty, scientists, clinicians, industry executives, and development agencies in the state.  
The interviews, for the most part, confirmed the areas of specialization in Iowa identified in the 
quantitative analysis. They also, however, highlighted several new and emerging areas of R&D focus and 
some key theme areas that were not readily apparent within the quantitative datasets. One challenge in 
using quantitative data is the rapid rate of change in scientific enterprise. Peer review systems—whether 
used for federal grant awards, citation analysis, or in reputation rankings—tend to lag emerging new 
fields of inquiry, missing younger and new scientific talent. One objective of the qualitative interviews 
was to capture emerging areas, faculty, and fields of inquiry at each of the three universities.  
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After performing the qualitative interviews, conclusions were formed that placed each of the identified 
strength areas into one of three categories: 
• Established Strengths—Comprising the “powerhouse” disciplines in which Iowa has a clear 
leadership position on which to build. 
• Strong and Growing—Comprising fields that are fast growing in general (such as genetics and 
bioinformatics in which the state is particularly strong but need further development) but less fully 
established than the preceding category. 
• Emerging and Notable—Comprising smaller or embryonic programs that still show significant 
potential for bioscience development in Iowa. 
 
Figure 7: Iowa’s Strength Areas Based on Qualitative Assessment 
 
Bioinformatics and genomics are strongly positioned in Iowa at both the University of Iowa and Iowa 
State. However, genomics and post-genomic sciences are the basic pillar upon which much bioscience 
progress will be made. Other states are investing heavily in initiatives to enhance their genomics, 
proteomics, metabolomics, and bioinformatics infrastructures and bolster their positions in these critically 
important fields. While this field is a key strength in the state and was classified as “strong and growing” 
in Iowa, it is an area of great competition and growth where momentum must be maintained. 
In the modern biosciences, seldom does an area of focus stand on its own. Rather, the biosciences should 
be viewed as a system of interrelated disciplines and areas of study that support and assist one another. 
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For this reason, the NIH and similar organizations are focusing more grant-making attention on 
multidisciplinary institutes, centers, and research teams. Figure 8 illustrates some of the interrelationships 
and supporting links that exist among Iowa’s bioscience strength areas. These and other links are explored 
in detail in the analyses that follow regarding technology platforms and opportunities. 
 
Figure 8: Interrelationships Among Iowa’s Interview-Identified Bioscience Strength Areas 
The links between strength areas are critical to the emergence of bioscience core competencies in Iowa. 
As in any system, a change in one of the parameters (strength areas) is likely to affect the operation of 
others. For example, an enhanced center for the support of drug development with associated pilot 
facilities likely would increase the attention of various medical and veterinary disciplines on drug 
discovery activities. Equally, such an enhancement could spur biosystems engineering work on bio-
processing activities for drugs or lead to an increased nanotechnology focus on drug delivery.  
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Biosecurity platforms). These core competency areas are summarized in Figure 9, which shows the 
strengths identified by Battelle’s quantitative and qualitative analyses, together with recommended 
technology platforms for resulting bioscience development. 
 
Figure 9: Iowa’s Validated Research Strengths Leading to Recommended Platforms 
As Figure 9 illustrates, Battelle sees opportunity for Iowa to develop its bioscience economy upon 
multiple short- or near-term “platforms.” These include the following:  
• BioEconomy Platform—Using plant and animal biomass and waste streams to generate chemicals, 
energy, fuels, and materials for industrial and commercial applications.  
• Advanced Food and Feed Platform—Using Iowa’s established strengths in plant and animal 
sciences, production agriculture, food science, nutrition, and processing technology to develop and 
produce functional foods and nutraceuticals. 
• Animal Systems Platform— Using Iowa’s bioscience and genomics expertise to establish a 
leadership position in the modeling of animal systems and in the development of technologies and 
applications for genes, genetic markers, transgenic animals, chimeric animals, and cloning. 
• Integrated Post-Genomic Medicine Platform—Using Iowa’s genomics expertise and specific 
disease/disorder skills, in conjunction with epidemiologic data and Iowa’s stable population, to 
produce rapid advances in post-genomic medicine and associated discoveries. 
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• Integrated Drug Discovery, Development, Piloting, and Production Platform—Leveraging 
Iowa’s strengths in basic biomedical research, drug development, and Good Manufacturing 
Practice(s) (GMP) production into an integrated pipeline of new drugs and therapeutics. 
• Integrated Biosecurity Platform—Deploying the strengths of Iowa’s institutions in human, animal, 
and plant disease prevention, protection, and treatment to establish an integrated approach to securing 
the environment, food production systems, and human health and safety. 
These six areas represent broad platforms upon which a significant R&D base, business base, and 
bioscience economy may be built in Iowa in the near to short term. They each specifically draw upon 
Iowa’s institutional expertise in multiple fields, because multidisciplinary research increasingly is gaining 
importance in driving funding, new study areas, technologies, discoveries, and commercializable 
innovations. In each case, the analysis shows that these platforms match well with large and rapidly 
growing projected domestic and international markets. In most cases, the markets are characterized in 
terms of having expanding multibillion-dollar existing and emerging potential.  In addition to these broad 
platforms, biomedical imaging is a niche platform that is an opportunity for developing in the near term.  
Each of the bioscience development platforms presents unique opportunities for bioscience-based 
economic advancement in Iowa.  In the section that follows, some of the specific strengths for each 
platform are outlined. 
BioEconomy Platform Strengths to Leverage 
The BioEconomy Platform uses plant and animal biomass and waste streams to generate chemicals, 
energy, fuels, and materials for industrial and commercial applications.  The rapid development of Iowa’s 
leadership position in the BioEconomy will be built upon an existing base of strengths.  
Key Industry Strengths  A significant base of companies currently manufacturing fuels, chemicals, 
and materials from biorenewable resources 
 A large-scale source of raw biomass feedstocks generated by Iowa’s 
highly productive agricultural sector 
 An infrastructure conducive to the movement of bulk materials and 
finished products 
 A well-educated, productive workforce and workforce development system
Strengths of Lead R&D 
University:  Iowa State 
University 
 Plant Sciences Institute and its associated centers, including the Center 
for Bioinformatics, Center for Plant Genomics, Center for Plant Trans-
formation, Center for Designer Crops, Center for Responses to Environ-
mental Stresses, and the Center for Plant Breeding 
 Agriculture and Home Economics Experiment Station and its associated 
centers/institutes including the Center for Crops Utilization Research 
(CCUR) and the Center for Integrated Animal Genomics (CIAG) 
 Center for Catalysis 
 Center for Sustainable Environmental Technologies 
 Biomass Energy Conversion Facility 
 Center for Industrial Research and Service (CIRAS) 
 Individual departmental strengths 
 Agricultural and manufacturing extension services 
 Incubator and research park space and services 
Supporting Strengths: 
University of Iowa 
 Center for Biocatalysis and Bioprocessing 
 Incubator and research park space and services 
Supporting Strengths: 
University of Northern 
Iowa 
 The Center for Ag-Based Industrial Lubricants 
 Bio-based aggregates via UNI Metal Casting Center 
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Advanced Food and Feed Platform Strengths to Leverage 
The Advanced Food and Feed Platform uses Iowa’s established strengths in plant and animal sciences, 
production agriculture, food science, nutrition, and processing technology to develop and produce 
functional foods and nutraceuticals. 
Key Industry 
Strengths 
 A significant base of companies currently in the agricultural processing 
sector (however, few in the food processing sector)  
 Highly productive soils and agricultural production sector 
 An infrastructure conducive to the movement of bulk materials and 
finished products 
 A well-educated, productive workforce and workforce development 
system 
Strengths of Lead 
R&D University:  Iowa 
State University 
 Food Science and Human Nutrition Department 
 NIH Funded Botanical Supplement Center 
 Institute for Food Safety and Security 
 Plant Sciences Institute and its associated centers, including the Center 
for Bioinformatics, Center for Plant Genomics, Center for Plant 
Transformation, Center for Designer Crops, Center for Responses to 
Environmental Stresses, and the Center for Plant Breeding 
 Agriculture and Home Economics Experiment Station and its associated 
centers/institutes including the Center for Crops Utilization Research 
(CCUR), Center for Integrated Animal Genomics (CIAG), the NASA 
Food Technology Commercial Space Center, and the ISU Meat Lab 
 Center for Designing Foods to Improve Nutrition 
 Individual departmental strengths 
 Agricultural and manufacturing extension activities 
 Incubator and research park space and services 
Supporting Strengths: 
University of Iowa 
 Collaborator with ISU on botanical supplement investigations 
 Human health impacts of diet and nutrition 
 Free radical/oxidative expertise 
Animal Systems Platform Strengths to Leverage 
The Animal Systems Platform uses Iowa’s bioscience expertise to establish a leadership position in the 
modeling of animal systems and in the development of technologies and applications for transgenic 
animals, chimeric animals, and cloning. 
Key Industry 
Strengths 
 A base of companies currently producing biologics products from 
animal pathways (e.g., TransOva, Proliant) and in animal health (e.g., 
Fort Dodge) 
 Efficient food animal production sector 
 A well-educated, productive workforce and workforce development 
system 
Strengths of Lead 
R&D University:  Iowa 
State University 
 Agriculture and Home Economics Experiment Station and its associated 
centers/institutes including the Center for Integrated Animal Genomics 
(CIAG), the NASA Food Technology Commercial Space Center, and 
the ISU Meat Lab 
 Animal Gene Transfer Facility 
 ISU Extension’s Beef and Pork Centers 
 Plant Sciences Institute resources in bioinformatics and other related 
areas) 
 Individual departmental strengths especially in Animal Sciences 
Department and the College of Veterinary Medicine 
 Agricultural and manufacturing extension services 
 Incubator and research park space and services 
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Supporting Strengths: 
University of Iowa 
 Transgenic Animal Core Facilities and Vector Core Facilities.  Able to 
work on animal models of disease and assessing reversibility with gene 
transfer. 
 
Integrated Post-Genomic Medicine Platform Strengths to Leverage 
The Integrated Post-Genomic Medicine Platform uses Iowa’s genomics expertise and specific 
disease/disorder skills, in conjunction with epidemiologic data and Iowa’s stable population, to produce 
rapid advances in post-genomic medicine and associated discoveries. 
Key Industry 
Strengths 
 A small base of companies in the drugs and biologics sector 
 A stable and participative population for clinical trials 
 A well-educated, productive workforce and workforce development 
system 
Strengths of Lead 
R&D University:  
University of Iowa 
 Bioinformatics Center and deep associated expertise in genetics and 
genetic analysis 
 Epidemiology 
 Transgenic Animal Core Facilities 
 Tissue banks in certain subspecialties 
 Large and stable clinical population 
 GMP drug and biologic production facilities 
Supporting Strengths: 
Iowa State University 
 Genetics and bioinformatics 
 Statistics 
 
Integrated Drug Discovery, Development, Piloting, and Production Platform Strengths to 
Leverage 
The Integrated Drug Discovery, Development, Piloting, and Production Platform leverages Iowa’s 
strengths in basic biomedical research, drug development, and GMP production into an integrated 
pipeline of new drugs and therapeutics. 
Key Industry 
Strengths 
 A small base of companies in the drugs and biologics sector 
 A stable and participative population for clinical trials 
 A well-educated, productive workforce and workforce development 
system 
Strengths of Lead 
R&D University:  
University of Iowa 
 GMP production facilities already registered with the Food and Drug 
Administration (FDA) and working in partnership with pharmaceutical 
and biotechnology industries (Pharmaceutical Services) 
 Center for Advanced Drug Development, providing services to internal 
research groups and to external industry 
 Major research programs in pharmacology , pharmaceutics, medicinal 
chemistry, biochemistry, immunology, epidemiology, chemical and 
biomedical engineering 
 Biologics capabilities at the Center for Biocatalysis and Bioprocessing 
 Comprehensive Cancer Center 
 Clinical Trials Office 
 College of Public Health 
Supporting Strengths: 
Iowa State University 
 Veterinary medicine drugs and biologics 
 Animal models and systems, and clinical trials 
 Animal toxicology 
 Chemistry 
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Integrated Biosecurity Platform Strengths to Leverage 
The Integrated Biosecurity Platform deploys the strengths of Iowa’s institutions in human, animal, and 
plant disease prevention, protection, and treatment to establish an integrated approach to securing the 
environment, food production systems, and human health and safety. 
Key Industry 
Strengths 
 A small base of companies in the drugs and biologics sector, including 
vaccine development 
 Broad relevant industry base in agricultural production, agricultural 
chemicals, processing and transportation 
 A well-educated, productive workforce and workforce development 
system 
Strengths of Lead 
R&D University:  
University of Iowa 
Note:  It is anticipated that in the initial years of development the lead 
institution will be the University of Iowa.  This is based on an initial 
human approach to biosecurity based on the existing Biodefense 
Planning Grant and the focus on respiratory infectious diseases.  As 
biosecurity becomes a larger focus area in Iowa, Iowa State University 
will become increasingly engaged in a co-leadership position to provide 
integration of human health with animal health, agrosecurity, and 
environmental biosecurity. 
 
 Epidemiology 
 Infectious diseases 
 Microbiology 
 State Hygienic Lab with plans for significant expansion including BSL3 
facilities for handling of biological and chemical materials 
 Significant recent success in securing NIH funding for 
o Biodefense Planning Grant 
o Respiratory Pathogens Research Contract 
o Related program project grants 
 College of Public Health 
 College of Pharmacy 
 GMP drug and biologic production facilities 
Supporting Strengths: 
Iowa State University 
 Institute for Food Safety and Security 
 Agriculture and Home Economics Experiment Station and its associated 
centers/institutes including the Food Safety Consortium and the 
Biosafety Initiative for Genetically Modified Products 
 Center for Food Security and Public Health 
 Department of Homeland Security groups on animal diseases and on 
post-harvest food security 
 College of Veterinary Medicine 
 Animal infectious diseases and pathology 
 Plant diseases/plant pathology 
 Analytical chemistry 
 Environmental systems engineering, monitoring, sensors and controls 
 Linear Accelerator Facility 
 
Note: Iowa is also home to the USDA Animal Health Research Laboratory. 
Ground was broken in early 2004 on a $460 million renovation project for 
the center in Ames. 
Biomedical Imaging Niche Platform 
The University of Iowa has had significant recent success in securing funding and strong industry 
relationships in biomedical imaging, with a specific focus on advanced lung imaging systems and 
software.  In March of 2004, the Iowa Comprehensive Lung Imaging Center (I-Clic) opened to leverage 
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distinct strengths in quantitative imaging techniques applied to normal lung states and lung disease 
pathology.  I-Clic will provide researchers with access to a dedicated imaging center equipped with the 
latest state-of-the art imaging equipment.  The research team also will work closely with leading imaging 
equipment manufacturers in regards to future directions in imaging technologies. 
The imaging effort at the University of Iowa is combining the College of Engineering Imaging Group 
(CEIG) with the College of Medicine I-Clic, with the intent to create the Iowa Biomedical Imaging 
Institute.  This entity will cover image acquisition, new device development, very advanced image 
processing, image segmentation, image matching, image storage and retrieval, image display, and image 
analysis.  It is important to note from an economic development perspective that this group has strong ties 
to major industries (Siemens, Olympus, Stereotaxis, plus new drug discovery trials, etc.), very strong NIH 
support, strong input into public policy nationally in relation to imaging, and very strong FDA inter-
actions.  Business spin-offs are already occurring, with two companies (Vida Technologies and 
Endographics) that together have approximately $2 million in federal Small Business Innovation 
Research (SBIR) funding.  There are plans to merge both companies into a single entity.  The imaging 
effort is continuing to develop, with new faculty recruits.  In addition, the ISU linear accelerator facility 
might be leveraged to further these scientific pursuits. 
Given the importance of advanced biomedical imaging as a provider of new insights that lead to new 
biomedical discoveries, and the potential to work on imaging devices, algorithms, and software business 
opportunities, Battelle sees this as a short-term niche for development in Iowa.   
Longer-Term Core Competency Opportunities 
In addition to the broad technology platforms, several areas of emerging, longer-term opportunity 
represent the potential for additional sector development. These areas consist of relatively compact groups 
of people working in leading-edge fields, new formative centers just recently pulled together, or estab-
lished areas of expertise in which further investment in infrastructure and/or personnel are required to 
sustain or accelerate development momentum.  
These four longer-term opportunity areas are as follows: 
• Host-Parasite Biology and Systems—Examining the interaction and symbiotic beneficial relation-
ships between hosts and parasitic organisms, with an initial emphasis on immunologic response. 
• Instrumentation, Devices, and Sensors—Using Iowa’s skills in engineering, chemistry, biology and 
related fields to produce novel tools for instrumentation, analysis, invasive and non-invasive imaging, 
diagnostics, and biosensors.  An immediate opportunity exists in the area of Biomedical Imaging, 
with initial focus on lung imaging. 
• Formation of a Cardiovascular Research Institute—Mirroring Iowa’s success with The University 
of Iowa’s Comprehensive Cancer Center to build a similarly resourced and dedicated scientific 
institute for advancing cardiovascular and cardiopulmonary research and development. 
• Formation of a Free Radical Research Institute—Cementing Iowa’s existing world leadership 
position in free radical and oxygen biology research within a formal institute with associated facilities 
and funding. 
It should be noted that the list of near- or short-term competencies on which Iowa should focus will need 
to be nurtured and developed over the long-term as well.  A number of these near-term competencies are 
ready to be initiated and involve ISU as a key leader. In addition, other cross-cutting, enabling 
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technologies will affect the above long-term list, and investments will need to be considered.  One 
example of these technologies is the emerging bioinformatics capabilities at ISU. 
SUMMARY 
This assessment of Iowa’s position in the biosciences highlights a state that has significant promise to be 
among the nation’s bioscience leaders in selective fields. Iowa institutions have substantial strengths in 
the “three legs of the bioscience stool”—human, animal, and plant biosciences. In particular, the 
bioscience operations of both Iowa State University and the University of Iowa show fundamental 
bioscience technology platform strengths that can be further enhanced by increased collaborations 
between the institutions and with industry.8 
 
 
                                                 
8 Platforms are not intended to supplant or replace the existing structure of Iowa State University in its agbioscience 
work. Battelle notes that Iowa State University has established a well-structured suite of centers under the umbrella 
of the Plant Sciences Institute and other formal Presidential initiatives, and recognition of this is shown in its 
analysis and recommendations in the Phase I report, The State of Iowa Biosciences Path for Development: Economic 
and Core Competency Analyses. It is highly important to Iowa’s future in the BioEconomy that the ISU Plant 
Sciences Institute and its related centers continue to be funded and supported. 
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Iowa’s Competitive Position in the Biosciences: 
Building a Bioscience-Driven Economy 
KEY SUCCESS FACTORS 
Boston, San Diego, the San Francisco Bay Area, the Research Triangle Park region, and the 
Baltimore/Washington region are generally regarded as among the nation’s premier centers for research 
and testing and drugs and pharmaceuticals; Minneapolis, Memphis, and many others are leaders in medial 
devices.  For each segment of the biosciences, geographical concentrations vary.  For instance, Iowa 
stands out in agricultural biotechnology.  The state has a large base of employment (more than 5 percent 
of total U.S. employment) in the agricultural feedstock and chemicals subsector, a subsector that focuses 
on practical implementation of biotechnologies using bioresources.  In addition, the concentration of this 
industry in the state is 3.5 times that of the industry nationally.  A recent separate report identifies only 
two states, South Carolina and Tennessee, as having a higher concentration than Iowa in the agricultural 
feedstock and chemicals subsector.9 
Examining best practice states revealed a number of factors that have enabled these states to succeed in 
growing their bioscience bases. These success factors are highlighted below. 
Engaged universities taking an active leadership role  
Outstanding research universities are an absolute prerequisite for a state to become a serious contender in 
most areas of the biosciences, with the possible exception of medical devices (although this sector is also 
requiring more academic collaboration).  However, research 
stature must be paired with the ability to engage industry, 
directly or indirectly, to convert research knowledge into 
economic activity through technology transfer and commercial-
ization.  To do so requires that one or more of a state’s research 
universities become committed to engaging with and helping to 
build a local bioscience industry.   
Iowa Assessment.  Iowa’s regent universities demonstrate a 
growing willingness to engage in bioscience technology 
development, commercialization, and industry collaborations; 
but, a number of barriers (financial, operational, philosophical, 
and procedural) could prevent Iowa from having the type of 
university/industry relationships that drive other leading 
bioscience states.  For instance, the universities are generally not 
taking equity positions in companies in place of higher licensing 
fees and royalty payments on intellectual property. Also, it is 
unclear whether the State of Iowa is constitutionally prohibited 
from taking an equity position in a company. Both Arizona and Utah have amendments on their Fall 2004 
ballots for voter approval to enable universities to take equity in their intellectual property, and Oregon 
voters passed a similar measure in the Fall of 2003. 
                                                 
9 Battelle Technology Partnership Practice and SSTI.  Laboratories of Innovation: State Bioscience Initiatives 2004, 
www.bio.org, June 2004. 
Key Success Factors 
• Engaged universities taking an 
active leadership role 
• Intensive networking across 
sectors and with industry 
• Available capital covering all 
stages of the business cycle 
• Discretionary federal or other 
R&D funding support 
• Workforce and talent pool on 
which to build and sustain efforts 
• Access to specialized facilities 
and equipment 
• Stable and supportive business, 
tax, regulatory, and incentive 
policies 
• Patience and a long-term 
perspective 
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From a measurable quantitative standpoint, Iowa institutions have not excelled overall in terms of the 
impact that their research is having on economic development.  Table 9 compares Iowa universities on 
various metrics of technology transfer performance (as compiled by the Association of University 
Technology Managers [AUTM]).  These 3-year data compare the performance of the U of I and ISU with 
the nation as a whole and with three peer Midwest universities on selective measures developed by 
Battelle.  This table identifies seven normalized performance metrics to measure technology transfer 
performance of research universities.  As can be seen, Iowa’s universities typically perform in the median 
of all universities and, in several instances, even outperform the top quartile of all universities.  But, the 
metrics do suggest areas for improvement such as licensing of start-ups by all Iowa institutions and 
indicate variation among institutions on other measures. For example, in comparison to such leading 
Midwest universities as Wisconsin and Minnesota, Iowa’s universities do not fare as well in such 
performance metrics as licensing income and start-ups; although, measurable variation exists among 
Iowa’s research universities in terms of performance in these metrics.  
 
Table 9: Iowa Technology Transfer Performance 
 
Source: Association of University Technology Managers 
Intensive networking across sectors and with industry  
The most successful clusters facilitate extensive and intensive networking not only between academe and 
industry, but also within industry as well.  Momentum in bioscience development is built as bioscience 
company employees come together to share industry knowledge, brainstorm on potential scientific and 
technological advancements, discuss collaboration opportunities, mentor one another, and reach a shared 
agenda for advancing policies supportive of cluster growth.  In a few leading regions, like Silicon Valley, 
this networking has occurred naturally, with formal facilitating organizations coming quite late in the 
game.  However, in most states and regions, the organizations and networks designed to spur such 
catalytic interactions have been built from the ground up; otherwise, the desired degree, scale, and 
intensity of networking will not occur.   
Metric
University of 
Iowa Research 
Foundation
Iowa State 
University
University of 
Northern Iowa
University of 
Illinois-Chicago 
and Urbana-
Champaign
University of 
Wisconsin-
Madison/WARF
University of 
Minnesota
Top Quartile 
U.S. 
Universities
Median         
U.S. Universities
Total Sponsored Research Expenditures $794,976,617 $613,100,000 $6,779,779 $1,883,129,760 $1,820,604,000 $1,367,656,000 $757,655,364 $365,472,746
Invention Disclosures Received 237 329 3 616 918 683 319 134
Patent Applications Filed 232 225 4 401 548 460 240 106
U.S. Patents Issued 101 103 2 107 260 145 77 35
Licenses & Options Executed 94 713 5 211 401 233 78 30
Licenses & Options Yielding License 
Income 308 1181 8 482 609 684 166 66
Gross License Income Received $17,496,246 $14,561,640 $149,572 $21,484,331 $79,226,941 $65,741,410 $12,236,212 $2,871,721
Start-Up Companies Formed 3 9 1 23 13 28 10 4
Disclosures per $10 M Sponsored R&D 8.94 16.14 13.77 9.83 15.16 15.03 14.53 11.47
Patents Issued per $10 M Sponsored 
R&D 3.84 5.06 8.97 1.70 4.31 3.25 4.13 2.96
Licenses Executed per $10 M Sponsored 
R&D 3.53 34.78 26.78 3.39 6.60 5.17 4.13 2.74
License Income per $10 M Sponsored 
R&D $476,704 $572,437 $708,168 $191,435 $897,966 $1,086,003 $384,794 $148,659
Average Revenue per License $171,284 $35,761 $48,351 $133,728 $390,255 $293,552 $230,394 $117,105
Start-Ups per $10 M Sponsored R&D 0.10 0.44 5.49 0.36 0.22 0.63 0.59 0.30
Start-Ups per License Executed 0.08 0.04 0.25 0.33 0.10 0.36 0.56 0.33
FY 2000-2002 AUTM Licensing Data
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Iowa Assessment.  In Iowa, some elements of the bioscience industry are networking through the Iowa 
Biotechnology Association and the BIOWA Development Association. The Iowa Biotechnology 
Association (IBA) was formed in 1994 to advance opportunities in Iowa for the improvement of the 
human environmental and economic well-being through the development and application of value-added 
technologies in the life sciences. Working cooperatively, the members hope to enhance the ability to 
commercialize new technologies in a timely manner and reduce the lead time for deployment. Activities 
of the association are designed to give companies doing business in Iowa an edge in delivering timely 
new products to consumers through the sharing of ideas regarding the transfer and development of 
technologies.  IBA holds an annual statewide conference to promote issues and topics relevant to the life 
sciences and provide networking opportunities between industry, academia, and governmental organi-
zations. The BIOWA Development Association is a nonprofit organization that supports and promotes 
the growth and development of Iowa’s bioeconomy.  It defines bioeconomy as an economy where the 
basic building blocks for industry and the raw materials for energy are derived from plant-based 
(renewable) sources.  While both of these organizations are beginning to link Iowa’s bioscience 
community, they have limited resources and are still in early stages of development.  Iowa State 
University is also working to encourage networking through its Bioscience Mixer events.  Despite these 
organizational efforts, Iowa has not yet achieved the critical mass of events, companies, and participants 
required to generate catalytic interactions.   
Available capital covering all stages of the business cycle 
Leading bioscience states share one characteristic—they are home to an indigenous venture capital 
community that is oriented toward early-stage financing and committed to the growth of local companies 
and investment opportunities.  The presence of state-based capital and venture capital funds is critical to 
bioscience cluster development.  It is equally critical that adequate funding resources be available to 
support each stage of commercialization and business development—from the very earliest proof-of 
concept/prototype and pre-seed funding, to seed and venture capital rounds of A, B, and C financing.   
Iowa Assessment.  Currently, Iowa’s universities have extremely limited access to discretionary funds for 
the earliest stage of commercialization of their research innovations.  This is limiting the movement of 
ideas from bench to early-stage venture formation.  In other words, what is lacking is funding to build the 
“farm team,” from which some members will graduate to the “major leagues” where Series A venture 
financing normally begins.  While a limited number of venture funds exist in Iowa, only a handful at most 
are focused on the earliest stage, high-risk investments and even fewer on investment in bioscience 
business ventures.  Significant gaps are apparent in access to funding at each stage in bioscience venture 
growth in Iowa.  
The federal SBIR and Small Business Technology Transfer (STTR) Program is one source of early-stage 
funding.  Typically, most bioscience funding comes through the NIH SBIR program.  As Table 10 
indicates, SBIR funds flowing to Iowa have increased significantly during the past 3 years.  However, the 
state’s portion of total NIH national funding allocation is very small (0.5 percent on average). This 
percentage has not increased between FY 2001 and FY 2003, indicating that Iowa is failing to tap this 
large and growing source of very early stage capital. 
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Table 10: Iowa’s Level of NIH SBIR/STTR Awards 
 Iowa NIH 
SBIR/STTR Awards 
U.S. SBIR/STTR 
Awards 
Iowa as a Percent of NIH 
SBIR/STTR Awards 
FY 2001 $1,787,635 $419,448,220 0.4% 
FY 2002 $2,814,781 $496,178,981 0.6% 
FY 2003 $2,952,478 $541,494,021 0.5% 
Total 2001–2003 $7,554,894 $1,457,121,222 0.5% 
% Change 2001–2003 65.2% 29.1%  
 
While NIH SBIR funding is most closely related to the biosciences, SBIR programs funded through 
USDA and NSF also are relevant.  While Iowa’s percent of total U.S. SBIR/STTR awards is extremely 
small, there was a significant increase in SBIR funds awarded to companies in Iowa between FY 2001 
and FY 2002 (Table 11). 
 
Table 11: Iowa’s Total Level of SBIR/STTR Awards 
 Iowa Total 
SBIR/STTR Awards 
U.S. Total SBIR/STTR 
Awards 
Iowa as a Percent of U.S. 
SBIR/STTR Awards 
FY 2001 S2,186,836 $1,221,487,825 0.18% 
FY 2002 S5,914,136 $1,596,552,717 0.37% 
Total 2001–2002 S8,100,972 $2,818,405,542 0.29% 
% Change 2001–2002 170.4% 30.7%  
 
Finally, only $27 million of venture capital was invested in Iowa companies between 1998 and 2003.  Of 
this amount, $14.5 million or slightly more than 50 percent was invested in Iowa bioscience companies.  
However, the majority of the investment in the biosciences in Iowa occurred in one year—1998 
(Table 12). 
 
Table 12: Iowa’s Venture Capital Trends 
Year Total Venture Capital 
Investments 
Bioscience VC Investments Bio Share of Annual 
Total VC Funding 
1998 $24,161,000 $11,841,000 49.0% 
1999 $27,000,000 0 0.0% 
2000 $17,496,000 $700,000 4.0% 
2001 $4,350,000 0 0.0% 
2002 $2,000,000 $2,000,000 100.0% 
2003 $8,200,000 0 0.0% 
Total $27,091,000 $14,541,000 53.6% 
 
Recent state initiatives to address capital gaps, including formation of a fund of funds, the Iowa Values 
Fund, and tax incentives for investors, should help to position Iowa to secure additional funding for these 
bioscience ventures in the future. 
Discretionary federal or other R&D funding support 
Building generic R&D assets into an effective attractor of technology investment requires leverage of 
substantial, ongoing, external, discretionary funding.  Technology leaders like Silicon Valley, Boston, and 
San Diego were able to leverage decades of heavy defense contracting, while Baltimore and Washington 
leveraged growing congressional support of federal laboratories operated by the NIH, National Institute of 
Standards and Technology, and the FDA.  
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Iowa Assessment.  Iowa has some federal institutions directly relevant to bioscience development, 
including the Ames Laboratory of the Department of Energy and the USDA’s National Centers for 
Animal Health, also in Ames.  The National Centers for Animal Health is particularly relevant because 
President Bush’s proposed 2005 budget includes $178 million to complete a million-square-foot addition 
and renovation of the laboratories. The money would finish the project at a total cost of $460 million. 
Iowa thus has assets to leverage and build upon, but to date these resources have not proven to be key 
drivers of commercial bioscience and cluster development in the state.   
As discussed previously, from the standpoint of academic funding for R&D, the State of Iowa is 
performing well for its size. With $439.8 million in research funds, Iowa ranks 24th in total university 
R&D funding (according to the NSF)—notably exceeding its population rank of 30th.  Within the 
academic R&D arena, the state is performing particularly well in the biosciences, with 66 percent of all 
academic research funds falling under this definition. This level of performance places Iowa 21st in the 
nation.  
Iowa’s comparatively strong performance in bioscience R&D cannot, however, be taken for granted. The 
biosciences are a key target for growth in many states; and, in recent years, Iowa’s total growth in 
bioscience funding has not kept pace with that of the nation—resulting in a slightly declining bioscience 
R&D market share of total academic R&D. 
Workforce and talent pool on which to build and sustain efforts.   
Like any knowledge-based industry, bioscience companies need a supply of qualified and well-trained 
scientists, technicians, managers, and production and support personnel.  Successful bioscience regions 
contain a critical mass of experienced management and entrepreneurial talent, in combination with 
sufficient job opportunities to attract and retain world-class researchers, scientists, and technical 
professionals.  Furthermore, these successful regions have coordinated workforce training, skills 
development, and other programs to provide basic and customized public workforce education in close 
partnership with industry.   
Iowa Assessment.  In 2002, Iowa had about 6,000 people employed in biological science occupations, as 
illustrated in Figure 10.  More than half were employed as medical and clinical laboratory technicians.  
Another quarter were employed as agricultural, food and nutrition scientists and technicians.  Fourteen 
percent were employed as biological scientists and technicians, and 4 percent were employed as 
biomedical and biochemical scientists and engineers.10 
The comparatively small size of the commercial bioscience sector, in combination with Iowa’s 
traditionally strong K-12, community college, and university strengths, have proven adequate in 
supplying the necessary scientific and production talent for bioscience growth.  However, it is clear that 
the base of experienced managers for bioscience companies is thin, and the growth of companies will be 
limited if experienced management teams are not readily available for start-up and growing enterprises.  
Also, more jobs are needed in the state to absorb the talent pool graduating from these institutions. 
                                                 
10 U.S. Bureau of Labor Statistics Occupational Employment Statistics and Battelle calculations, FY 2000–2002.  
Data are averages of FY 2000–2002 information. 
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Figure 10:  Biological Science Occupations in the Iowa Workforce, 2000–2002 
Access to specialized facilities and equipment 
Pursuing bioscience advancement takes considerable resources, among the most costly of which are the 
specialized facilities, infrastructure, and equipment required for bioscience R&D and production 
activities.  The extremely high costs of specialized equipment can rapidly absorb the scarce financial 
resources of start-up enterprises, placing their development potential and futures at risk.  Successful 
bioscience regions have a variety of specialized incubators, facilities, and supporting infrastructural 
resources required to meet fledgling company needs.  Start-up enterprises are able, in these regions, to 
lease wet-lab space, rent time on specialized equipment, and access prototyping and piloting resources 
locally.  
Iowa Assessment.  Iowa has made considerable progress in this area—with on-the-ground investment in a 
series of highly valuable bioscience resources (such as GMP facilities, drug development services, animal 
labs, catalyst development centers, fermentation facilities, virtual reality labs, and biomass conversion 
facilities).  These resources are of great value, and difficult for other states to quickly replicate.  Further-
more, Iowa is seeking to expand its resources in this area with new high-level biosecurity and hygienic 
lab facilities in Iowa City and state-funded bioprocessing facilities on ISU’s research park in Ames.  It is 
evident that in plant, animal, and human biosciences, Iowa has some strong infrastructure resources to 
leverage in support of the core bioscience platforms identified earlier in this report. 
In addition, both Iowa State University and the University of Iowa have research parks that are home to a 
wide array of biotechnology companies. Three incubators affiliated with Iowa State University service 
biotechnology companies; and the Technology Innovation Center at the University of Iowa fosters new 
business ventures, including bioscience firms. Two additional incubators are under development in 
Davenport and Cedar Valley, and the University of Northern Iowa has incubator development plans 
underway. 
 Iowa’s Bioscience Pathway for Development 
 
 37 
Stable and supportive business, tax, regulatory, and incentive policies 
Bioscience companies need a regulatory climate and operating environment that encourage and support 
the growth of their industry.  The ideal environment combines tax and incentive policies that recognize 
the long development cycle required to bring new bioscience discoveries to market, combined with a 
political environment that expresses a long-term and reliable commitment to the needs of the industry.  
Business development and growth incentives need to be easy to understand, easy to apply for, and 
relevant to the specific needs of the bioscience sector.   
Iowa Assessment.  In Iowa, the state has made considerable progress in formulating specialized business 
support programs and easing access to them through a single pre-application administered by the IDED.  
In building a more supportive environment, however, improvements are needed in areas such as tax code 
and legislative support for cluster initiatives. For instance, Iowa has a technology transfer tax credit that is 
currently unworkable and needs to be revised in order to be useful in spinning off firms.  In addition, 
Iowa has an R&D tax credit; however, it is not transferable and so of limited value to early-stage 
bioscience firms that are not yet generating income.  Many states assist bioscience firms by allowing them 
to carry over net operating losses.  Iowa could consider these and other initiatives to support the state’s 
bioscience firms. 
Patience and a long-term perspective 
A short-term perspective will not work in bioscience-based economic development (or in any true effort 
to build and restructure an economic base).  The lesson to be learned from each of the most successful 
technology states and regions is that success takes time.  Silicon Valley and Route 128 trace their origins 
in electronics to the 1950s and in biosciences to the 1970s.  Research Triangle Park represents a 50-year 
strategy that has only recently found its footing in the biosciences and is still working to develop full 
capability in the entrepreneurial sector.  In contrast, Maryland and San Diego are considered as “coming 
on quick;” but, both still took 12 to 14 years to really develop.   
Iowa Assessment.  The building of Iowa as a center for agriculture, farming equipment, and other visible 
Iowa sectors did not occur overnight—they grew with concerted efforts over many decades to accomplish 
their national stature.  Bioscience development requires a long-term effort to which the state must solidly 
commit. Due to gubernatorial and legislative leadership, Iowa has emerged as both a large and specialized 
state in agricultural feedstocks and chemicals, one of five key industry segments that make up the 
biosciences. 
Summary of Key Success Factors 
Table 13 compares the lessons learned from the best practices of other states in bioscience economic 
development with Iowa’s current situation. 
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Table 13:  Comparison of Iowa to Best-Practice States and Regions on Key Success Factors 
Factors of 
Success 
Best Practice 
States/Regions 
Iowa 
Situation 
Engaged 
universities 
taking an 
active 
leadership 
role 
 Universities are engaged in 
economic development and 
committed to technology transfer. 
 Universities have created 
vehicles for technology 
commercialization. 
 Universities committed to in-state 
economic impact of technology 
transfer and commercialization. 
 Universities appear willing to take a 
stronger role in economic 
development, but lack the resources. 
 Policies, procedures, and perceptions 
hamper university faculty 
engagement in start-ups and industry 
collaboration. 
 Investment and vehicles required to 
facilitate technology commercial-
ization activity. 
Intensive 
networking 
across 
sectors and 
with industry 
 Active technology intermediary 
organizations provide a focal 
point for state’s bioscience and 
biotechnology efforts. 
 These organizations play a 
critical role in networking 
academic, industry, 
governmental, and nonprofit 
groups, encouraging cross-
fertilization of ideas and 
opportunities that lead to joint 
endeavors. 
 State has a technology office or 
senior bioscience advocate to 
promote industry liaison and 
support. 
 Industry environment is such that 
next-generation spin-offs 
regularly occur and may be 
actively encouraged by 
“parenting” companies. 
 IBA is small and only has one full-
time staff member. Limited in ability to 
provide wide range of events and 
interaction opportunities.  
 BIOWA Development Association is 
embryonic but is getting industry, 
academe, and government in 
alignment on BioEconomy issues and 
opportunities. 
 ISU is operating bioscience mixers to 
encourage industry-to-industry and 
industry-to-academe links. 
 There is no state technology office or 
bioscience advocate. 
 The few larger bioscience-related 
companies in Iowa are controlling IP 
closely and are not generating a 
major web of spin-offs. 
 There is no strong history of a 
university genealogy tree of 
bioscience spin-offs. 
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Table 13:  Comparison of Iowa to Best-Practice States and Regions on Key Success Factors (continued) 
Factors of 
Success 
Best Practice 
States/Regions 
Iowa 
Situation 
Available 
capital 
covering all 
stages of the 
business 
cycle 
 Best practice states and regions 
have created programs to 
address the commercialization, 
pre-seed, and seed financing 
gaps to help establish firms. 
 Active informal angel networks 
are investing in the biosciences. 
 Established, in-state venture 
capital firms are investing in 
biosciences and linked to major 
out-of-state VC leaders for 
syndicated investments. 
 Public and philanthropic 
investment funds support early-
stage business development and 
assist in bioscience business 
growth. 
 Limited pre-seed/seed capital or 
prototype development funds are 
available. 
 Some venture capital and angel 
investors are in Iowa, but very few 
are interested in bioscience 
investments. 
 National venture capital firms 
generally lack interest in and 
awareness of Iowa bioscience 
investment opportunities. 
 Limited philanthropic community is 
not focused on major investment in 
economic development. 
 Agriculture-related organizations are 
able to invest in value-added ag and 
other agbioscience endeavors. 
 State Values Fund and additional 
initiatives support business 
development initiatives. 
Discretionary 
federal or 
other R&D 
funding 
support 
 Every major technology region in 
the U.S. has received significant 
federal discretionary funding. 
 One or more federally designated 
centers exist that serve as 
anchors for the state’s or region’s 
bioscience base. 
 Iowa universities are gaining a solid 
share of federal R&D dollars (ranked 
above state population rank). 
 Federal investment is being made in 
animal health facilities (expanding), 
and opportunities exist in biosecurity. 
 State and federal support exists for 
alternative energy and related 
biomass facilities. 
Workforce 
and talent 
pool on 
which to 
build and 
sustain 
efforts 
 Strong track-record exists in 
developing internal talent and 
attracting new talent to the state. 
 Major base of management talent 
is experienced in cluster and 
entrepreneurial endeavors. 
 Educational institutions at all 
levels are responsive to the 
training of students to meet the 
need for bioscience workers at all 
skill levels, including scientists, 
technicians, and production 
workers. 
 Historically, Iowa has a high quality of 
K-12 education, and growing 
strengths in career academies 
(although none in biosciences yet). 
 Very strong community college 
system is quick to react to the 
workforce training needs of industry 
(including bioscience industry). 
 Very good quality of degreed 
scientists graduate from regent 
universities. 
 Industry expresses satisfaction in 
ability to recruit scientists and R&D 
personnel. 
 Iowa is losing younger adults 
because of lack of job opportunities 
and also a perceived lack of “things to 
do.” 
 Very shallow pool of experienced 
entrepreneurial talent and start-up 
managers exists in the biosciences. 
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Table 13:  Comparison of Iowa to Best-Practice States and Regions on Key Success Factors (continued) 
Factors of 
Success 
Best Practice 
States/Regions 
Iowa 
Situation 
Access to 
specialized 
facilities and 
equipment 
 Leading bioscience regions have 
private markets that provide 
facilities offering space for 
bioscience companies. 
 Specialized bioscience research 
parks, incubators, and 
accelerators are common. 
 Access to specialized facilities 
and equipment, such as core labs 
and animal facilities, is readily 
available for industry and 
collaborations. 
 ISU is operating incubators, but they 
are near capacity.  U of I is operating 
incubator at Oakdale Research Park.  
UNI incubator is planned. 
 ISU and U of I incubators are familiar 
with bioscience needs. 
 Conflict of interest and other 
procedural impediments reduce 
faculty entrepreneurial access to 
university resources. 
 Several key facility and equipment 
investments have been made to 
support the biosciences, including 
GMP facilities, drug development 
services, biomass conversion 
facilities, chemical catalyst 
development facilities, bioreactors, 
etc. 
 Current interaction between industry 
and bioscience resources is limited, 
as is equipment located within regent 
institutions. 
Stable and 
supportive 
business, tax, 
regulatory, 
and incentive 
policies 
 Incentives encourage growth of 
technology-driven firms through 
modern economic development 
tool kit. 
 Tax structure is designed to 
encourage and reward R&D. 
 Government resources, 
incentives, and funding are easy 
to access. 
 Brand name/image established 
around specific technology areas. 
 Varieties of economic development 
incentive and assistance programs 
are offered through the state, with 
single pre-app facilitation. 
 Tax structure, and some incentive 
structures, is not yet aligned to needs 
of bioscience or other R&D-based 
growth technology sectors. 
 Cost for business operations is 
reasonably low vs. coastal locations 
and many other major markets. 
 Iowa does not yet have an 
established bioscience marketing 
campaign, although agricultural 
heritage and BioEconomy advance-
ments are helping on agbiosciences.  
State is making major commitment to 
high-profile events, such as Bio 2004. 
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Table 13:  Comparison of Iowa to Best-Practice States and Regions on Key Success Factors (continued) 
Factors of 
Success 
Best Practice 
States/Regions 
Iowa 
Situation 
Patience and 
a long-term 
perspective 
 Building a critical mass of 
bioscience resources and firms 
occurs over many years or 
decades. 
 Companies are built locally, 
retained locally, and not apt to 
leave. 
 Universities, government, non-
profits, philanthropies, and 
industry trade groups are in 
agreement and alignment on 
long-term commitment to growing 
and supporting the sector. 
 States are willing to accept that 
cluster development requires 
geographic co-location benefits 
and that one or two metro areas 
may benefit more from the cluster 
initially until state tax returns can 
be used to spread benefits 
throughout state. 
 Commercial biosciences are a 
relatively new focus for Iowa except 
for ag-related bioscience. 
 Lack of capital is causing some lack 
of local anchoring of technology start-
ups.  Movement out of state to follow 
capital is causing discouragement in 
Iowa. 
 No formal alignment or shared 
strategy on biosciences serves as a 
driver for Iowa’s economic 
development across all leading 
organizations and groups. 
 Lack of recognition of the state-wide 
agricultural industry as a key element 
of the state’s bioscience industry is 
compounded by the misperception 
that only those activities related to 
university research parks make up 
the bioscience industry, creating 
tension regarding funding of key 
university bioscience investments that 
will benefit the entire state. 
 
STRENGTHS, WEAKNESSES, OPPORTUNITIES, AND THREATS ANALYSIS 
This section presents an analysis of the strengths, weaknesses, opportunities, and threats (SWOT) facing 
the region in building a bioscience sector for the future. This analysis is based on more than 500 
interviews conducted with leaders from industry, academia, government, and technology intermediaries, 
in addition to data analysis conducted earlier.  This analysis was accomplished through one-on-one 
interviews, small group discussions, and focus groups involving leaders throughout the state.   
This SWOT analysis follows a methodology similar to a business planning process. In preparing its 
business plan, a company undertakes a similar exercise, identifying its internal strengths and weaknesses 
and taking into account and addressing external factors, including markets and opportunities and adverse 
events and threats. In the following review, Iowa’s bioscience base is examined much as a business would 
examine itself. It should be understood that, in some instances, perceptions of a significant nature have 
been included.  While such perceptions may not be universally supported, they become potential barriers 
if believed to be true, and therefore must be overcome. 
Strengths  
The State of Iowa and some of its key communities are recognizing the biosciences as a distinct area of 
development opportunity and, as a result, are putting in place key initiatives.  
The State of Iowa has been quite innovative and flexible in the development of incentive and assistance 
programs for Iowa industry.  A distinct economic development emphasis has been and continues to be 
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placed on the biosciences as an economic development focus area.  Recently, the State of Iowa has 
allocated significant funding for marketing Iowa as a prime location for bioscience development and 
business locations.  Iowa’s government and associated institutions are making progress in providing 
specific economic-development assistance products and services to encourage bioscience development 
and commercialization in the state.  The Iowa Values Fund, for example, is capable of providing direct 
assistance to bioscience companies for improvements to space (including leasehold space); and the state 
has shown unusual flexibility in meeting bricks-and-mortar space needs for companies. Similarly, 
communities such as Ames and Davenport are examining ways to support and grow bioscience-related 
businesses, products, and services.  For example, the Ames Chamber of Commerce, in collaboration with 
city and county government and ISU, is promoting Ames as a biotechnology hub. The Iowa Legislature 
also has been active, introducing 16 bills related to ag-biotech and bioscience, and passing four. The 
legislation introduced in Iowa has decidedly favored biotechnology, supporting ag-biotech as an 
important tool that can help Iowa maintain its position as an agricultural leader. 
Iowa is addressing current workforce needs and is developing additional programs and initiatives to 
enhance workforce development, attraction, and retention for the bioscience industry. 
Most bioscience firms interviewed indicate that they have been able to find quality workers.  This is 
further confirmed in a recent study11 by Ruth Consulting of 50 Iowa bioscience firms.  Companies 
indicate that they are experiencing positive recruitment trends, most particularly for scientific and 
production positions. At the 4-year and graduate-degree levels, both ISU and the U of I are viewed as a 
source of graduates with a good work ethic and attention to quality; companies have experienced low 
turnover rates from such hires.   
The State of Iowa has been particularly progressive in developing support initiatives for workforce 
development, including new job training programs that may use tax-exempt bonds and industrial revenue 
bonds (IRBs) to fund training.  Colleges can issue IRBs and then have the debt retired through payroll 
taxes. Up to 50 percent of on-the-job salary reimbursement during training can be offered.  Incumbent job 
training funding is available up to $25,000 a year for on-site customized job training (using own or hired 
instructors).  The 260G program provides funding for workforce enhancement in new areas where skill 
gaps in the Iowa workforce are identified or expected to occur, with 20 percent of the training cost paid 
by industry, and the remaining 80 percent supported through a grant program and diversion of payroll 
taxes from existing workforce payments.  In addition, IDED’s Human Resource Consortium is working to 
recruit people back to Iowa.  This professionally operated program is holding national events in which the 
Governor participates.  Using alumni lists provided by state universities, IDED is building a database of 
14,000 alumni interested in receiving further news and information about Iowa. 
Iowa also has placed an emphasis on support for 2-year programs and workforce skills training, a process 
facilitated by the large and innovative community college system.  Workforce education and development 
in Iowa benefits from a strong and dynamic community college system, which comprises 15 institutions.  
Iowa’s community colleges serve a broad constituency.  For example, Kirkwood Community College has 
15,000 students, making it the third largest higher education institution in Iowa.  Between 87 and 
90 percent of community college graduates remain in Iowa after graduation. 
                                                 
11 Swim, Bill, Ph.D.  A Training Needs Assessment of 50 Iowa Biotech Companies.  Ruth Consulting Group Limited 
for the Iowa Department of Economic Development.  2004. 
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Technology infrastructure, including research parks, incubators, and other commercialization space, 
exists, particularly around research universities; although unmet needs remain.   
Both the University of Iowa and Iowa State University have research parks close to their main campuses 
(ISU’s park is adjacent to the campus, while the U of I park is at Oakdale, 8 miles from the main campus).  
In both cases, these research parks contain incubator space.   
In addition to the incubators, access to space for business start-ups at the regent universities has been and 
continues to be addressed.  ISU has demonstrated flexibility in allowing limited use of main campus lab 
space and facilities in the earliest stages of research commercialization.  ISU also maintains new 
incubator space for plant sciences ventures within the Carver Co-Lab.  The main ISU incubator at the 
research park contains 8,500 square feet of space, all of which is currently full.  But, other university and 
non-university communities have technology infrastructure issues that need to be addressed. 
Iowa’s research universities show strengths in a number of technology platforms for both the short and 
long term, and both faculty and administrative interest exists in partnering with industry in technology 
transfer and commercialization efforts.   
Within the academic R&D arena, the state is performing particularly well in the biosciences, with 
66 percent of all academic research funds falling under this definition. This level of performance places 
Iowa 21st in the nation. Iowa’s rankings in the three major macro-categories of bioscience R&D are 19th 
in medical sciences, 20th in agricultural sciences, and 22nd in biological sciences. While in all three cases 
Iowa’s performance exceeds its ranking among the states in population, a higher ranking in federal funds 
for agricultural sciences might be expected given the state’s strengths in agriculture. 
Iowa has significant promise to be among the nation’s bioscience research leaders in selective fields. Iowa 
institutions have substantive strengths in the “three legs of the bioscience stool”—plant, animal, and 
human biosciences. In particular, the bioscience operations of both ISU and U of I show fundamental 
strengths in bioscience technology platforms that can be further enhanced by increased collaborations 
between the institutions and with industry. 
Both ISU and the U of I have made considerable progress in structuring their programs, projects, centers, 
and initiatives to facilitate the commercialization of innovation.  The Kaufmann Foundation has provided 
limited funding to an ISU planned initiative to utilize experienced faculty entrepreneurs as mentors to 
other faculty start-ups. ISU has allowed companies to start on campus and provided access to laboratory 
space for preliminary needs, while also facilitating more formal relationships at the ISU incubator and co-
lab facilities.  ISU’s interest includes working with existing bioscience firms in terms of expansion and 
new product development.  For example, Proliant (while not a university-related start-up) has had 
excellent access to ISU resources, including using labs, renting pilot space, and performing collaborative 
studies. 
The ISU Extension activities play a very important role in linking the university and its pragmatic 
research discoveries to the agriculture, processing, and industrial sectors.  The ISU Extension is a 
substantial $78 million operation and impacts critical areas of the Iowa economy through the operation of 
multiple services, including the Iowa Manufacturing Extension Partnership, the CIRAS, Extension to 
Agriculture and Natural Resources, 4-H youth development, and a broad suite of continuing education 
and communications services. 
The U of I Law School, College of Business, and College of Medicine are working to form a biomedical 
venture group with faculty, staff, and students to help faculty move their commercialization concepts 
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forward.  The U of I College of Medicine has appointed one of its physicians (an experienced 
entrepreneur) as Director for Economic Development and is actively engaged in preliminary work to 
encourage entrepreneurship and provide mentoring through experienced faculty entrepreneurs.   
The State of Iowa has a broad and growing base of bioscience companies, many of which have high 
profiles in their respective bioscience sectors.  Companies such as Pioneer in agricultural biotech and 
Fort Dodge Animal Health in veterinary medicine help to place Iowa on the bioscience corporate 
radar. 
Almost 83,000 people were employed in the biosciences in Iowa in 2002.  Three bioscience subsectors, 
organic and agricultural chemicals, agricultural processing, and agricultural machinery and equipment, 
are well positioned to be the foundation of a comprehensive economic-development strategy. Medical-
related subsectors, though not yet core strengths, demonstrate characteristics that place them in the 
category of emerging potential drivers.  Above-average employment growth relative to the United States 
indicates that these subsectors can be crucial parts of the bioscience industry’s future. 
In addition, the bioscience industry is geographically dispersed across the state. While bioscience 
companies are concentrated in the Ames–Des Moines and Iowa City–Cedar-Rapids corridors, the 
bioscience commercial sector is quite broadly distributed geographically in the state, with companies as 
far afield as Sioux Center and Eddyville. 
Iowa’s long-term history in industrial and agricultural production provides an infrastructure and 
resource base suited to the support of certain bioscience platforms. 
Iowa is well positioned and structured to provide efficient distribution of the bulk and specialty products 
that result, or may result, from the BioEconomy initiatives.  The state has in-place infrastructure that 
currently carries bulk chemicals and agricultural commodities from the state to external processing 
locations—a resource that will be equally useful for chemicals, fuels, plastics, and fiber from 
biorenewable resources and for advanced food ingredients and finished products from the Advanced 
Foods and Feed Platform.  Iowa’s agricultural heritage also provides multiple advantages for bioscience 
development, including convenient access to bulk biomass feedstocks and a growing expertise in value-
added product production from agricultural raw materials and resources.  Iowa has great state pride in its 
agricultural heritage, and the ag-biosciences (both plant and animal) are a natural technology pathway for 
building upon this strength and legacy of expertise.  Iowa also has been a leading adopter of new 
technology in agricultural production, and its primary agricultural production and ag-processing sectors 
are technology savvy. 
Iowa provides a stable quality of life that holds appeal in a time of change and uncertainty.   
Iowa is a state of small towns and cities with a small-town feel.  The state enjoys a comparatively low 
cost of living, low crime rates, short commuting times, and an excellent public education system.  People 
seem to put down roots in the Midwest, and the state is having considerable success in winning people 
back who had once left to pursue opportunities on the East and West Coasts.  There is a sense of place in 
Iowa that evokes longevity and security, an atmosphere that may be intangible but nonetheless valuable in 
an American society that is increasingly stressful and perhaps insecure.  Iowa also is an egalitarian state in 
which no single place dominates state politics and progress—it is a place of dispersed population, 
employment, and resources. 
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Weaknesses 
To take full advantage of its research base, Iowa needs to find ways to address a lack of experienced 
bioscience entrepreneurs and managers who can fulfill management duties in new start-ups or provide 
mentoring to new bioscience enterprises.  
Lack of experience makes new businesses a more high-risk venture and makes the attraction of seed and 
venture capital that much more difficult. Because a fully mature cluster of firms with successful role 
models that have grown to become mid-sized and larger firms has not yet occurred, most firms are still 
small in size and have few experienced resources and support structures. There is a relative lack of 
experienced serial entrepreneurs with bioscience company expertise available for hire by start-ups and 
growing small firms.  Instead, these seasoned professionals have to be recruited from outside the state, 
whether as chief executive officers, chief operating officers, chief financial officers, or in senior sales and 
marketing positions.  Overall, Iowa lacks an ingrained entrepreneurial culture that encourages and 
rewards risk taking. 
Furthermore, such firms need and desire more mentoring and advice. While the Pappajohn Centers are in 
the coaching business, they are insufficiently staffed and lack the depth of experienced bioscience entre-
preneurs to offer in-depth assistance.  Companies interviewed cited the Pappajohn Centers as useful for 
performing market research and other basic tasks and also for providing access to interns for bioscience 
companies.    
There is lack of sufficient wet-lab space in some areas of Iowa, particularly for seed and pre-seed stage 
entrepreneurial endeavors.   
In one sense, the unmet demand for space is a positive sign of growth and development.  On the other 
hand, even more mature bioscience regions of the country face challenges in offering sufficient lab space.  
Access to university lab space could facilitate early-stage commercialization investigations; but, legal, 
financial, and other community factors restrict such access.  In addition to the problem of available space 
is the location of that space.  Particularly with research and testing and drug and pharmaceutical firms, 
entrepreneurs want to be close to medical schools and centers.  The U of I research park/incubator, for 
example, is perceived to be too distant from the university.   
The perception among entrepreneurial faculty, investors, and bioscience industry leaders is that Iowa 
university-based entrepreneurial activity and momentum are being constrained by mixed institutional 
messages and support for the biosciences, including its commercialization in the state. 
Universities feel the pressure from the state to be economic development engines, but do not believe they 
are receiving the support required to facilitate this enhanced mission.  Higher education state funding is 
down $105 million, or 15 percent, since FY 2001, and the line item for economic development that has 
supported much of the technology transfer and commercialization efforts at universities has been reduced 
by more than 60 percent in the same time period.  These cuts are seen as limiting the ability of the 
universities to respond to the commercialization challenges and criticisms regarding entrepreneurial 
support and assistance capacity. 
While varying among the research institutions, and most strongly expressed at the University of Iowa, 
concerns were expressed with Board of Regents policy and direction.  Faculty does not perceive an 
institutional imperative to commercialize their research and see little incentive to do so.  As a result, there 
is a relatively low volume of entrepreneurial faculty coming forward at the regent universities.  While 
bioscience-based economic development is understood by many in academia to be a key priority for the 
 Iowa’s Bioscience Pathway for Development 
 
 46 
state, faculty remain unsure of the seriousness of the state commitment given the current restraints and 
barriers, whether they be starting spin-off firms or commercializing their intellectual property.   
Encouraging the state’s researchers to assist in economic development will require changes in university 
internal reward systems and require appropriate peer approval and recognition.  Some of the key issues 
that need to be addressed, as identified in the interviews, include the following: 
• Access to space for firms and for technology commercialization 
• Change in policies to allow for academic release time to pursue entrepreneurial endeavors in addition 
to academic recognition regarding leave for entrepreneurial pursuit 
• Conflict-of-interest/conflict-of-management policies, their interpretation and management 
• Timely disposal and response to disclosures, patents, and licensing decisions 
• Lack of commercialization tools, such as market and technology assessment support and prototype 
development funds 
• Limited support in finding licensees of intellectual property 
• Willingness to offer cutting-edge approaches to partnering with industry, e.g., taking equity rather 
than fees/royalties, start-up licenses, etc.  (Note: While supposedly permitted to take equity, the 
universities report few instances in recent years of doing so, even though this is an accepted national 
practice in public as well as private research universities.)   
• Lack of state-based pre-seed/seed financial support. 
Resources appear insufficient to allow the technology transfer and licensing operations of Iowa’s 
public universities to move at a “commercial pace.”  Companies and entrepreneurs raised concerns 
regarding multiple cases in which processes took many months to advance. 
As is true of most public research universities in the country, technology transfer at Iowa universities has 
limited staffing and resources.  This results in an inability to move as quickly as the technology transfer 
professionals might desire because of large workloads.  It also means some important but not critical 
work, such as identifying partners, conducting outreach, and providing support for the SBIR program may 
not be conducted.  Major issues appear to be related to (1) amount of time taken to process intellectual 
property disclosures and reach decisions; (2) university efforts to place too high a value on only the 
research, resulting in protracted negotiations; and (3) a perceived conservatism and fear that after home 
runs happen, the university will be accused of failing to capture the full value. 
As the AUTM data indicate in Table 9, Iowa’s universities perform in the median of all universities and, 
in several instances, even outperform the top quartile of all universities.  But, the metrics do suggest areas 
for improvement such as licensing of start-ups by all Iowa institutions and indicate variation among 
institutions on the other measures. Furthermore, it is not the general practice for universities currently to 
take equity positions in companies in return for providing a low license and royalty on intellectual 
property.  However, there appears to be ambiguity about how and whether universities can take equity.  
ISU’s ISURF believes it can take equity in lieu of license fees and anticipates becoming more active in 
the future.  In addition, UNI Research Foundation has begun taking equity stakes in start-up ventures.  
The State of Iowa is not able to take an equity position in a company since there are constitutional 
restrictions on such activity; creative ways are required to overcome this problem.  Both Arizona and 
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Utah have amendments on their Fall 2004 ballots for voter approval to enable universities to take equity 
in their intellectual property, and Oregon voters passed a similar measure in the Fall of 2003. 
Overall, successful commercialization of bioscience discoveries and technologies in Iowa may require a 
comprehensive review of policies and relaxed return expectations at the IP-generating universities. By 
adopting policies that are more flexible for companies forming and operating in-state, the regent 
universities may enhance the market value of this intellectual property, attract additional research stars 
who are increasingly attracted to opportunities for commercialization, and further contribute to the state’s 
economic future. 
Capital gaps for the biosciences exist, with the biggest gap being in the pre-seed and seed stages of 
support (investments less than $2 million). 
On the commercialization front, financing for start-ups, spin-offs, and younger bioscience firms has been 
difficult to secure in Iowa. There is an evident lack of pre-seed, seed, and venture capital available in 
Iowa to fund new ventures in the biosciences. Lack of local capital resources is limiting entrepreneurship 
on campuses and reducing the volume of innovation-based companies in the state. The scarcity of venture 
capital was confirmed in interviews with multiple start-up companies in the state.   
Research leaders throughout the state note a significant need for seed capital and pre-seed funds.  Because 
Iowa’s venture capital firms are not interested in the very early seed stage—instead they are mostly active 
in the second and third venture capital rounds for companies that have reached market and a certain 
threshold of success—capital availability for start-up enterprises is scarce.  Some local angels have been 
involved in university-originated start-ups, but the volume of activity is quite limited. Seed funding 
organizations (angel networks, community seed funds, etc.) are not coordinated or well connected and 
need mentoring and investment guidance to make bioscience investments. While the State of Iowa has 
numerous programs that provide incentives through tax credits to companies, they do not appear to be 
well structured for bioscience firms that are not generating taxable income in the near term. 
None of the Iowa-based venture capital firms interviewed by Battelle were able to name a venture-backed 
bioscience company in Iowa that has gone on to be a substantial growth success, e.g., role model.  In 
addition, some former players in the biotech and bioscience venture capital arena are now no longer 
interested in this sector.  To maximize their limited investment dollars, several Iowa VC firms are making 
many investments in out-of-state deals.  The largest fund interviewed, for example, only has three Iowa 
investments out of a total of 13.  
Finally, while the largest public pension fund in Iowa does invest in venture capital, it utilizes 
discretionary professional managers who select the funds for investment. There is no specific focus on the 
biosciences or on investments in Iowa. Deals in Iowa are forwarded to the funds for consideration, but 
there is no state-enacted incentive or investment guarantee to address fiduciary concerns. Several other 
state pension funds (Pennsylvania, Maryland, Oregon, California, and Wisconsin) have become involved 
in efforts to accomplish the dual objectives of targeted investments in the biosciences and attention to in-
state firms in ways that are consistent with their respective fiduciary standards of return on investment. 
Iowa’s public pension fund may wish to examine ways, working with its discretionary professional 
managers and reviewing the experiences of other state pension funds, in which it might contribute to 
addressing the capital gaps facing bioscience firms in the state. This must be done in accordance with its 
policies, legislative base, and stated return-on-investment policy. 
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Recent state initiatives to address capital gaps, including formation of a fund of funds, the Iowa 
Values Fund, and tax incentives for investors, should better position Iowa to secure sufficient 
funding for these bioscience ventures in the future.  Specifically, IDED is offering the following 
innovative programs to assist firms in accessing state programs and capital resources: 
• A single pre-application for assistance that serves to inform IDED staff who will work to find the 
right package of state programs to meet company needs.   
• The Iowa Values Fund, which includes business development and assistance for start-ups or 
expansions as part of its core focus.12   
• The Iowa Fund of Funds, an initiative formed under legislation to create the ICIC and the ICIB.  ICIC 
is working to build the Fund of Funds, which will be organized as a private, for-profit limited 
partnership, authorized to make investments in private venture capital funds (which must have or 
commit to establishing a base of operations in Iowa).  In addition, ICIB has been established to 
oversee the issuance of tax credits to guarantee, at least partially, investments in the Fund of Funds. 
• Capital availability via the use of the insurance company premiums tax to serve as funding sources 
for addressing some of the capital gaps for the biosciences.   
• The Entrepreneurial Ventures Program, which provides up to $250,000 for royalty repayment funding 
or use in the acquisition of intellectual property.  
• The Iowa Agriculture Innovation Center, which is operating under a $1 million, 1-year grant from the 
USDA and a $500,000 match.  The program is producer and innovation focused, providing services 
in business plan preparation (under contract with small business development centers [SBDCs]), 
raising interest in value-added products, and creating a “blue book” showing all uses for each 
commodity.  The Center’s work concentrates on the processing end of the chain (in projects that are 
at least 51 percent producer owned).  
The State of Iowa also has limited philanthropic resources available to finance bioscience initiatives and 
commercialization endeavors.  John Pappajohn has been generous in his funding of entrepreneurship 
development centers; but, for the most part, Iowa lacks a strongly committed philanthropic sector with a 
history of involvement in the state’s economy.  In other states, such as Pennsylvania, Arizona, and 
Missouri, private foundations have been instrumental partners in supporting bioscience and other 
technology initiatives. 
The tools to support the commercialization of the state’s research and technology base are not fully in 
place or developed, such as prototype development.   
The institutions see a need to help faculty entrepreneurs with commercialization research, prototype 
development, market studies, etc., which can help “de-risk” their potential projects.  However, the 
institutions do not have financial resources to provide the type of services required.  Faculty needs 
resources for proof-of-concept work to determine whether a technology has commercial potential.  This 
activity is not supported by academic research dollars and is too “basic” for outside industry support.  
There is thus a “moving forward” gap that prevents many potential university technologies from 
progressing beyond the intellectual concept phase.  It should also be noted that Iowa’s universities are 
inclined to be driven and to measure their own success by the amount of federal funds and the indirects 
                                                 
12 Other emphasis areas for the Iowa Values Fund are in university research and development, workforce training, 
quality of life, and school infrastructure. 
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they generate—not by meeting the specific R&D needs and corresponding commercial opportunities they 
present for the state. 
The emerging bioscience industry cluster in Iowa is not as well connected, supported, and assisted as it 
needs to be. 
The Iowa Biotechnology Association is a very small operation and is quite limited in the activities and 
support services it can sustain from membership dues.  BIOWA is a newer organization particularly 
focused on biorenewables, but the two organizations have only recently begun to work together.  
Bioscience companies in Iowa do not yet seem to be well connected to or networked with one another.  
Companies interviewed in group settings did not seem to know of one another’s capabilities. While there 
is a cluster of bioscience companies in the rectangle formed between Des Moines, Ames, Cedar Rapids, 
and Iowa City, many Iowa bioscience companies are scattered in isolated areas around the state (making 
communications, networking, and access to specialized help difficult to obtain but even more important).  
Also, many bioscience companies in Iowa seem to lack ambition to grow beyond 10 or so employees. 
According to Ruth Consulting, scientist entrepreneurs found they could no longer manage the company 
beyond this point and so deliberately limited growth to remain a small business rather than being 
entrepreneurial driven, wanting to become a giant.  
While Iowa has a strong and innovative community college system, gaps remain that need to be 
addressed if Iowa is to have the talent pool essential to address the needs of this growing but diversified 
set of industries.   
The cost of lab space for customized bioscience programs is a challenge for community colleges, and 
ways must be found to support specialized high-cost programs in the biosciences. A critical mass of 
customers is needed to justify the investment, a critical mass that exists in few places in the state.  There 
is no bioscience career academy formed in Iowa. Poor levels of articulation exist between community 
colleges and the regent universities (particularly U of I, which will accept few community college credits 
in its biology program).  Further ways must be found to encourage more terminal degree technician 
programs in the biosciences to meet industry needs.  Currently, nearly one-third of vocational technical 
students transfer to 4-year institutions.  An excellent model, the Eddyville Biotech Training Center, could 
be better used throughout the state by offering complex core courses on-site and linking to community 
colleges statewide for general coursework.   
Iowa does not have a strong track record in many of the industry sectors that relate to, support, or can 
spur growth in some of the bioscience core platform areas. 
Both the BioEconomy and Advanced Food and Feed Platforms are naturals given the breadth and depth 
of Iowa’s academic expertise and the primary production resource base for raw materials and feedstocks 
to these sectors.  However, in moving up the value chain, Iowa faces challenges because it is not a major 
center for chemical products manufacturing, plastics, or other “value-added” BioEconomy products, nor 
is it a center for food processing and the manufacturing of finished food products.  While Iowa has strong 
R&D expertise related to drugs, biologics, and other human and animal medical products, it also lacks a 
strong industry base in these fields (except in veterinary products).   
Iowa’s state business incentives, tax policies, etc., have not yet been geared to the explicit support of 
bioscience sector growth. 
In recent years, the state has enacted a number of changes in its economic development “tool kit” to 
address the needs for venture capital, the need to have funds to invest directly in firm product 
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development (Iowa Values Fund), and other measures.  Although much has occurred, current state 
policies and incentives are still designed to favor projects that create a significant number of jobs (no 
matter what the quality of those jobs may be).  Modern technology-based economic development, 
however, benefits more from incentives aimed at R&D and wealth creation, and at job quality as opposed 
to quantity.  Incentives and policy still appear to favor “brawn-based” manufacturing jobs over the types 
of employment at the forefront in the innovation economy.   
Opportunities  
Iowa may be in a good position to attract the serial entrepreneurial management (including sales and 
regulatory) back to Iowa to help grow its bioscience cluster.   
New Link Genetics in Ames, for example, has had a good experience in working to attract M.D.’s and 
Ph.D.’s to move to Iowa, with many of the scientific staff being recruited from the National Cancer 
Institute in Bethesda, Maryland.  It appears that the nation contains a significant volume of people who 
are attracted to return to the family supportive environment and livability of the Midwest.  The State of 
Iowa is a recognized national leader in actively facilitating the attraction of these “returnees” through 
specialized recruiting and promotional initiatives, and these efforts could be used to give greater focus to 
the biosciences.  
Iowa has an opportunity to market and brand itself broadly in the biosciences with strengths in animal, 
plant, and life sciences that can increase its bioscience visibility in several markets concurrently. 
It is important that all “three legs of the bioscience stool” be recognized as integral to the future economic 
growth of Iowa, namely human, animal, and plant biosciences. Agricultural biosciences have much higher 
legislative and public visibility in the state than do human medical sciences. While it is good that 
agricultural bioscience is recognized for its significant value to the current and future health of the Iowa 
economy, it is not good to have a weaker understanding of the strong position of Iowa in human 
bioscience R&D.  
Bioscience start-up successes currently get very little press or celebration in Iowa or elsewhere. Even 
within the research community, university spin-offs are not events that have garnered much positive 
feedback or recognition.  
Iowa has the opportunity to build on its technology and research strengths by developing private-public 
partnerships in technology commercialization to address critical gaps.  
Angel and seed financing, SBIR support, and prototype development might be related functions and 
activities that can be organized through a nonprofit with a for-profit arm to share some of the costs and 
expertise needed, such as due diligence and market intelligence.  These activities focused on technology 
commercialization can complement technology transfer in the research universities.  The state’s co-ops 
and trade associations might consider investing a portion of their “check-off” dues into forming and 
operating these technology commercialization engines as well.  The St. Louis BioGenerator is an example 
of the private and public sectors coming together to form such an organization, although its charge does 
not include all of the items listed above.  Other examples include Baylor Medical Ventures and the 
Oklahoma Technology Commercialization Center. 
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Iowa, through the Board of Regents and the Iowa Values Fund, is allocating some funds to address 
steps necessary for building research platforms to help ensure their competitiveness nationally and 
globally. 
The State of Iowa is funding some specific initiatives at the regent universities with an eye toward 
bioscience-based economic development.  From the Iowa Values Fund, $25 million has been allocated to 
fund a biologics facility for plant proteins at Iowa State University, expand wet-lab space at the 
University of Iowa’s Oakdale campus, and establish an innovation accelerator and incubator at the 
University of Northern Iowa. The Board of Regents also has a proposal to the Iowa Legislature to raise 
funds for infrastructure improvement at the universities, including life science instructional programs. 
Iowa has a base of firms, universities, and business service providers beginning to work together; and 
these existing relationships present an opportunity upon which to build.     
One concrete example of networking to address the capital availability gap is already underway.  IDED 
has initiated a forum for bringing together venture capitalists and angels, and there may be a $60 million 
potential for raising investment funds from the insurance industry in Iowa (the state’s insurance com-
panies reached an agreement with the Governor to use a premium tax reduction to fund $60 million in 
venture deals). There also may be potential to engage the larger Iowa companies, such as Pioneer, etc., in 
forming an investment fund for early-stage bioscience ventures.  
It also should be noted that several venture capital firms in the state seemed unaware of the smaller 
bioscience firms in the state that have moved beyond R&D and have small markets for their products.  As 
a result, there is an opportunity to create an event in which the smaller (circa 10 employees) bioscience 
firms in the state can be introduced to potential partners and venture funding sources.   
Finally, the IBA and BIOWA are beginning to collaborate and discuss shared roles.  
Iowa has an opportunity to take greater advantage of its federal labs and facilities to build its 
bioscience future.  
Iowa has the National Animal Disease Lab located in Ames that may further advance the state’s position 
on technology platforms.  Experiences elsewhere show that such federal facilities are critical in building 
bioscience-driven economies.  Discussions to further link the state health lab and the Center for Disease 
Control and Prevention are underway, and there is always an opportunity to work with the state’s 
Congressional Delegation and others to secure federal funds strategically to implement this bioscience 
strategy. 
Economic trends impart a sense of urgency and favor Iowa’s progress on BioEconomy and other 
initiatives. 
The historic highs being reached in fossil fuels, petroleum-based gasoline, and related chemical products 
favor those in Iowa who have invested in biorenewable alternatives.  In the near term this may increase 
cash flows and capital availability for expanding these industries, while in the mid- to long term the 
vulnerability of U.S. economic security to foreign oil supplies may engender further federal support for 
biorenewable resource development and associated technologies.  Iowa’s strengths in infectious diseases, 
agricultural and food safety, and other related fields also provide a strong position for economic advances 
based on biosecurity and agrosecurity federally funded initiatives.  A rapidly growing world population 
and an increasing focus on human health and nutrition also favor Iowa’s platform development in 
advanced food and feed and animal systems. 
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Historically, Iowa has had an agricultural sector that quickly adopts and applies technology 
breakthroughs and thus offers a good business climate in which transgenic and genetically modified 
organism (GMO) work can be undertaken on a pilot or demonstration basis. 
While Europe, Asia, and even parts of North America react to unscientific threats and perceptions 
regarding dangers from GMO products, Iowa has a window of opportunity, based on a realistic and 
pragmatic approach to genetics and transgenics, that may facilitate its development and cementing of a 
leadership position in a clear growth field.  Iowans are taking a scientific approach to the commercial-
ization and use of transgenics, but also doing so with attention to risk evaluation and mitigation.  Indeed, 
it is in Iowa that protocols for transgenic security and product handling are being developed—protocols 
likely to be accepted as standards on a world stage. 
Threats 
State financial support, due to declining state revenues, has reduced the ability of Iowa’s research 
universities to position themselves as globally competitive in the biosciences.    
State government financial support has declined significantly during the past 5 years. The result has been 
program cuts, faculty salary freezes, an inability to invest in new technologies and infrastructure, and a 
general fear for the future among the Iowa education and scientific community. At a time when higher 
education research institutions represent a strong economic investment, Iowa has had to reduce rather 
than increase investment. A lack of sufficient state funding could put at risk some of the core strengths 
and resulting technology platforms.  In recent years Iowa’s total growth in bioscience funding has not 
kept pace with that of the nation, resulting in a slightly declining bioscience R&D market share of total 
academic R&D.   
Iowa’s state budget has caused a decline in funding to the regent universities.  This, in turn, has caused 
the universities to cut any programs and initiatives that are not central to their academic research and 
teaching missions.  Economic development, entrepreneurship, and commercialization activities that are 
crucial to the state’s economic future have been major components of the cutbacks.  Continued declining 
funding for the regent institutions will continue to restrict their ability to efficiently perform commercial-
ization, technology transfer, business assistance, and other services contributing to entrepreneurship and 
technology commercialization in Iowa.   
It also should be noted that Iowa’s state financial situation may improve as commodity prices increase.  
With more freedom to allocate financial resources to higher education and the regent universities, Iowa 
may run the risk that its research universities will see fewer imperatives for engaging in economic 
development and revert to more traditional academic pursuits. 
Effective partnerships among the bioscience industry, higher education, and the public sector are not 
fully optimized, resulting in potential firms, talent, or technology seeking opportunities elsewhere.   
In the past, firms have felt that announced partnerships have not fully blossomed; and concern exists that 
a similar fate will await the implementation of an Iowa Bioscience Strategy.  If this were to occur, it 
would set back critical private-sector commitment and interest by many years, perhaps even fatally, as 
there are narrow windows of time and opportunity in many of the markets Iowa seeks to penetrate.  A 
number of interviewees expressed concern that, if Iowa’s private and public sectors do not step up to the 
plate, existing as well as newly established biosciences firms are likely to migrate elsewhere.  Issues of 
capital, space, and business climate must be adequately addressed and deep ties made between bioscience 
firms and the state’s indigenous resources to make future migration less likely. 
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Other states are aggressively pursuing bioscience development.   
All 50 states have one or more initiatives to support the development of the biosciences, and at least 
26 states have targeted the biosciences.  Ohio’s Third Frontier effort, with more than $1 billion in state 
funds, has awarded funds to six centers to date, half of which are in the biosciences.  The State of Florida 
and a county have announced a commitment of $510 million to build a new Scripps Research Institute in 
South Florida.  States have provided funds (such as Arizona providing $440 million) for new bioscience 
research facilities in their state.  Unless Iowa makes ongoing commitments for the facilities, faculty, and 
technology transfer it needs to optimize the benefits of its technology platforms, it may lose its 
competitive advantage. 
Competitiveness among higher education institutions could adversely affect the state’s bioscience 
potential as other universities are pursuing the biosciences as a key area of focus for their future. 
Just as states are investing in the biosciences, so are higher education institutions, many of which are 
offering sizable packages to attract star and emerging star faculty to their universities.  Again, Iowa could 
be placed in a noncompetitive position were it not able to retain its stars as well as recruit stars for the 
future through endowed chairs, adequate facilities and equipment, and recruitment packages that ensure 
competitiveness.  In the highly competitive arena of the biosciences, where national universities are 
working hard to attract top talent, Iowa’s human capital strengths in university-based bioscience R&D 
could be lost to other states.  Faculty and scientists may be attracted to higher-paying jobs and more richly 
endowed laboratories and facilities in states where investments continue to be made in spite of revenue 
shortfalls. 
Other states may have a more entrepreneurial, risk-taking culture and are more willing to invest now 
for the long haul, resulting in firms starting or growing elsewhere rather than in Iowa.  Other regions 
may be able to address the need for risk capital or technology commercialization more quickly and with 
more commitment than Iowa.   
The bottom line is that good research and research reputation matters, but so does the creation of firms 
and jobs that directly or indirectly come from these research engines.  Iowa must address some key gaps 
crucial to building not only critical mass of research but a critical mass of firms in the biosciences, 
including wet-lab space, technology commercialization support, angel and seed capital, and technology 
connected to firm and wealth creation.   
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Bioscience Strategies and Actions 
As previously noted, it is technology-based economic development, driven by innovation, talent, and 
investment capital, that is shaping the future of successful U.S. state economies. Therefore, if Iowa is to 
succeed in developing a bioscience-driven economy, it must ensure its competitive position in three ways: 
• Iowa must nurture bioscience research within its core platforms and encourage and facilitate the 
movement of R&D into new entrepreneurial bioscience enterprises and existing firms, thereby 
helping to ensure that its bioscience industry is constantly focused on technological innovation. 
• Iowa must have the talent base of knowledgeable workers at all levels—from technician to 
postdoctorate—that can develop and apply knowledge to the advancement of bioscience 
developments. 
• Iowa must have capital markets receptive and prone to investing in innovative firms and 
entrepreneurs developing and applying cutting-edge technology to bioscience products and processes. 
The following strategic plan has been designed to be driven by industry and capitalize on Iowa’s 
comparative bioscience advantages, while ensuring that future investments are focused on building the 
technology, knowledge, and capital that will ensure Iowa’s economic success for years to come. 
VISION 
With strong public-private leadership and long-term commitment on the part of Iowa’s research 
institutions, business community, nonprofit community, and state and local governments, it is reasonable 
to expect that Iowa can achieve the following vision by 2014: 
Iowa is a leading Midwestern state with a comprehensive set of strengths in the plant, animal, 
and human sciences.  Iowa is a leader in the application of biorenewable resources to create 
value-added products and has become a significant player in the production of advanced food 
products, drugs, biologics, and related biomedical technologies.  The Iowa biosciences are 
characterized by strong public-private and industry-university relationships, resulting in a 
strong base of bioscience companies operating in Iowa in the development and production of 
plant, animal, and human bioscience products.   
MISSION   
To achieve this vision, Iowa must approach its future in the biosciences by focusing on the following: 
• Investing in the further development of key R&D platforms at Iowa’s regent universities, 
including facilities, equipment, scientific resources, and the attraction and retention of Eminent 
Scholars and their research teams to generate commercializable innovations from these investments. 
• Putting in place incentives, programs, and organizations that will facilitate and encourage the 
translation of bioscience innovation into products, processes, and other mechanisms of 
economic value and wealth creation for Iowa. 
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• Securing capital funding sources that will provide the financial resources necessary to move 
innovative technology from the research bench to commercialization and into fully fledged 
entrepreneurial businesses growing and expanding from their base in Iowa. 
• Applying itself to the creation of an educational, economic, and social environment conducive to 
the creation, attraction, and retention of human talent at all key bioscience business skill levels—
from R&D scientists to experienced management and production personnel. 
GAP ANALYSIS 
For Iowa to achieve its mission and accomplish its bioscience economic development vision, several key 
issues will need to be addressed.  These issues represent current gaps in creating an integrated, wealth-
generating continuum that begins with R&D and culminates in full-scale and ongoing bioscience business 
operations.  Figure 11 summarizes the key gaps that must be addressed in order to realize Iowa’s 
bioscience development potential. 
 
Figure 11: Iowa’s Key Gaps Along the Biosciences Development Continuum 
 
The following section proposes strategies and actions to address and fill these gaps. 
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STRATEGIES AND ACTIONS 
While Iowa has considerable existing strengths in the biosciences and significant platforms upon which to 
build bioscience economic development, assistance and action are required to realize the development 
potential and advance Iowa ahead of its competition.  As the SWOT and gap analyses identified, Iowa has 
some significant weaknesses to offset and gaps to fill in order to optimally advance the biosciences as a 
key driver of the Iowa economy. 
For the biosciences to realize their potential as a major economic engine for Iowa, the state must 
simultaneously address both the strengthening of research drivers and the efficient development of 
commercial enterprise from research innovations.  Four strategies have been identified that will entail 
20 associated actions to further develop Iowa’s bioscience research base and build a critical mass of 
bioscience companies. 
• Strategy One:  Build Iowa’s bioscience research capacity around selected technology platforms 
focusing on investments in talent, facilities, and equipment. 
• Strategy Two:  Encourage and facilitate the commercialization of bioscience R&D to enhance 
opportunities for start-up, emerging, and existing Iowa firms. 
• Strategy Three:  Foster a business environment that supports, sustains, and encourages the growth 
and sustainability of bioscience firms in Iowa. 
• Strategy Four:  Invest in and develop Iowa’s bioscience talent pool. 
These strategies and associated actions are summarized in Table 14, followed by a detailed narrative 
description and explanation on subsequent pages.  Implementation of these strategies and actions is 
anticipated as a 5-year period.  Immediate priorities should be undertaken in the next year to 18 months, 
short-term priorities in 18 months to 3 years, and mid-term priorities in 3 to 5 year time period. 
 
Table 14:  Iowa Bioscience Strategies and Actions 
Strategy Actions Priority 
Strategy One: 
Build Iowa’s 
bioscience 
research capacity 
around selected 
technology 
platforms 
focusing on 
investments in 
talent, facilities, 
and equipment. 
 Undertake key recruitment, capacity building, 
and required investments to ensure rapid 
scientific progress in the core bioscience 
platforms.  
 Create an Endowed Chairs Program to attract 
world-class, entrepreneurial talent in the core 
bioscience platforms. 
 Form a Strategic Technology Platform 
Infrastructure Fund to strengthen and accelerate 
the scientific and commercialization work of the core 
bioscience platforms.  
 Engage Iowa’s Congressional Delegation in 
discussions pertaining to federal funding and 
specific project support. 
 Institute an industry-university matching grant 
program dedicated to the identified bioscience 
technology platforms to encourage relationships 
between academic researchers and industry. 
Short-term 
 
 
Short-term 
 
 
Short-term 
 
 
Immediate 
 
 
Immediate 
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Table 14:  Iowa Bioscience Strategies and Actions (continued) 
Strategy Actions Priority 
Strategy Two: 
Encourage and 
facilitate the 
commercialization 
of bioscience 
R&D to enhance 
opportunities for 
start-up, 
emerging, and 
existing Iowa 
firms. 
 
 Create and Fund an Economic Development 
Director position on the Iowa Board of Regents 
to provide catalytic support for regent university 
economic development initiatives.  
 Develop and implement policies and procedures that 
actively encourage faculty entrepreneurship and 
commercialization activities at the regent 
universities. 
 Increase funding to the regent universities to 
allow for sufficient staffing and resources for 
commercialization activities. 
 Establish and fund a University Entrepreneurs 
Center at each university. 
 Form a statewide commercialization 
intermediary for supporting, building, and 
sustaining development of new bioscience business 
enterprises in Iowa.   
Immediate 
 
 
Immediate 
 
 
Immediate 
 
 
Short-term 
 
Immediate 
 
 
Strategy Three:    
Foster a business 
environment that 
supports, 
sustains, and 
encourages the 
growth and 
sustainability of 
bioscience firms 
in Iowa. 
 
 Form the Iowa Bioscience Alliance to facilitate 
communications, foster joint approaches to issues, 
and develop a critical mass of support to stimulate 
actions required to realize Iowa’s bioscience vision. 
 Establish a State Bioscience Advocate position, 
reporting to the Director of IDED, to drive the 
implementation of this strategy. 
 Implement Iowa’s bioscience image and brand 
through aggressive marketing, public relations, and 
signature events. 
 Review and make necessary changes to state 
incentives (including the Iowa Values Fund), tax 
policies, and legal code to be responsive to the 
needs of growing bioscience firms. 
 Conduct an economic impact study to measure 
the projected returns to the state and its regions that 
are estimated to result from proposed bioscience 
investments.  The study should pay special attention 
to geographic equity and the diffusion of innovation 
benefits throughout the state. 
 Develop a training program for state and local 
economic development professionals that would 
include information on university bioscience 
technology platforms and technical capabilities, the 
specialized needs of bioscience companies, and 
programs and incentives that can be used to assist 
new bioscience ventures and expanding and/or 
relocating firms. 
Short-term 
 
 
Short-term 
 
 
Immediate 
 
 
Short-term 
 
 
 
Short-term 
 
 
 
 
Mid-term 
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Table 14:  Iowa Bioscience Strategies and Actions (continued) 
Strategy Actions Priority 
Strategy Four:  
Invest in and 
develop Iowa’s 
bioscience talent 
pool.  
 Improve K-12 scientific education by focusing on 
stimulating interest among Iowa’s children in 
science, thereby preparing them for careers in 
Iowa’s growing bioscience sectors. 
 Develop a bioscience vocational career education 
program and ensure seamless delivery between 
secondary and community college programs that 
serve Iowa’s growing concentration of bioscience 
employers. 
 Streamline bioscience articulation agreements 
within and between community colleges and Iowa’s 
regent universities to allow students to transfer 
credits between academic institutions.   
 Leverage alumni associations and the state’s 
Human Resources Recruitment Consortium to 
attract to Iowa bioscience professionals, including 
experienced bioscience managers.   
Mid-term 
 
 
Mid-term 
 
 
 
Short-term 
 
 
 
Immediate 
 
STRATEGY ONE:  BUILD IOWA’S BIOSCIENCE RESEARCH CAPACITY AROUND 
SELECTED TECHNOLOGY PLATFORMS FOCUSING ON INVESTMENTS IN TALENT, 
FACILITIES, AND EQUIPMENT. 
World-class higher education and academic R&D infrastructure are absolute prerequisites for any state to 
become a world-class center for bioscience industry development.  Strong research universities, 
comprising leading academicians and clinician-scientists in bioscience and biomedical fields, are the 
hallmark of successful bioscience states and regions.  Generally, it is rare to have a cluster of bioscience 
firms without a correspondingly strong set of academic research institutions nearby. 
A recent study by the U.S. Small Business Administration, the National Commission on 
Entrepreneurship, and the Kaufmann Center for Entrepreneurial Leadership concluded the following: 
University expenditures on research and development promote higher new firm birth rates.  The 
phenomenon is identical to that described by other researchers as “spillover” effect.  Just like 
business firms, research universities form local innovative activity centers, from which knowledge 
spillovers and growth in specialized markets generate higher rates of new firm formation in one 
or more industries.  The glue that holds these clusters together is the effort universities are 
putting into mechanisms to promote commercialization of the inventions that emerge from their 
laboratories.13 
As previously noted, Iowa has a significant base of academic R&D expertise in all “three legs of the 
bioscience stool”—plant, animal, and human biosciences.  These strengths have already resulted in 
                                                 
13 U.S. Small Business Administration, The National Commission on Entrepreneurship, and the Kaufmann Center 
for Entrepreneurial Leadership. The Influence of R&D Expenditures on New Firm Formation and Economic 
Growth.  2002, page 24. 
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bioscience economic development for Iowa, not only in terms of the attraction of significant R&D dollars 
into the state and the research employment that creates, but also in terms of new bioscience business 
ventures, value-added production from Iowa’s biological commodities, and innovations for exploitation 
by Iowa’s established base of bioscience-related corporations. 
Iowa’s regent universities have been active 
participants in economic development, including 
bioscience-based economic development:   
• The University of Iowa Research Park on the 
Oakdale Campus contains 29 companies, 
employing approximately 1,500 individuals at an 
average salary of $50,000.14  Capital investment 
in the park is approximately $120 million. 
• The University of Northern Iowa’s leading work 
in bio-based lubricants has resulted in new 
business formation in Iowa; and its Strategic 
Marketing Services program has provided 
research, planning, and feasibility services to 
more than 250 companies in Iowa and the 
Midwest.15   
• Iowa State University, as the state’s land grant 
institution, has a track record of being 
exceptionally proactive in applied agricultural 
R&D and the diffusion of its research knowledge 
and services through the ISU agriculture and 
manufacturing extension services. ISU’s 
Research Park is home to 43 private and public 
firms, with the Research Park tenants responsible 
for significant economic impacts, including 
$76.3 million in total output, $29.5 million in 
labor income and almost 700 jobs.16  In addition, 
on a typical annual basis, ISU assists more than 
300 general business clients through its 
SBDC/Pappajohn Center.  It also provides 
services to 40 prospective technology business 
start-ups on an annual basis and has upwards of 
20 early-stage active technology clients at any 
given time. 
Despite the historic and current efforts, there is 
significant opportunity to move these activities 
                                                 
14 Source: University of Iowa. 
15 Source: University of Northern Iowa. 
16 Swenson, David. “The Economic Value of the ISU Research Park and its Tenants.”  Department of Economics, 
Iowa State University.  February 2003. 
Statistics on Assistance to Industry 
Iowa State University 
 In FY 2003 businesses (including commodity 
groups) funded 406 research projects at ISU 
totaling $14.9 million.  In addition, businesses 
funded 55 nonresearch projects totaling 
$11.5 million.   
 CIRAS provided technical assistance to approx-
imately 170 companies (in many cases multiple 
times) during calendar year 2003.  
 In FY 2003, IPRT provided short-term technical 
assistance to companies through 82 projects 
and assisted companies with 26 SBIR/STTR 
awards. 
 SBDC/Pappajohn Center provided 6,000 hours 
of professional and student consulting assis-
tance to start-up and existing companies and 
worked with 40 technology-based companies 
located at or affiliated with the ISU Research 
Park. 
 It is estimated that about three inquiries from 
industry are handled each day through the Point 
of Contact system (in addition to non-company 
inquiries).  
University of Iowa 
 In FY 2003, businesses funded 371 research 
agreements at The University of Iowa. These 
generated $33.3 million in support. Over the 
past 5 years, 1,887 corporate research 
agreements generated $167.8 million in 
industrial research support. The FY 2003 total 
of $33.3 million represented 9.5 percent of the 
$352.3 million in total external support reported 
by the University during the year. 
 The UI SBDC/PappaJohn Center provided more 
than 4,000 hours of consulting assistance to 
more than 400 clients, approximately 68% of 
which were start-ups. In addition, the Center 
provided services to 50 early-stage technology 
start-ups, offered 16 workshops, and handled 
approximately 10 inquiries per day. 
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further and accelerate the emergence of Iowa as a bioscience business leader.  Doing so will require not 
only some changes, in particular streamlining and enhanced funding of commercialization and technology 
transfer operations at the universities, it also will require investments to reinforce and expand the 
universities’ R&D capabilities in the core bioscience development platforms identified as keys to the 
development of a high-growth bioscience economy for Iowa. 
The core competency evaluation identified six major platforms for short-term bioscience development in 
Iowa and four longer-term or niche opportunity areas as indicated in Table 15.   
 
Table 15:  Iowa’s Bioscience Core Competency Platforms 
Major Short-Term Platforms Iowa State University 
University of 
Iowa 
University of 
Northern Iowa 
BioEconomy +++ + ++ 
Advanced Food and Feed +++ +  
Animal Systems +++ +  
Post-Genomic Medicine + +++  
Drug Discovery and Development + +++  
Biosecurity ++ +++ + 
Niche or Longer-Term Platforms Iowa State University 
University of 
Iowa 
University of 
Northern Iowa 
Host-Parasite Biology and Systems ++ ++  
Devices and Sensors (initial emphasis 
on lung imaging/biomedical imaging) 
++ +++ + 
Cardiovascular Research Institute + +++  
Free Radical Research Institute  +++  
Key:  +++ Lead or Primary Role    ++ Important, Integral Role     + Minor, Supporting Role 
 
Evident in Table 15 is the fact that all three of the regent universities have a role to play in the develop-
ment and ongoing operations of the platforms.  In the case of each platform, there is also a logical lead 
university taking a primary role in platform development.   
Unfortunately, the current situation of state funding cuts in addition to increased competition from other 
states will make significant bioscience economic development growth stemming from university R&D 
more difficult.  Universities do not have the resources to pursue the necessary actions with the vigor 
required for true success, and the substantial resources committed by competing states could siphon off 
Iowa’s best and brightest who will be attracted by major recruitment packages and the promise of state-
of-the-art research and laboratory facilities.  Those faculty, students, and others interested in commercial-
ization of their research innovations will be particularly vulnerable to out-of-state recruiting as competing 
states seek to attract those most likely to stimulate bioscience economic development. 
As noted in the tactics outlined below, for Iowa to realize the opportunity that bioscience development 
presents, it must take action to reinforce and direct investment toward cementing its leadership position 
on the core bioscience platforms. 
It is imperative, however, that the further development and enhancement of Iowa’s bioscience platforms 
not be seen as a solution addressed only by reallocating existing university resources.  The various states 
and regions with which Iowa will be competing for bioscience economic growth and development have 
been active in the infusion of new state funding and the proactive pursuit of federal research grants and 
infrastructural support.  In addition, partnerships with industry and industry associations may form a 
supplementary route to enhanced funding streams for platform development.   
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Tactics 
• Focus Iowa’s bioscience efforts by targeting the further development of core bioscience platform 
areas—thereby accelerating Iowa’s momentum and building upon its strength.  Each platform cannot 
be pursued simultaneously, so priorities must be established. 
• Focus the state’s research infrastructure investments on supporting platform development and 
accelerating the movement of research innovations toward commercialization. 
• Establish clear motivation and imperatives for university faculty, staff, and student engagement in 
translational work and the proactive commercialization of marketable research discoveries. 
• Reinforce the R&D talent base through the strategic recruitment of Eminent Scholars and faculty 
entrepreneurs to key positions within each of the core platforms. 
• Leverage Iowa’s “three legs of the bioscience stool” strengths via increased cross-institutional 
collaborations—thereby maximizing expertise, resources, complementary competencies, and outside-
the-box approaches across institutions. 
• Build and expand the basic bioscience research base at the regent universities to ensure a strong long-
term pipeline of discoveries feeding into translational and applied bioscience research. 
Actions for Strategy One: 
Action One: Undertake key recruitment, capacity building, and required investments to ensure rapid 
scientific progress in the core bioscience platforms.  
Action Two:  Create an Endowed Chairs Program to attract world-class, entrepreneurial talent in the core 
bioscience platforms. 
Action Three:  Form a Strategic Technology Platform Infrastructure Fund to strengthen and accelerate the 
scientific and commercialization work of the core bioscience platforms.   
Action Four: Engage Iowa’s Congressional Delegation in discussions pertaining to federal funding and 
specific project support. 
Action Five:  Institute an industry-university matching grant program dedicated to the identified 
bioscience technology platforms to encourage relationships between academic researchers and industry. 
Action One:  Undertake key recruitment, capacity building, and required investments to 
ensure rapid scientific progress in the core bioscience platforms.   
Rationale:  World-class science and innovation require world-class faculty and top-quality graduate 
students.  The attraction and retention of high-quality scientists and researchers also depend on providing 
them with top-notch resources, staff, and support to pursue their research in an efficient and effective 
manner.  While Battelle has identified the bioscience platforms that it perceives as presenting solid 
opportunities for bioscience development in the state, each of these platforms requires some reinforcing 
investments to help assure their status and rapid development progress. 
Action Specifics:   Each bioscience development platform presents unique opportunities for bioscience-
based economic advancement in Iowa.  While serving the overall vision and mission previously outlined, 
each platform may have its own vision, strengths to build upon, and needs to address.  The following 
section outlines some of the specific opportunities and actions for each platform that might be addressed.  
However, it is important to recognize that the development of each platform will demand flexibility and 
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adjustments in order to ensure that opportunities are leveraged as they present themselves and that 
emerging areas are seized as the consortium evolves over time.   
BioEconomy Platform—While Iowa already has substantial capabilities on both the production and R&D 
sides of the BioEconomy, cementing Iowa’s leadership in the field will require further strategic 
investment and actions.  Specific activities and needs might include the following: 
• Creating the BioEconomy Academic Consortium, headquartered at Iowa State University, staffed 
with a full-time Director and two staff assistants ($300,000 annually). 
• Providing $1 million in initial funding for a competitive matching grant program to be administered 
by the platform Executive Committee.  As noted in the Phase I report, a moderate amount of annual 
research funding is likely to stimulate significant applied research returns at UNI.  UNI has been 
particularly productive in bioeconomy-related research programs.  Therefore, it is recommended that 
$300,000 of the $1 million be set aside for a competitive grant program at UNI. 
• Investing in shared infrastructure and student training in biobased products and technology at ISU.  
Shared infrastructure will include dedicated space on the ISU campus for program offices and 
laboratories for bench-scale research in biobased products and expanded space and utilities for 
existing pilot-plant facilities.  Infrastructure funds also will be used to purchase, install, and operate 
instrumentation required for a comprehensive platform in biorenewables research and development.  
Funds for student training will be used to provide industrial internships for graduate students and 
support faculty in developing and teaching courses in biorenewable resources.  Estimates provided by 
ISU indicate a potential financial investment required of $8,625,000 over a 5-year time period. 
Advanced Food and Feed Platform—Specific activities and needs might include the following: 
• Creating the Advanced Food and Feed Academic Consortium, headquartered at Iowa State 
University, staffed with a full-time Director and two staff assistants ($300,000 annually). 
• Enhancing ISU’s existing strengths by hiring faculty with complementary skills, providing needed 
research instruments and equipment, and upgrading research facilities.  Estimates provided by ISU 
indicate a potential financial investment required of $8,565,000 over a 5-year time period.  The focus 
of the research and development activities will include  
o Discovery of substances in microorganisms, plants, and animals that have health-promoting or 
disease prevention effects in humans and livestock;  
o Proof of concept involving animal experiments and human clinical trials; 
o Product development involving plant and animal breeding or genetic engineering or more 
traditional food processing; and 
o Development of suitable processing technologies to deliver foods and ingredients having 
maximum health benefits. 
• Investigating the opportunity to expand the academic side of the consortium into an Advanced Food 
and Feed Products Institute.  
• Providing $500,000 in initial funding for a competitive matching grant program to be administered by 
the platform Executive Committee. 
• Connecting ISU research labs to clinical labs and expertise at U of I. 
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• Expanding sensory expertise and associated facilities and linking them to U of I for toxicology and 
allergen analysis. 
• Utilizing IDED’s role in active work to recruit food processing companies and associated 
manufacturing firms to reinforce the comparatively small current base in Iowa. 
Animal Systems Platform—Specific activities and needs might include the following: 
• Creating the Animal Systems Academic Consortium, headquartered at Iowa State University, staffed 
with a full-time Director and two staff assistants.  This could be expanded into an Animal Systems 
Institute along the lines of the Iowa State University Plant Sciences Institute ($300,000 annually). 
• Providing $500,000 in initial funding for a competitive matching grant program to be administered by 
the platform Executive Committee. 
• Creating an Animal Systems Institute at ISU to expand efforts of existing centers of excellence within 
the Consortium by providing start-up funding, graduate student training, and state-of-the-art equip-
ment for advanced analysis in the areas of molecular biology, genomics, and proteomics to advance 
life sciences research and providing funds to support advanced genomic sequencing of animals and 
microbes to advance economic development and discovery.  Estimates provided by ISU indicate a 
potential financial investment required of $6,250,000 over a 5-year time period.   
Integrated Post-Genomic Medicine Platform—Specific activities and needs might include the following: 
• Developing a comprehensive database for clinical phenotyping and retrieval of biological samples for 
deoxyribonucleic acid analysis.  Development of such a database and retrieval system will give Iowa 
a major advantage in genomic medicine.  Estimates provided by the University of Iowa indicate a 
potential financial investment required of $8,935,000 over a 5-year time period. 
• Creating the Genomic Medicine Academic Consortium, headquartered at the University of Iowa, 
staffed with a full-time Director and two staff assistants ($300,000 annually). 
• Providing $500,000 in initial funding for a competitive matching grant program to be administered by 
the platform Executive Committee. 
Integrated Drug Discovery, Development, Piloting, and Production Platform—Specific activities and 
needs might include the following: 
• Making near-term investment in resources and infrastructure to provide basic drug discovery services 
and a potential commercialization pathway for existing areas of research. 
• Developing a larger-scale Drug Discovery Center catalyzing in-depth, bench-to-bedside drug 
opportunities. 
• Developing and operating the Drug Discovery Center.  U of I estimates that this will require 
$5,835,000 for the first 5  years.  Additional resources required for pharmaceuticals and biologics 
development, outreach and marketing, quality control, medical direction of clinical trials and faculty 
with expertise in targeted drug delivery would total $4,660,000 over a 5-year period. 
• Creating the Drug and Biologics Academic Consortium, headquartered at the University of Iowa, 
staffed with a full-time Director and two staff assistants.  The Director is envisioned to hold the post 
of Director of Pharmaceuticals and Biologics Development. 
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• Providing $500,000 in initial funding for a competitive matching grant program to be administered by 
the platform Executive Committee. 
Integrated Biosecurity Platform—Specific activities and needs might include the following: 
• Creating the Integrated Biosecurity Academic Consortium, staffed with an initial full-time Co-
Director headquartered at the University of Iowa and then supplemented by an additional Co-Director 
at Iowa State University.  Each Co-Director will have two dedicated staff ($300,000 annually at each 
university).  This could be built into an Institute for Integrated Biosecurity over time, with member-
ship from U of I, ISU, UNI, the USDA Animal Health Research Laboratory and other Iowa parties.  
Within the Institute, research groups could be created to focus on 
o Infectious disease prevention, diagnostics, and treatment; 
o Monitoring, detection, and analytical devices; 
o Decontamination processes and equipment; and 
o Vaccine development and production. 
• Providing $500,000 in initial funding for a competitive matching grant program to be administered by 
the platform Executive Committee. 
• Creating, in the near term, a Center for Infectious Diseases, Therapeutics, Development and Evalua-
tion at the University of Iowa with direct links to the Drug Discovery and Development Platform.  
Initial focus could be on respiratory diseases and pathogens.  The U of I estimates a 5-year required 
budget for the Center at $8,425,000. 
Biomedical Imaging Niche Platform:  In light of the University of Iowa’s significant recent success in 
securing funding and strong industry relationships in biomedical imaging, and given the importance of 
advanced biomedical imaging as a provider of new insights that lead to new biomedical discoveries, and 
the opportunity to work on imaging devices, algorithms, and software business opportunities, Battelle 
sees this as a short-term niche opportunity for development in Iowa.  The following resources might be 
allocated to the biomedical imaging niche platform: 
• $200,000 in annual funding to support a Platform Director at the University of Iowa, plus one 
assistant and associated operating cost. 
• $300,000 in initial funds for a competitive matching grant program to be administered by the platform 
Executive Committee. 
Resource Requirements:  
The academic consortia will require funding.  As noted above, each platform at the academic level will 
require a full-time Director and two support personnel to guide platform development activities and 
provide the direct links to the related industry groups and individual business partners.  Each academic 
consortium should be allocated funding to cover these staff positions and associated operating costs. 
Funding for the platform consortium staffing should be allocated for 5 years.  A review of platform 
performance should be performed after 5 years to assess further funding needs. 
 
 Iowa’s Bioscience Pathway for Development 
 
 66 
 
Platform 
Academic 
Consortium 
Staffing 
Competitive 
Matching Grant 
Program 
Special Projects and 
Investments 
BioEconomy $300,000 $1,000,000 $1,725,000 per year for 5 years 
for shared infrastructure and 
training 
Advanced Food and 
Feed 
$300,000 $500,000 $1,713,000 per year for 5 years 
for shared infrastructure, key 
faculty, and staff scientists 
Animal Systems $300,000 $500,000 $1,250,000 per year for 5 years 
for shared infrastructure support, 
advanced sequencing projects, 
and advanced analysis in 
genomics and proteomics 
Post-Genomic 
Medicine 
$300,000 $500,000 $1,787,000 per year for 5 years – 
for Genomics/Phenotype 
Database and Retrieval System 
Drug Discovery, 
Development, Piloting, 
and Production 
Covered under 
special projects 
budget 
$500,000 $1,167,000 per year for 5 years – 
for Drug Discovery Center’s 
development and operation. 
$932,000 per year for 5 years – 
for staffing and platform 
reinforcement investments 
Biosecurity $300,000 each at 
two hubs 
($600,000 total) 
$500,000 $1,685,000 per year for 5 years – 
for Center for Infectious Diseases, 
Therapeutics, Development and 
Evaluation 
Biomedical Imaging 
(Niche Platform) 
$200,000 $300,000  
 
Time Frame:  Short-term 
Lead Organization(s): Iowa Board of 
Regents and the individual regent 
universities 
Action Two:  Create an Endowed 
Chairs Program to attract world-
class, entrepreneurial talent in the 
core bioscience platforms.   
Rationale:  Numerous states, including 
Georgia, Missouri, Oklahoma, Florida, 
and South Carolina, have developed or 
are developing endowed chairs in an 
effort to develop world-class research 
excellence. Endowments are created by 
investing a donation that then provides 
ongoing income, with the recipient 
university deciding how much of the 
annual earnings will be spent on the 
Examples of Endowed Chairs Programs  
 Missouri will fund an endowed chairs program beginning in 
FY 2007 requiring both a nonstate commitment of a 
$2 million endowment or $100,000 per year for 20 years, 
and a university and state commitment of $100,000 per 
year for 20 years.  
 Oklahoma and Florida are working on legislation to 
eliminate the backlog of state funding for endowed chairs. 
Oklahoma Governor Henry recently authorized a bond 
issue to match donations as part of his Economic 
Development Generating Excellence (EDGE) initiative. 
(Currently, $52 million in private donations is waiting for 
matching funds).  
 In South Carolina, Clemson University will tap into state 
lottery funds set aside last year by the General Assembly 
for an endowed chairs program. BMW Manufacturing Corp. 
pledged $10 million, with another $5 million to be raised by 
suppliers, for the state to match. Clemson will use the funds 
to recruit engineers and scientists to the school's new 
graduate program in automotive systems integration.  
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faculty member.  The general consensus is that it takes an endowment of about $3 million to support a top 
researcher. What is also agreed upon is that endowed chairs represent an important tool in building a 
research hub capable of attracting large federal grants, commercializing technology, and spawning start-
up companies.  
The experience of the Georgia Research Alliance (GRA) with entrepreneurial endowed chairs points to 
the success such appointments can promote (Figure 12).  The Eminent Scholars Program is a central 
component of the GRA strategy, which, over its 10 years of operation, has attracted 32 scholars. The 
grants are aimed at entrepreneurial professors.  A large percentage of the endowed chairs actually bring 
with them an existing company or relocate with the interest of commercializing their research.  In all, 
GRA has linked more than a dozen start-up companies to the Eminent Scholars Program and estimates 
that about $800 million in federal and private funding has been captured by Georgia as a result of the 
program. GRA, which helps allocate $30 million to $35 million a year in state funding, provides 
$750,000 to establish each Eminent Scholar chair. That amount has to be matched by the host institution. 
In addition, GRA provides funding to build and renovate labs or to outfit them with sophisticated 
equipment. 
 
Figure 12:  Georgia Research Alliance Model 
In taking a similar approach, Iowa can help strengthen key bioscience research platforms—working to 
attract senior Eminent Scholars in the platform fields who have existing entrepreneurial experience and 
may actually relocate companies with them. 
Action Specifics:  An entrepreneurial endowed chair position should be established within each of the six 
main platforms over several years.  In addition, it is recommended that an endowed entrepreneurial chair 
be established at the University of Iowa College of Medicine in biomedical imaging to help cement and 
University research 
attracts additional VC 
and industry funding
Georgia
economic
growth
GRA Economic
Development Impact
$1.2 billion
total
27 Eminent Scholars 
at Georgia universities
Eminent Scholars 
secure incremental 
funding of $900 
million
E inent Scholars 
secure incre ental 
funding of $900 
illion
Georgia Universities
• 750 jobs
• $550 million total 
investment 
in infrastructure
Economic Impact
• 75 start-ups
• 2,000 high-tech jobs
• $500 million in external 
investment
GRA secures state 
funding for research 
infrastructure and 
Eminent Scholars
A secures state 
funding for research 
infrastructure and 
E inent Scholars
$300
million
total
State of 
Georgia
 Iowa’s Bioscience Pathway for Development 
 
 68 
build upon recent major advances in advanced lung imaging.  Thus, a total of seven endowed entre-
preneurial chairs are recommended, distributed as shown in Table 16. 
Table 16:  Proposed Bioscience Endowed Chairs 
Major Short-Term Platforms Iowa State University University of Iowa 
University of 
Northern Iowa 
BioEconomy EE Chair   
Advanced Food and Feed EE Chair   
Animal Systems EE Chair   
Post-Genomic Medicine  EE Chair  
Drug Discovery and Development  EE Chair  
Biosecurity  EE Chair  
Niche Platform Iowa State University University of Iowa 
University of 
Northern Iowa 
Biomedical Imaging  EE Chair  
 
It is recommended that, in each case, the endowment be used to attract a scholar and associated team 
members, recruited nationally and internationally, who could bring with them a related start-up business 
venture or a concept for near-term commercialization.  
Resource Requirements:  Each of the seven endowed chair positions will require an endowment of 
$3 million, for a total combined endowment requirement of $21 million.  It is recommended that the State 
of Iowa provide one-third of the endowments ($7 million) in direct funding, with a requirement that 
recipient universities seek private donations for the remaining two-thirds ($14 million).  Private donors, 
industry, and trade groups related to each platform within Iowa will be likely sources of supporting funds. 
These chairs should be funded in accordance with the technology platform priorities.  In other words, 
those platforms with the highest priority should receive funding for an Eminent Scholar first.  It is 
anticipated that Eminent Scholars for two platforms could be funded per year, so that within 4 years all 
the platforms’ Eminent Scholars could be funded.   
Time Frame:  Short-term 
Lead Organization(s):  Iowa Board of Regents and the individual regent universities 
Action Three:  Form a Strategic Technology Platform Infrastructure Fund to strengthen 
and accelerate the scientific and commercialization work of the core bioscience platforms.   
Rationale:  As noted previously, bioscience-based economic development holds great potential for Iowa; 
but, the state is in competition with other states that are making considerable investments in building their 
bioscience technology base.  California, for example, is investing $100 million in a bioengineering and 
biotechnology institute, while much of Georgia’s $300 million spent over 10 years has gone to support 
the development of core research facilities.  Texas appropriated $800 million for seven new or expanded 
health science research centers.  Attracting and retaining world-class bioscience R&D talent in Iowa 
require world-class facilities, infrastructure, and scientific resources. 
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Action Specifics:  Iowa faces two primary issues 
in both enhancing and building more robust 
technology platforms:   
• The need for facilities and equipment for each 
platform area  
• The need for technology infrastructure 
investments in pilot plants, demonstration 
facilities, and other translational facilities and 
equipment that enable the platforms to move 
research downstream so that it is more market 
ready for industry use and adaptation.   
The proposed Strategic Technology Platform 
Infrastructure Fund will serve as a vehicle to make 
strategic state investments in key areas that serve 
to build both research stature and technology 
commercialization capabilities.  As a result of the 
Iowa Values Fund, nearly $30 million in invest-
ments are being made to address facilities and 
commercialization; however, additional invest-
ments are still needed for facilities, equipment, 
technology infrastructure related to technology 
platforms.  
It is suggested that the Strategic Technology 
Platform Infrastructure Fund have two 
components:  
• A matching grant program to catalyze key 
investments required to strengthen and 
accelerate the scientific and commercialization 
work of the core bioscience platforms   
• A one-time investment fund for other 
specialized infrastructure needs (such as wet 
labs, incubator space, specialized equipment, 
etc.) related to one or more platforms.  
It is recommended that the Iowa Values Fund 
administer and manage this fund since it is 
consistent with its current efforts and its Board 
represents a partnership of several state agencies, 
including the IDED and Board of Regents. 
Guidelines will need to be established for this two-element fund once initial financing is provided.  The 
state should not use a rigid time frame for awarding funds, but instead should establish criteria that will 
drive the utilization of the fund based on appropriate measures, such as economic impact, linkages to one 
or more platforms, etc. 
Examples of States’ Investments in the 
Biosciences  
 California is investing $100 million in a 
bioengineering and biotechnology institute and 
$500 million in pension funds toward the 
California Biotechnology Program 
 Georgia has invested more than $300 million 
over a 10-year period to build core research 
facilities and to attract Eminent Scholars, the 
majority of whom are in the life sciences. It has 
created a $1 billion Georgia Cancer Coalition 
that is designed to make Georgia a national 
leader in cancer prevention, treatment, and 
research 
 Texas appropriated $800 million for seven new 
or expanded health science research centers. 
 In 2002, Arizona's public and private leaders 
raised $90 million to support the development of 
the Translational Genomics Research Institute 
(TGen), a nonprofit biomedical research institute 
whose mission is to make and translate genomic 
discoveries into advances in human health.  In 
2003, the Legislature and Governor approved 
$440 million to fund university research facilities, 
primarily in the biosciences. 
 The State of Florida committed $310 million in 
one-time federal economic-stimulus funds and 
nearly $200 million more in county and local 
resources to recruit the Scripps Institute to 
locate an East Coast facility on a 2,000-acre site 
in West Palm Beach. The state has also 
provided $30 million to create three Centers of 
Excellence, two of which are in the biosciences, 
and recently announced that it would invest up 
to $1 billion of its $102 billion employee pension 
fund in venture capital.  An initial $350 million 
will be invested during the next 12 months. 
 Anticipating more than $500 million in increased 
tax revenue over the next decade from growth of 
the bioscience sector, Kansas passed an 
Economic Growth Act that authorizes creation of 
a Kansas Bioscience Authority with the capacity 
to provide funding for faculty recruitment, 
research collaboration, and additional facilities. 
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Resource Requirements:  Using the benefit of low-interest rates, bond financing is an obvious route to 
generate the investment dollars required to support major capital and infrastructure investments in the 
core bioscience platforms. Consideration should be given to using some of the state’s bonding capacity to 
move from a “pay-as-you-go” philosophy to an investment philosophy, particularly for what may emerge 
as major strategic projects whose price tags would be too large in any one year for the state to make 
investments.  By enabling general fund bond financing of the fund at approximately $170 million, or 
$97 million in the first 5 years and $73 million in the second 5 years, actual investments can be made over 
several years, enabling the state to make strategic investments as opportunities arise. These are indeed 
investments in Iowa’s economic future. 
Time Frame:  Short-term 
Lead Organization(s):  Iowa Values Fund, which includes staff support provided by the IDED and the 
Iowa Board of Regents  
Action Four:  Engage Iowa’s Congressional Delegation in discussions pertaining to federal 
funding and specific project support. 
Rationale:  Historically, federal R&D support has played a very important, if often unheralded, role in 
building up the core competencies of leading technology regions.  The importance of discretionary R&D 
support in building Silicon Valley and the Route 128 corridor in Massachusetts has been well docu-
mented.  The recent rise of northern Virginia as a leading Internet region and the rise of Maryland as a 
center for the biosciences also reflect years of strong federal discretionary R&D support. 
Today, many states, through their public and private representatives, have been working more closely 
with their Congressional Delegations to ensure federal investments that help create the research and 
research infrastructure anchors that help build bioscience economies. As noted under “Key Success 
Factors,” one key lesson for states and regions building a bioscience economy is the importance of federal 
funds for federally designated centers and institutes, whether the funding comes in the form of operating 
or capital funds.  Almost every major mature bioscience region or state in the nation has one or more 
federal “anchors” that have contributed to building its bioscience base, e.g., the National Institute of 
Environmental Health Sciences in Research Triangle Park, Lincoln and Draper Labs in Boston, and NIH 
in Maryland.  Discretionary federal funding unfettered by federal mission also plays a role in enabling 
exploratory research to be undertaken that may lead, many years later, to applications in the health and 
biomedical arenas.  
Increasingly, states, ranging from Missouri and Pennsylvania to Ohio and Connecticut, are seeing the 
benefits from such federal investments.  Missouri’s efforts in working with its Congressional Delegation 
have brought in $25 million a year for the past several years.  This funding is helping to build the 
University of Missouri System’s research infrastructure, which has been adversely affected by a shortage 
of state capital funds.  Research infrastructure funding is generally not available from federal grant 
programs, necessitating efforts to identify and secure discretionary federal funding support. 
Action Specifics:  Iowa needs to identify key areas where the state can compete successfully for federal 
discretionary funding.  Iowa should work closely with its Congressional Delegation to ensure that the 
state and its research institutions are given strong consideration and viewed as a key region for bioscience 
research funding.  It is suggested that Iowa’s research universities, state government, and industry leader-
ship identify annually those parts of this bioscience strategy that could benefit from federal funding and 
investment.  This multiyear strategy provides the basis for identifying an annual Iowa Congressional 
Delegation agenda to secure discretionary federal infrastructure and research funding support.  Federal 
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legislators need to be presented with specific projects for which they may work to secure funding.  When 
equipped with a specific project “ask,” Congressional Representatives and Senators are far more likely to 
be able to take the actions required to apply leverage to funding agencies or introduce financing bills. 
Resource Requirements:  No new resources will be required for this action; rather, this function needs to 
be lodged in some organization and actively undertaken and updated. 
Time Frame:  Short-term 
Lead Organization(s):  IDED and the Iowa Board of Regents 
Action Five:  Institute an industry-university matching grant program dedicated to the 
identified bioscience technology platforms to encourage relationships between academic 
researchers and industry. 
Rationale:  To build a strong, nationally competitive, research enterprise, research universities and 
organizations are increasingly partnering with local, regional, and national firms.  While Iowa does not 
yet have a critical mass of bioscience firms in each of the platform areas, there are representative 
companies in each of the platforms that may form the foundation for enhanced industry-university 
relationships.  Finding ways to link the needs of firms and the expertise of bioscience faculty and to 
undertake collaborative research, translational research, and applications can benefit faculty interested in 
seeing their ideas developed.  For the state and its citizens, this represents a way for higher education 
institutions to be accessible and beneficial to industry.  Numerous states have initiated matching grant 
programs and other seeding efforts to promote active industry-university joint research relationships.  
Examples include the following: 
• The Kentucky Research Voucher program 
• Utah Centers of Excellence program 
• Pennsylvania Ben Franklin program 
• California’s Regional Technology Alliance program. 
Utah’s program, for example, is budgeted at approximately $2 million per year, supporting approximately 
15 projects at any given time, with allocations up to a maximum of $200,000 per project.  The state 
funding must be matched by industrial partners.  Since 1986, a total of 80 projects have been funded at a 
cumulative investment of $832 million, matched 10:1 by funds from industrial partners. 
Action Specifics:  To assist Iowa’s existing bioscience base, encourage industry-university 
collaborations, and spur new enterprise development, a Bioscience Matching Challenge Grant Program is 
proposed.  Funds would be awarded on a competitive basis with a 3:1 industry match required, including 
at least a 1:1 cash match.  Funding would total at least $100,000 to $250,000 per year, with maximum 
awards limited to 3 years.  This level of funding can provide the scale of impact required to spur high-
level, collaborative research.  University intellectual property policies would apply; however, the industry 
participant would have a “first right of refusal” for an exclusive licensing option for a funded project. 
Resource Requirements:  Total state funding through bond financing would begin at $1.5 million to 
$3 million in the first year and ramp up to $3 million by year 5 and then to $5 million by year 10.  The 
program should focus on the biosciences for the first few years but be expanded to IT and advanced 
manufacturing in future years. 
Time Frame:  Immediately 
Lead Organization(s):  IDED 
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STRATEGY TWO:  ENCOURAGE AND FACILITATE THE COMMERCIALIZATION OF 
BIOSCIENCE R&D TO ENHANCE OPPORTUNITIES FOR START-UP, EMERGING, 
AND EXISTING IOWA FIRMS. 
To accomplish sustainable economic development, the state also must focus significant efforts on 
converting research innovations into commercial business enterprises.  The path from innovation at the 
bench to a successful company deploying the innovation in the marketplace is complex, and Iowa’s 
investments need to be properly aligned in order to ensure success at each major factor in the path to 
commercialization.   
Historically, Iowa is not among the most dynamic of states when it comes to entrepreneurship and new 
business development.  The Progressive Policy Institute’s 2002 State New Economy Index ranks Iowa in 
the bottom quartile of states for “economic dynamism,” a metric defining a state’s ability to foster the 
creation of new firms, support firms that innovate, and cultivate a culture that is epitomized by fast-
growing, entrepreneurial companies.  The Progressive Policy Institute found Iowa to rank 37th in the 
nation in the number of scientists and engineers in the workforce, 32nd in industry investment in R&D, 
42nd in venture capital, and 32nd in innovation capacity17—so there is certainly a need to upgrade the 
state’s performance in the innovation-driven economy.   
Economic payoffs from investing in the commercialization of the biosciences can be significant.  One 
study found that 31 percent of new products and 11 percent of new processes in the biomedical field 
could not have developed without substantial delay had there not been academic research.18  However, 
research by itself does not generate substantive economic development results.  What has to happen to 
engender economic development is the conversion of research discoveries into marketable products and 
services, providing jobs, income, and revenues through a value-added output chain.  Figure 13 illustrates 
one example of the economic value chain that indicates the conceptual benefits that result from 
commercialization and value-adding activities. 
Technology commercialization and the building of economic value chains involve bridging the gap 
between innovations and discoveries and the commercial development of those discoveries by bioscience 
businesses.  There are three macro-level components that a state must adequately address to achieve 
commercialization success: 
• The technology transfer functions, including policies, structure, incentives, and approach.  Cutting-
edge programs actively encourage faculty and student engagement in commercialization initiatives 
and aggressively pursue faculty disclosures, patenting, and licensing.  New business enterprise 
formations are actively encouraged where justified, as well as the active marketing of university IP to 
existing business enterprises.  In leading universities, such functions are also being expanded to 
include active technology commercialization. 
 
                                                 
17 http://neweconomyindex.org/states/2002/iowa.html. 
18 Edwin Mansfield, “Academic Research and Industrial Innovation”, Research Policy, 1998, 26:773-776 
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Figure 13:  Multiple Stages of Value Capture from Innovation through Production 
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Increasing economic development value for Iowa
 
 
• Commercialization activities, including assessing 
the market and commercial viability of intellectual 
property, finding funding support to assess the 
value of research discoveries, developing a 
commercialization plan, and funding proof-of-
concept/reduction-to-practice development.  
Purdue University, for example, has structured 
funding mechanisms to support this.  
• Firm start-up support, whereby the technology 
transfer and commercialization functions are 
broadened to provide searches for seed capital, 
management talent, and marketing assistance.  
Some universities have created third-party 
intermediaries to play this role (examples include 
Baylor, the Mayo Clinic, and Carnegie Mellon 
University), and some communities have formed 
stand-alone organizations such as the St. Louis 
BioGenerator and the Oklahoma Technology Commercialization Center.  
Within Iowa, the commercialization pathway needs to begin with a consistent message from both state 
and university leadership, that active faculty engagement in discovery disclosures and commercialization 
is encouraged.  In a recent study published by the Southern Growth Policies Board,19 it was discovered 
that a common theme among best-practice universities in commercialization and economic development 
                                                 
19 Tornatzky, Louis, Paul Waugaman, and Denis O. Gray. “Innovation U.: New University Roles in a Knowledge 
Economy.”  Southern Growth Policies Board, 2002. 
Purdue University’s Gateways Program 
Purdue University’s Gateways Program 
assists Purdue University researchers and 
other Indiana entrepreneurs in the commer-
cialization of intellectual property. The program 
provides a range of services including 
business plan development, test marketing, 
and financial and technical advice.  The 
Gateways Program uses a methodology that is 
often employed by high-performing firms in 
growing industries to identify, evaluate, and 
assist commercial business opportunities.  
Their “stage-gate” process includes matching 
clients with market-specific mentors, helping 
clients identify a clear pathway to develop-
ment, developing early-stage gap financing 
resources, and assisting with the formation of 
a management team.  
Source: Battelle Technology Partnership Practice 
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is a highly engaged senior university leadership 
team that is actively pursuing commercializa-
tion as a major university agenda.  The authors 
of this study note the following: 
Government leaders that have an 
interest in steering their state-based 
public institutions toward greater 
partnering need to be mindful of the 
leadership issue and how important it is 
to make careful choices at this level.  
University CEOs and other senior 
leaders will typically be in their jobs 
five to 10 years.  If they are hostile, 
inexperienced, or immune to this 
agenda, nothing much will happen 
during their watch. 
Other factors found to be of substantial 
importance at best-practice universities in the 
Southern Growth Policies Board study include 
the following: 
• Targeted recruitment of administrators and 
faculty experienced in university technology commercialization and corporate partnerships 
• Policies and reward structures to incentivize faculty engagement in commercialization and industry 
partnerships 
• An established and celebrated local lore regarding successful faculty entrepreneurs, important job 
creation initiatives, and projects that significantly helped local industry 
• Commercialization and partnering institutionalized for the long-term within the university, and a deep 
pool of staff dedicated to realizing the vision 
• An aligned set of university rules and regulations that serve to favor commercialization, 
entrepreneurship, and corporate partnering 
• Customer-friendly policies and contact points to facilitate relationships with the private sector 
• Efficient and well-funded technology transfer enterprises 
• Active assistance and outreach to existing industry and businesses 
• Entrepreneurial development services, including incubation facilities, entrepreneurship education, 
research parks with space for spin-off and corporate partners, outreach programs to engage 
community entrepreneurs, and well-formed relationships with venture financing sources 
• Placement and career services working to place students at in-state employers and establish early 
relationships via internships 
• Active university involvement in state and local economic development agencies 
Baylor’s BCM Technologies
BCM Technologies (BCMT), a wholly owned 
subsidiary of Baylor College of Medicine (BCM), was 
established in 1983 to help commercialize technology 
generated by the college. BCMT helps BCM’s 
licensing office decide whether a given BCM invention 
is better commercialized by a license or by formation 
of a spin-off company.  In the latter case, it catalyzes 
formation of a locally based company through a pre-
seed investment and provision of interim management 
services.  BCMT staff draft the preliminary business 
plan for the company, structure the company’s initial 
ownership including any shares granted to BCM in 
consideration of IP rights, serve as directors and 
interim executive management, and pitch the first-
stage investment deal.  BCMT also helps recruit the 
spin-offs first management team and structures a first 
formal round of investment in which the College 
endowment and outsiders may participate.  In the past 
10 years, 16 BCMT spin-outs have raised more than 
$300 million in capital from 30 different investment 
groups.  BCMT claims a 40 percent “internal rate of 
return” on its investment portfolio and has returned 
substantial cash to BCM. 
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• Participation in joint advisory 
boards and councils with the 
private sector to help align 
research and assistance programs 
with the needs of industry. 
While the regent universities have an 
important role to play in the path to 
commercialization, the burden of 
such activity must not be seen as 
theirs alone.  Economic development 
in Iowa should be a priority for all in 
the state—legislators, administrators, 
community leaders, business leaders, 
educators, and the general citizenry.  
This broader support for entrepre-
neurship and commercialization 
needs to be anchored in a state-
supported commercialization agency 
separate from, but working collabo-
ratively with, the university system.  
Numerous successful examples of 
such commercialization agencies 
exist throughout the United States, 
with components of their missions 
usually containing some or all of the 
following:  
• Assistance provided directly by experienced successful serial entrepreneurs for business plan 
development, market assessments, technology assessments, and other planning activities 
• Operation of competitive seed and prototype development funds 
• Access to competitive seed and early-stage financing funding, usually via administration of state-
funded venture financing pools 
• Close linkages to private angel investors and the venture capital community 
• Access to an experienced pool of managers and operations talent who can staff, mentor, or advise 
start-up enterprises 
• Coordination of, and access to, entrepreneurial and business skill development courses 
• Operation of a proof-of-concept/prototype development fund 
• Support and advice for accessing SBIR/STTR funds and other sources of early-stage financing. 
Placing these activities within a stand-alone, state-supported intermediary organization has several 
advantages.  It allows for the hiring of managers, personnel, and support staff who are dedicated to, and 
experienced in, start-up assistance and entrepreneurship.  It provides a clear partner organization for 
universities and other technology commercialization engines, ensuring that the burden of state technology 
commercialization not fall on them alone.  It provides private venture funders with a source of business 
Oklahoma Technology Commercialization Center (OTCC)
OTCC plays an important, and generally neglected, role in 
Oklahoma by positioning Oklahoma entrepreneurs to grow 
viable businesses. One key way is by helping start-ups focus 
their business plans and strategies through hands-on 
educational and training support and detailed consulting. OTCC 
also helps entrepreneurs secure angel financing and other 
early-stage funding (including a state seed fund program that it 
operates). OTCC has helped organize 44 angel investor groups 
across Oklahoma, involving 300 investors with a net worth of 
$2 billion. 
 
In addition, OTCC has established a certified Service Provider 
Program, which identifies proven, quality service providers 
(representing intellectual property law, corporate law, business 
consultants, marketing, engineering, science, and financial 
consulting), who are interested in providing assistance and 
support to technology entrepreneurs. 
 
The most important contribution of OTCC is its activities in 
helping to stimulate investment deal flow, as well as improving 
the quality of deal flow to private investors. In its first 2 years of 
operation, OTCC served 467 clients, of which 268 have 
received detailed project assistance and 74 have been 
presented before angel investor and other financing sources 
with nearly $15 million in hard-to-find pre-seed and seed capital 
dollars raised, leveraging more than four times the amount of 
state investment in OTCC operations. 
 Iowa’s Bioscience Pathway for Development 
 
 76 
funding opportunities that have been through a proven and professional process of advice, assistance, and 
due diligence—helping to lower investment risk.  Finally, such an organization can hire and pay the 
experienced serial entrepreneurial managers that make this work; with their salaries covered in part by 
their administration of a pre-seed fund for biosciences, operation of a prototype development fund, and 
ongoing coaching and mentoring to start-ups.  An additional task of this organization is to recruit such 
professionals to manage these functions with the intent to locate and place them into senior positions with 
start-ups within 18 months after being recruited to this intermediary, helping to build a talent capacity in 
Iowa. 
Clearly then, bioscience technology commercialization in Iowa needs to be accomplished through a series 
of initiatives with no single organization responsible for the entire effort:   
• The regent universities have a strong responsibility to mine their R&D to identify commercialization 
opportunities and assist in the early-stage development of those technologies most promising for 
commercial success.  Through efficient technology transfer, new business support services, 
entrepreneurial education, and business incubation initiatives, the regent universities will be a key 
driver of early-stage bioscience venture formation, in addition to encouraging R&D partnerships with 
Iowa bioscience industry.   
• State government has an important role to play in providing a reliable, long-term funding stream to 
support the above university activities, but also must be proactively engaged in the organization and 
funding of a stand-alone technology commercialization intermediary organization ensuring that non-
university–based entrepreneurs have a contact point for assistance and that university-birthed start-
ups have the professional advice, assistance, and access to funding that is required to move them to 
the next level of growth.  Successful bioscience economic development is also facilitated by the 
establishment of formal and informal networks of experienced company leaders, entrepreneurs, and 
professional advisors able to mentor one another, provide a unified voice on policies and issues of 
importance to their industry, and have a strong place at the table for influencing R&D and other 
related bioscience support directions for the state. 
Tactics 
The following key tactics will help position Iowa to accomplish this strategy: 
• Optimally leveraging academic R&D, intellectual resources, and scientific infrastructure to realize 
business growth and wealth creation in the State of Iowa from its regent universities 
• Providing long-term financial support to both academe and a stand-alone commercialization 
intermediary organization to provide consistent guidance and support to entrepreneurial endeavors 
from conception to accessing major venture capital rounds and other expansion capital resources 
• Addressing the need for networking opportunities for would-be and experienced entrepreneurs and 
technology commercialization personnel. 
Actions for Strategy Two:   
Action One: Create an Economic Development Director position at the Iowa Board of Regents to provide 
catalytic support for regent university economic development initiatives.  
Action Two: Develop and implement policies and procedures that actively encourage faculty 
entrepreneurship and commercialization activities at the regent universities. 
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Action Three: Increase funding to the regent universities to allow for sufficient staffing and resources for 
commercialization activities. 
Action Four:  Establish and fund a University Entrepreneurs Center at each university. 
Action Five:  Form a statewide commercialization intermediary for supporting, building, and sustaining 
new bioscience business enterprise development in Iowa.   
Action One:  Create and fund an Economic Development Director position on the Iowa 
Board of Regents to provide catalytic support for regent university economic development 
initiatives.  
Rationale: Iowa’s bioscience R&D base largely resides within the regent universities.  As such, it is 
imperative that the regent universities be brought into alignment in terms of the provision and support of 
economic development, corporate partnering, technology commercialization, and faculty entre-
preneurship.  Currently, there are distinct differences between the resources, capabilities, and impetus for 
economic development action across the universities.  Iowa State University’s history as a land grant 
institution brings with it a culture of outreach, industry collaboration, and technology transfer.  The more 
traditional academic structure of the University of Iowa, on the other hand, has placed a lesser emphasis 
on such activity.  By appointing an economic development director as a senior staff member of the Board 
of Regents, the Regents will be able to support and encourage efforts to make the technology platforms 
more robust; help address barriers and 
impediments to technology transfer, 
commercialization, and industry 
partnering; and otherwise play a 
catalytic role with each university.  In 
addition, this position can serve as staff 
support to the newly created, industry-
driven, economic development 
committee that has been formed by the 
Regents to pursue similar initiatives.  
Providing direct support for this 
committee will help ensure that the 
guidance provided regarding new 
initiatives and revised policies and 
procedures is implemented. 
Action Specifics:  This position on the 
Board of Regents will need to be 
staffed by a person with several key 
characteristics: (1) experience in 
collaborations between industry and 
academe, (2) credibility within the 
academic community, and (3) under-
standing of the basic requirements of moving technology from the bench to the marketplace.  A person 
with a background in academe, but with significant industry and business development experience, would 
be ideal. 
Yale University’s Office of Cooperative Research 
Yale University’s Office of Cooperative Research highlights the 
following reasons for universities to be involved in start-ups: 
 
 Public Benefit and Academic Mission.  The generation 
of widely applicable public benefits from research 
discoveries made at the university is consistent with the 
academic mission and goals of the faculty of all major 
institutions. 
 Economic Development.  New ventures formed to 
undertake the commercialization of inventions provide 
opportunities to promote the development of the local 
economy. 
 Faculty Recruitment and Retention.  It has become 
more common for faculty members being recruited to 
the university to inquire about opportunities to become 
involved with existing as well as start-up companies in 
the area.  It is also increasingly common for faculty 
spouses to look for private sector companies for 
employment. 
 Financial Incentives.  Universities will accept equity as 
part of the consideration for licensing intellectual 
property or assisting in the formation of a new venture. 
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The Regent Economic Development Director would be responsible for aligning the regent universities in 
Iowa on delivery of the core actions outlined for them within this bioscience strategy.  The Director 
would work to ensure that economic development and commercialization are maintained as high-priority 
activities at each of the regent universities and that the Regents provide sufficient leverage with the state 
to help ensure that these important activities are adequately funded.  The Director will staff the newly 
created, industry-driven, economic development committee and work to carry out its directives.  In 
addition, the position also will coordinate with the proposed Bioscience Advocate within IDED (Strategy 
Three, Action Two) regarding proposed initiatives, policies, procedures, and university reporting 
requirements and information collection.   In neither case is the intent to use these positions to create 
more administrative reporting; the clear intent of both positions is to create catalysts for action working 
with higher education, industry, and others.   
Resource Requirements:  $150,000 per year including support costs for the first 5 years 
Time Frame:  Immediate 
Lead Organization(s):  Iowa Board of Regents 
Action Two: Develop and implement policies and procedures that actively encourage 
faculty entrepreneurship and commercialization activities at the regent universities. 
Rationale:   For Iowa to succeed as a center for bioscience sector growth, its R&D-generating institutions 
must be places that celebrate and facilitate the movement of discovery to commercialization.  Doing so 
requires that many issues be addressed, including faculty incentives; conflict-of-interest policies; access 
to commercialization space; and provision of advice and professional assistance, technology transfer, and 
incubation services.  University faculty has the responsibility to pursue scholarship and to educate the 
next generation of scholars and practitioners.  In addition, in an academic medical center or veterinary 
college setting, there is the added mission of clinical practice.  As such, there are considerable require-
ments placed on the time and energy of faculty; it is, therefore, imperative that the pathway to 
commercialization of their innovations be seen as well-supported and “doable.”  Those states and regions 
of the country that are performing well as technology growth poles tend to share a factor in common—
they are home to universities that have embraced the commercialization mission and put in place policies, 
procedures, and proactive services to facilitate it. 
Action Specifics:  One of the characteristics of best-practice universities in technology development and 
commercialization is that they have established a culture and policies that provide clear rewards and 
incentives for faculty engagement in commercialization, translational research, and industry 
collaborations. Such support has to be expressed vigorously from the highest levels of university 
administration, with a clear message sent to deans and department heads that technology 
commercialization is viewed equal in importance to research and education missions. 
Actions taken in relation to university procedures and policies must be seen by the faculty to be 
supportive of entrepreneurial and commercialization activities.  This requires that the university’s 
administration is seen as being “on the entrepreneurial faculty members’ side,” working with them to find 
ways to make necessary actions happen.  Being flexible in the provision of entrepreneurial leave, 
allowing very early-stage tech commercialization efforts to occur within faculty members’ on-campus 
labs, and actively celebrating faculty commercialization efforts in university communications are the 
types of activity required. 
 Iowa’s Bioscience Pathway for Development 
 
 79 
University administration also can be directly supportive of faculty entrepreneurship by funding 
“entrepreneurial fellows,” positions in which active university financial support is provided to scholars 
with highly promising technology commercialization opportunities.  Such fellowships also can be a 
means to retain highly promising postdocs and graduate students at the universities to assist in 
commercialization of their R&D work. 
Therefore, specific actions that the Iowa Board of Regents and the individual regent universities should 
pursue include the following: 
• Providing clear rewards and incentives for faculty engagement in commercialization of innovation 
with translational research, and ensuring technology commercialization is viewed equal in importance 
to research and education missions 
• Being flexible in allowing the very earliest investigations of commercialization and business start-up 
to occur within faculty labs 
• Providing flexible entrepreneurial leave policies 
• Funding “entrepreneurial fellows” positions, providing university support to those engaged in 
entrepreneurial R&D. 
Resource Requirements:  $200,000 per year for the first 5 years, including fellows and support costs to 
address various elements listed above 
Time Frame:  Immediate 
Lead Organization(s):  Iowa Board of 
Regents and the individual regent 
universities.  Potential requirement for 
state legislation and policy changes. 
Action Three:  Increase funding 
to the regent universities to allow 
for sufficient staffing and 
resources for commercialization 
activities. 
Rationale:  As the 21st century 
progresses, it is clear that knowledge 
and innovation are going to be the 
drivers of economic progress.  As 
such, those institutions that generate 
knowledge and innovation have to be 
equipped with the resources required to 
maximize their positive economic 
output.  Against this background, it is 
imperative that the State of Iowa make 
commercialization and industry 
partnering not only a core mission of 
its universities, but also one that is well 
funded and supported by the state.  
Wisconsin Alumni Research Foundation (WARF) 
Established in 1925, WARF’s mission is to support scientific 
research at UW by moving inventions to the marketplace and 
investing licensing proceeds to fund further research. It has 
been highly successful, and each year more than $1 billion of 
products are sold under license from the organization. WARF 
receives 360 disclosures annually and accepts 60 percent for 
patent applications. WARF licenses 100 to120 technologies per 
year and returns $40 million to $45 million back to the 
university. More than 300 UW faculty and researchers are 
currently receiving WARF patent royalties. 
  
WARF’s influence extends beyond the Madison campus as the 
organization also manages the WISys Technology Foundation, 
which provides patent and licensing services to the entire UW 
System. WISys, established in 2000 as a pilot project, is a 
wholly owned subsidiary of WARF. The foundation is currently 
handling disclosures for 12 of Wisconsin’s 13 four-year 
universities, and their portfolio includes some exciting 
technologies from campuses in Milwaukee to Eau Claire.  
 
WARF’s “What’s IN It For Wisconsin Business” campaign is 
designed to make the Madison-based foundation more 
accessible to companies throughout the state, as well as to 
educate them about the wealth of home-grown product 
potential—in the form of patented UW discoveries. Since 1993, 
WARF also has taken an equity position in 29 start-ups, many 
of them in Wisconsin. 
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Unfunded mandates to the universities, at a point in time when faculty salaries and other basics are 
essentially frozen, will be ineffectual.  Iowa cannot afford to lose the opportunity it has to assume a 
leadership position in key areas of the bioscience economy.  Instead, it must invest in its bioscience 
technology and innovation drivers. 
Action Specifics:  Each of the platforms will require investment and support in university-based 
commercialization and technology transfer, with specific services provided in the following areas: 
• Proactive mining of university R&D for commercialization opportunities (e.g., proof-of-
concept/prototype development support).  The current situation facing Iowa’s universities—limited 
staff and, depending on the institution, differing policy support for technology transfer and 
commercialization—leads to a less-than-optimal effort to encourage faculty disclosure and entre-
preneurial activity, including licensing and commercialization.  This situation runs the risk of missing 
opportunities among faculty who are not entrepreneurially or commercially inclined.  Instead, the 
universities should have staff experienced in recognizing innovations with commercial market 
opportunity and who are actively mining departments and research programs.  Each of the platforms 
will be established to directly facilitate commercialization, so this will be an integral function of each 
platform.  However, many opportunities also will exist at the universities outside of the direct 
platform areas, so at least one full-time employee (FTE) will be required at both ISU and U of I, plus 
a half-FTE at UNI. 
• Technology transfer and IP protection. Efficient technology transfer and IP protection operations, 
operating at a realistic commercial pace, are critical.  If these functions create significant bottlenecks 
and long delays in the commercialization process, then faculty may be dissuaded from commercial-
ization endeavors, market opportunities may be lost, and industry partners frustrated.  U of I needs 
additional resources to build its capabilities in this area to the same level as that enjoyed at ISU.   
• Preliminary technical and business development assistance to emerging faculty entrepreneurs and 
basic business plan development and application assistance for accessing the services and resources 
of the statewide commercialization intermediary organization.  Certain services are best delivered at 
the local, university-level, whereas others will be more efficiently provided through a statewide 
commercialization intermediary organization.  At the university level, staff will be required for very 
early-stage business development services to coordinate access to outside expertise and align services 
with the statewide commercialization intermediary. 
Ultimately, both ISU and U of I should be staffed with two FTEs to provide preliminary business 
development assistance (one bio-related and one for other opportunity areas).  UNI should have one 
FTE in a similar position.  Based on ISU-provided norms, funding for these positions will 
approximate $150,000 per FTE for salary, operating costs, and administrative support (a total of 
$750,000 for the five positions across the three universities).  ISU and U of I should each be allocated 
$250,000 per year to acquire services of outside experts in assisting very early-stage inquiries, while 
UNI should receive $100,000. 
• Maintenance, operation, and expansion of incubator facilities and key infrastructure facilities 
suited to the needs of fledgling bioscience companies.  Specific space suited to the needs of start-ups 
in the biosciences is required, as are certain infrastructural investments required to progress 
commercialization across platforms (such as the planned protein facility at the ISU Research Park). 
Incubator and infrastructure facility priorities will be established by the Academic Consortium for 
each platform working in consultation with the university-based technical and business development 
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assistance staff and with advisory input from the leadership of the statewide commercialization 
intermediary organization.  Funding for incubator and infrastructure improvements will come through 
the Strategic Technology Platform Infrastructure Fund (see Strategy One, Action Three).   
• Internal senior advocacy positions to assist faculty entrepreneurs with individual department issues 
and rapid resolution of any issues related to an individual’s entrepreneurship activity.  The technical 
and business assistance staff should work to provide problem resolution services at the department 
and college levels.  Issues, barriers, and problems unable to be resolved at this level should be 
referred to the Vice Provost for Research office at each university. 
• Industry liaison and the matching of faculty expertise to firm needs.  Formal staff is required at the 
universities to establish connections between platform research and researchers with industry, host 
industry visits, arrange for faculty to visit industry, and assist industry in accessing key university 
bioscience resources.  One FTE should be funded for each of the seven platforms (six main platforms 
and one niche), with the staff person located at the lead university designated for each platform.  In 
addition, the industry liaison should work extensively when appropriate within the existing infra-
structure of ISU’s Extension activities to help ensure that appropriate connections and linkages are 
able to be made and encourage Extension assistance and help in implementing this Bioscience 
Pathway. 
• Technology development/pre-seed funds.  A pool of funds should be established for each of the 
universities to administer that would be invested in very early-stage investigation of commercial-
ization opportunities based on faculty/university innovations.  While the statewide commercialization 
intermediary organization will be the principal conduit for start-up development funds, additional 
discretionary funding should be provided to each of the regent universities for use in very early-stage 
commercialization assessments and business formations.  Ultimately, ISU and the U of I should each 
be allocated $500,000 in annual funds in support of technology development and pre-seed funding, 
while UNI should initially receive $150,000.  In addition, each university should be encouraged to 
match this investment, doubling the size of the fund. 
• Faculty entrepreneurship success stories. These success stories should be identified and their use in 
on-campus communications materials and public relations stories actively promoted. The activities of 
National Academy members and department heads in patenting and business ventures to help seed 
credibility and support should be promoted. It is imperative that success stories be shared across 
campus as part of each university’s mission to actively promote and celebrate faculty entre-
preneurship and technology commercialization.  This function should be housed within the 
technology transfer office at each institution, with monthly meetings held with each platform to 
identify communications opportunities. 
• Faculty who have had problems with commercialization. These faculty members should be 
identified and engaged to profile the problems they experienced and to assist in work to remove and 
mitigate barriers.  To avoid the promulgation of negative experience stories and to communicate new 
attitudes and support for faculty entrepreneurships, those faculty known to have had negative 
experiences should be met with individually to solicit their support for the changes being made.  They 
should be asked to provide advice on changes and also to be circumspect in discussing past problems 
that may have been resolved or are in the process of being resolved. 
• On-campus bioscience industry and capital events.  Such events should be hosted to showcase the 
new attitude and support of the universities for technology commercialization, industry collaboration, 
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and faculty entrepreneurship.  They should be followed up with regular communications to these 
external parties highlighting progress and success stories.  Once support staff is in place, procedures 
refined, and all policies developed, the regent universities should be marketed through a showcase 
event to the bioscience industry and capital funding organizations. 
• Marketing and communications activities at each of the regent universities, targeted at proactively 
marketing each of the platforms to relevant industry groups and related associations.  One FTE per 
platform should be funded to lead the process of marketing the platform and the university’s 
capabilities and services. 
Resource Requirements:  In total, the university-based technology transfer, economic development, and 
commercialization activities will require the following annual resources, and it is proposed that these 
funds be gradually achieved over a 5-year period as detailed in the implementation section of this report. 
 
Activity Staffing and Operations Investment Funds and Infrastructure Funds 
Proactive mining of university 
R&D 
ISU = $200,000 
U of I = $200,000 
UNI = $200,000 
 
Technology transfer and IP 
protection 
ISU* = $3.3 million 
U of I = $2.2 million 
UNI = $300,000 
  
Preliminary technical and 
business development 
assistance 
ISU = $300,000 
U of I = $300,000 
UNI = $150,000 
$250,000 at ISU and U of I for 
accessing external expertise and 
$100,000 at UNI for same. 
Incubator facilities and key 
infrastructure facilities 
State support for incubator 
operations at each university. 
Investments as required over time to 
meet demonstrated demands.  
Investment through Strategic Platform 
Technology Infrastructure Fund. 
Internal senior advocacy 
positions 
Shared function of staff under 
technical and business development 
assistance. 
 
Industry liaison ISU = $150,000 for each of three 
platforms ($450,000). 
U of I = $150,000 for each of four 
platforms ($600,000). 
UNI = One FTE ($150,000) for work 
across all platforms UNI will engage 
in. 
 
Technology development/pre-
seed funds 
Shared function of staff under 
technical and business development 
assistance. 
$500,000 to be provided to ISU and U 
of I.  $150,000 to UNI. 
Identifying success stories Shared function of staff in marketing 
and communications. 
 
On-campus bioscience industry 
and capital events 
Shared function of staff in marketing 
and communications. 
 
Marketing and communications ISU = $150,000 for each of three 
platforms ($450,000). 
U of I = $150,000 for each of four 
platforms ($600,000). 
UNI = One FTE ($150,000) for work 
across all platforms UNI will engage 
in. 
 
* Amount for ISU is higher because of high volume of required activity in germplasm and other ag-related licenses. 
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Time Frame:  Immediate 
Lead Organization(s):  IDED in collaboration with Iowa Board of Regents.  Deployment of services and 
program design the responsibility of the individual regent universities 
Action Four:  Establish and fund a University Entrepreneurs Center at each university. 
Rationale:  Faculty members and scientists are obviously intelligent, well-educated individuals. In the 
sectors of interest to this report, this means that they will be well-versed in science and their specific 
niche area of bioscience.  It does not, however, mean they have any education, background, or experience 
in commercializing technology or building a business.  Just as science is advanced by education, training, 
mentoring, and collaborations among scientists, so too must be the skills of business venturing and 
technology commercialization.  
While the Pappajohn Centers established across Iowa, in addition to other entrepreneurial support 
organizations located at the universities, have done an excellent job in coaching a wide variety of 
businesses, it is recognized that they might not be sufficiently staffed nor have the bioscience-specific 
experience to offer the type of in-depth assistance that a bioscience entrepreneur may need. Companies 
interviewed cited the usefulness of the Pappajohn Centers for performing market research and other basic 
tasks and also for providing access to interns for bioscience companies; however, they also cited the need 
for the assistance of experienced “serial bioscience entrepreneurs” to help navigate the difficult business 
climate in which they operate.    
It is clear that opportunities for bioscientists to network with experienced entrepreneurs and build their 
skill set in commercialization have been quite limited and disjointed.  Opportunities for frequent 
networking and for the development of commercialization and basic entrepreneurship skills need to be 
provided for faculty, research staff, and students. 
Action Specifics:  Through leveraging the existing framework of entrepreneurial organizational 
assistance—whether it be by expanding the role of a Pappajohn Center, creating another organization, or 
blending efforts with initiatives underway at each campus—each University Entrepreneurs Center should 
focus its efforts on the following activities:  organizing and facilitating entrepreneurial events and 
networking opportunities; providing access to experienced mentors; and driving other initiatives that 
create a community around faculty, staff, and student entrepreneurship on campus.  How these centers are 
established and their linkages to Pappajohn and other efforts should be decisions made at each campus, 
reflecting their individual circumstances.   
Within the Colleges of Medicine and Engineering at the University of Iowa, an experienced faculty 
entrepreneur mentoring group is already taking form.  This type of structure is to be encouraged at each of 
the regent universities.  Services and mentoring for faculty and student entrepreneurs need to be 
coordinated through a specific organization at each campus.  This may involve leveraging the resources of 
the Pappajohn Centers; but, in most cases, a formal biomedical entrepreneur’s support group will need to 
be formed. 
As a component of the centers, formal on-campus entrepreneurship boot-camp courses should be 
developed that would be made available on a regular basis for faculty, staff, and students. A university 
incentive should be provided for participation and completion of the boot camp.  In addition, a specialized 
track for bioscience-related entrepreneurship should be created. 
Resource Requirements:  $150,000 at each of the regent universities to support formation and initial 
program development for bioscience entrepreneurship development and support, or $450,000 in total. 
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Time Frame:  Short-term 
Lead Organization(s):  University of Iowa and Iowa State University, with collaborative support from 
the University of Northern Iowa 
Action Five:  Form a statewide commercialization intermediary for supporting, building, 
and sustaining development of new bioscience business enterprises in Iowa.   
Rationale:  It is both unrealistic and unfair to expect that universities alone can drive and support 
technology commercialization and new venture formation in Iowa.  While universities are significant 
centers for innovation and discovery and also can be supportive environments for early steps on the 
commercialization and business formation pathway, it has been recognized in other parts of the country 
that a stand-alone intermediary commercialization entity is often the most realistic means of helping to 
ensure success.  In best-practice states and regions, this intermediary resource stands ready to receive the 
handoff of fledgling commercial entities from the academic sector.  Such a resource or entity usually must 
take the form of a professionally managed, well-funded organization dedicated to facilitating business 
growth, providing access to experienced management talent, and streamlining business access to the fuel 
for growth—expansion capital.  Currently, in Iowa, such an intermediary organization is needed but does 
not exist. 
Action Specifics:  As noted previously, economic development in Iowa should be a priority for all in the 
state—legislators, administrators, community leaders, business leaders, educators, and the general 
citizenry.  This broader support for entrepreneurship and commercialization needs to be anchored in a 
state-supported commercialization agency separate from, but working collaboratively with, the university 
system.   
The state commercialization intermediary organization would work to address technology, capital, and 
talent issues, including the following: 
• Assistance provided directly by experienced successful serial entrepreneurs for business plan 
development, due diligence, market assessments, technology assessments, and other planning 
activities 
• Operation of competitive seed and prototype development funds 
• Access to competitive seed and early-stage financing funding, via collaboration with Iowa’s state-
funded venture financing pools and ag-related venture pools 
• Close linkages to private angel investors and the venture capital community 
• Access to an experienced pool of managers and operations talent who can staff, mentor, or advise 
start-up enterprises 
• Coordination of, and access to, entrepreneurial and business skill development courses (provided in 
collaboration with the regent universities) 
• Operation of a proof-of-concept/prototype development fund 
• Support and advice for accessing SBIR/STTR funds and other sources of early-stage financing. 
It is important that the technology commercialization center focus on firms wishing to start and expand in 
Iowa.  In many cases, these firms will have strong growth prospects, but will not always represent the 
“home runs” on which the formal venture capital community focuses.  Yet, these firms represent real 
opportunities to create wealth and jobs in Iowa. 
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As noted previously, placing these activities within a stand-alone, state-supported intermediary 
organization has several advantages: 
• It allows for the hiring of managers, 
personnel, and support staff who are 
dedicated to and experienced in start-
up assistance and entrepreneurship.   
• It provides a clear partner 
organization for universities and 
other technology commercialization 
engines, assuring that the burden of 
state technology commercialization 
does not fall on them alone.  
• It provides private venture funders 
with a source of business funding 
opportunities that have been through 
a proven and professional process of 
advice, assistance, and due diligence, 
which all help to lower investment 
risk.   
• It can hire and pay the experienced 
serial entrepreneurial managers who 
make this work; their salaries can be covered in part by their administration of a pre-seed fund for 
biosciences, operation of a prototype development fund, and ongoing coaching and mentoring to 
start-ups.  An additional task of this organization is to recruit such professionals to manage these 
functions with the intent to locate and place them into senior positions with start-ups within 18 
months after being recruited to this intermediary, helping to build a talent capacity in Iowa. 
It is suggested that a requirement be put in place that any state or university-invested funds used in the 
formation and growth of a bioscience business venture be repaid in full in the event that the business 
venture locates or relocates more than 50 percent of its operations and staff outside of the State of Iowa. 
Resource Requirements:  The commercialization intermediary organization should receive $1 million 
from the State of Iowa to fund its first year of operations.  This should rise to $1.5 million in year 2 and 
plateau at $2 million in annual funding by year 3.  This will fund the provision of services outlined above, 
with the exception of the following additional requirements: 
• Prototype Development Fund at $3 million to $5 million capitalized in year 2 of the financial plan 
from bond financing   
• BioSeed Fund at $25 million in capitalization, but whose funding would come from the separately 
initiated Fund of Funds program. 
Time Frame:  Immediate 
Lead Organization(s):  IDED in collaboration with the regent universities. 
 
University Role in Industry Clusters  
A new report by the Center for Economic Development at 
Carnegie Mellon University documents case studies of the 
university role in promoting and sustaining industry clusters, 
and assesses the factors that are vital to successful 
university-industry cluster development.  
Key factors for universities are: 
• Breadth of Involvement - engaged universities are 
sources for research and technology, but also address 
other important factors such as business, marketing, 
legal, and workforce issues;  
• Strong Base of Relevant Research and Development; 
• Regional Alignment - the university must have the 
expertise and resources in appropriate areas that align 
with the needs of the clusters in the region.  
According to the report, the characteristics of clusters are 
also important if there is to be a regional impact. While the 
university can seed new firms and industries, the region must 
offer a fertile climate for them to flourish. Key factors related 
to the industry cluster are its pattern of organization, market 
trends, and the life cycle stage of the industry or technology. 
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STRATEGY THREE:    FOSTER A BUSINESS ENVIRONMENT THAT SUPPORTS, 
SUSTAINS, AND ENCOURAGES THE GROWTH AND SUSTAINABILITY OF BIOSCIENCE 
FIRMS IN IOWA.   
Lessons learned from best practices around the nation verify that bioscience-based economies are more 
likely to thrive in a stable and supportive business environment.  Establishing such a climate means 
achieving alignment in many areas that serve to support bioscience business growth, including 
• Business-friendly tax policies; 
• Incentives designed to support the needs and opportunities of bioscience companies; 
• A quality of life conducive to the attraction of top-quality scientific and business talent; 
• Competitive costs of doing business; 
• A supportive cluster of businesses achieving agglomeration economies and benefiting from 
specialized support resources and services that meet their business needs; and 
• A network of sector companies and related interests working to drive policies and support programs 
to enhance the climate for their types of businesses. 
Iowa has a business environment that is currently supporting the growth of bioscience companies through 
programs such as the Iowa Values Fund.  However, there are distinct opportunities to improve current 
bioscience business development conditions in the state.  As noted earlier, Iowa was ranked 38th in the 
nation in the Progressive Policy Institute’s New Economy Index,20 so there is certainly room to improve 
the innovation and business growth environment.  It is important to note that this strategy does not 
attempt to address all the business and operational environment issues that affect Iowa; rather, it serves to 
highlight those most critical issues that are directly relevant to bioscience cluster growth. 
Tactics 
The following tactics should be pursued to create a business climate in Iowa conducive to the creation, 
growth, and retention of bioscience businesses: 
• Encourage the development of an overarching, private-sector-driven, bioscience business association 
for the state that serves to motivate and spur action on business environment issues of greatest import 
to its membership. 
• Critically examine the full suite of economic development services and incentives offered by the state 
to ensure they meet the current and emerging needs of bioscience sector operations. 
• Examine the state’s business regulations, tax policies, and legal code to ensure that those aspects of 
the business environment dictated by the state are conducive to bioscience business development and 
competitive with those of best-practice bioscience states. 
• Continue to brand Iowa as a center for the biosciences, and market and promote the state over the 
long term to maintain a high bioscience visibility and brand awareness. 
• Ensure that economic developers and associated professionals at state and local levels are educated in 
the specialized needs of the bioscience sector and prepared to provide the support services necessary 
to promote bioscience industry growth in the state. 
                                                 
20 http://neweconomyindex.org/states/2002/iowa.html. 
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Actions for Strategy Three:   
Action One:  Form the Iowa Bioscience Alliance to facilitate communications, foster joint approaches to 
issues, and develop a critical mass of support to stimulate actions required to realize Iowa’s bioscience 
vision. 
Action Two:  Establish a State Bioscience Advocate position, reporting to the Director of IDED, to drive 
the implementation of this strategy. 
Action Three:  Implement Iowa’s bioscience image and brand through aggressive marketing, public 
relations, and signature events. 
Action Four:  Review and make necessary changes to state incentives (including the Iowa Values Fund), 
tax policies, and legal code to be responsive to the needs of growing bioscience firms. 
Action Five:  Conduct an economic impact study to measure the projected returns to the state and its 
regions that are estimated to result from proposed bioscience investments.  The study should pay special 
attention to geographic equity and the diffusion of innovation benefits throughout the state. 
Action Six:  Develop a training program for state and local economic development professionals that 
would include information on university bioscience technology platforms and technical capabilities, the 
specialized needs of bioscience companies, and programs and incentives that can be used to assist new 
bioscience ventures and expanding and/or relocating firms. 
Action One:  Form the Iowa Bioscience Alliance to facilitate communications, foster joint 
approaches to issues, and develop a critical mass of support to stimulate actions required to 
realize Iowa’s bioscience vision.   
Rationale:  Unlike traditional manufacturing, technology-driven firms, especially bioscience firms, relish 
networking opportunities and actively seek collaborations and partnerships.  As innovation- and 
knowledge-driven organizations, bioscience firms tend to attract leadership and management who need to 
keep abreast of trends in their industry and constantly monitor changes and opportunities that occur in the 
fast-changing world of bioscience and technology.  Networking opportunities also provide introductions 
to capital sources, service providers, and other important contacts.  States and regions trying to build a 
critical mass of bioscience firms have found that the scale and intensity of networking must be substantial 
to help spur value-added relationships.  Iowa has the beginnings of such a networking organization for the 
biosciences in the existing IBA and the growing BIOWA development Association for bioeconomy/ 
biorenewable initiatives.  Association operations have not yet been connected along with expanded state 
government support to provide the type of in-depth assistance and networking opportunities that exist in 
other leading states. 
Action Specifics:  Although each of the bioscience platforms impact specialized areas of the biosciences, 
there will be much commonality of issues and needs when it comes to growing clusters of bioscience 
firms around these platforms.  It is recommended that the common needs, issues, and opportunities be 
addressed through the formation of a statewide Iowa Bioscience Alliance, an umbrella organization under 
the IDED that will work with the IBA, BIOWA, and state commodity associations around four specialty 
bioscience interest groups focused on biotechnology, the bioeconomy, biosecurity, and advanced 
food/feed.  Figure 14 outlines a possible structure for the Alliance, its components, and for industry-
academic collaboration on R&D of interest to each sector. 
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Figure 14:  Model Structure for Bioscience Platform Advancement in Iowa:  Role of Bioscience Industry with 
the Iowa Bioscience Alliance 
 
By structuring the Alliance and its subcomponents in this fashion, Iowa will have a single unified entity 
for providing a shared voice for overall industry and bioscience business environment enhancement in the 
state.  The state also will have a structure that allows for the specialized and unique needs of each 
bioscience subsector and core platform to be addressed and for guiding joint industry-academic R&D 
projects of importance to the platform and its members.  The industry-university matching grant program 
(Strategy One, Action Five) would fall within this structure, with joint industry-academic R&D executive 
committees working to prioritize projects for funding. 
The Bioscience Alliance will serve as a unifying organization for the commercial bioscience sector in 
Iowa, working to ensure that state policies, workforce development initiatives, infrastructure, and 
resources are aligned to meet the various needs of the sector and its subsectors.  The Alliance also must 
play a key role as a steward for the Iowa Bioscience Pathway, working with the proposed State 
Bioscience Advocate and Board of Regents Economic Development Director to ensure a unified approach 
to strategy implementation and associated resource allocation. 
Academic Links to the Iowa Bioscience Alliance 
In addition to forming a business-oriented bioscience alliance, the structure shown in Figure 14 allows 
industry to be actively engaged with academia in joint projects in R&D and technology commercial-
ization.  At the academic level, each platform could have an “academic consortium.”  Figure 15 proposes 
a simplified approach—a single “biotechnology industry consortium” with three main academic platforms 
and the longer-term/niche platforms as core components (Drug Discovery and Development/Drugs-
Biologics, Genomic Medicine, Animal Systems, and the niche biomedical subplatforms).  In full 
structure, therefore, the model would be as shown in Figure 15 for the industry and academic consortia 
that would be working together. 
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Figure 15:  Model Structure for Bioscience Platform Advancement in Iowa 
 
This model is akin to the collaborative system being used in the BioEconomy platform in Iowa currently, 
so it builds upon a model already being deployed.  At ISU, what Battelle terms “academic consortium” is 
called a “coordinating council.”  In either case, each consortium serves to provide collaborative 
opportunities for researchers, scientists, and faculty from across various constituencies on each university 
campus to work together on platform-oriented initiatives, research projects, and commercialization 
opportunities.  As discussed in consultation with the universities, each of the academic consortia would be 
led by those in charge of the academic units identified as existing strengths within each platform, plus an 
industry representative.  Each of the consortia would work to perform the following functions: 
• Identify, solicit, and prioritize Iowa research initiatives for the platform 
• Work to pull faculty/scientist teams together with the skills to work on prioritized cross-disciplinary 
initiatives and projects 
• Provide input to faculty hiring, infrastructure development, and other key investments crucial to 
platform development on the academic side 
• Prioritize projects for putting forward to the matching grant program with industry and for additional 
platform-related funding opportunities 
• Coordinate the development of federal and additional external support for developing the platform in 
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• Coordinate events, conferences, and symposia related to the platform for in-state and out-of-state 
attendees 
• Participate in communications, public and government relations, and other outreach and marketing 
activities for the platform 
• Collaborate with a matching industry consortium that is representative of platform companies in Iowa 
and (in key strategic areas) outside of Iowa 
• Represent the academic side of the platform on a Joint Executive Committee that will comprise 
industry and academic leaders working together to coordinate university and industry approaches to 
the development of the platform and associated economic opportunities in Iowa. 
Each of the platform-specific academic consortia could have a designated full-time Director and two 
support personnel located at the lead university.  The Director of each platform also could sit on overall 
university councils at participating universities that serve to coordinate economic development and 
technology commercialization initiatives.  At ISU, such an overall university council exists in the form of 
the Coordinating Council of Technology Transfer, which also includes representatives from the key 
colleges, institutes, and IPRT.  Ways to accomplish similar objectives should be reviewed by U of I and 
UNI. 
It should be noted that the primary purpose of the platform-specific consortia is to help guide and 
facilitate the development of R&D initiatives that serve to advance near- or longer-term economic and 
commercialization opportunities in the platform within Iowa.  The consortia provide an umbrella 
organization under which academicians with interests related to the platform can interact with one another 
and representatives of industry to work on impactful initiatives.  As such, they serve to leverage the 
academic strengths of Iowa’s regent universities in the platform areas to help build and sustain 
commercial leadership within the state in each platform.  The platform consortia will not be responsible 
for technology transfer, technology commercialization functions, incubators, etc., since those are better 
operated under individual, university-wide organizational structures at each of the individual regent 
universities.  The platforms will generate practical innovations and advancements, but the commercial-
ization of these innovations will go through university commercialization pathways. 
As noted above, there could be corresponding industry consortia to include representatives of industries 
directly or indirectly engaged within each platform in Iowa (and outside of Iowa in certain instances).  To 
begin with, given the comparatively small base of bioscience companies in Iowa, it is suggested that a 
general “Biotechnology Industry Consortium” possibly cover multiple platforms on the human and 
animal biomedical side, with separate consortia formed for Biosecurity, the BioEconomy, and Advanced 
Food and Feed. 
A Joint Executive Committee could be formed for each platform, comprising equal representation from 
the industry and academic platform consortia.  This Executive Committee would serve in the crucial 
coordinating role for the industry-academe partnership, working to ensure that platform initiatives help 
advance academic strengths, industry growth, and sectoral economic development for Iowa.  The 
Executive Committee also would form a unified voice for setting priorities and for initiatives aimed at 
raising the profile of the platform with the state and other external parties.  Given the importance of 
bioscience development to the future of the Iowa economy, it is suggested that the Executive Committee 
meet monthly. 
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This model structure has several advantages: 
• It brings the universities and industry together to provide input and guidance on key R&D initiatives 
that present economic opportunities for advancing the platforms in Iowa. 
• It does not try to usurp traditional academic independence or research missions, but rather works to 
provide organizational and monetary incentives that reward industry-relevant research and 
translational R&D. 
• It provides, at the Executive Committee level, a unified voice for each platform, incorporating both 
industry and academic R&D perspectives. 
• It provides a feeder system for commercializable innovations from each platform that will 
o Provide IP for traditional licensing to corporate partners; 
o Provide opportunities for enhanced products for Iowa bioscience companies; and 
o Provide opportunities for new innovation-based start-up companies for Iowa, with these 
start-ups being served at the earliest stages of formation by each university and then by 
the statewide commercialization organization. 
The initial agenda of the Alliance might include the following items: 
• Guidance and advice in the marketing of the state “brand” 
• Formation of the academic and industry platform activities itemized above 
• Advocacy and support to elected officials to secure the resources needed to implement this strategy. 
• Development of an ongoing set of coordinated events and activities among all organizations in the 
state to increase the scale and intensity of networking in the biosciences 
• Formation of one or more work groups to implement key first year priorities of this strategy 
• Identification of creative private and public partnerships to implement key actions that otherwise 
might be resource constrained in their ability to be quickly implemented. 
Resource Requirements:  The formation and initial staffing of the Alliance should be assisted 
substantially by state funding at first and then at a reduced level as other partners co-invest in the Alliance 
over subsequent years.  The IDED will provide secretariat support to the Alliance.  The state also should 
provide, as discussed previously, an industry-university matching grant program that will be operated by 
the Alliance under the direction of the platform/group-specific R&D executive committees.  After the first 
year, the Alliance should be co-funded by the private sector, including utilities that can play an important 
role in this effort, universities, and government entities.  Annual operating costs for the Alliance are 
anticipated to be $400,000 for the first 5 years, with state funding support peaking in year 1 and declining 
to $100,000 by year 5. 
Time Frame:  Short-term 
Lead Organization(s):  The IBA, BIOWA Development Association, Iowa agricultural associations and 
commodity groups, and the Iowa Department of Economic Development 
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Action Two:  Establish a State Bioscience Advocate position, reporting to the Director of 
IDED, to drive the implementation of this strategy. 
Rationale: Iowa is unusual in not having a senior administration advisor or science office dedicated to 
guiding and securing in-state science and technology growth in general.  Bioscience economic develop-
ment, in particular, requires recognition and understanding of the unique and complex economic forces 
and business development factors that must be in alignment to support growth in this sector and its 
specialized subsectors.  Understanding these factors and working to guide related government policies, 
funding initiatives, incentive programs, and other development activities need to be the functions of a 
dedicated senior administration or science director.  The biosciences are fundamental to the future of 
Iowa’s economy, and state government must be equipped to receive top-level professional advice and 
input for ensuring the sector’s growth and sustainability. 
Action Specifics: Funds should be secured to designate a senior person in the Director of IDED’s Office 
to serve this role and function.  Among this person’s duties and responsibilities are 
• Serving as “eyes and ears” for the biosciences across all of state government; 
• Serving as state government’s lead person in working with the Alliance (see above) and others in the 
stewardship of this strategy; 
• Advocating within state government for the interests of the biosciences; and 
• Identifying and addressing gaps and issues and encouraging appropriate state agencies, departments, 
and organizations to respond and address these gaps and issues. 
In addition, the position also will coordinate with the proposed Economic Development Director on the 
Iowa Board of Regents (Strategy Two, Action One) regarding proposed initiatives, policies, procedures, 
and university reporting requirements and information collection. 
Resource Requirements:  A minimum budget of $125,000 in year 1 to $175,000 in year 5 will be 
needed to fund this position.   
Time Frame:  Short-term 
Lead Organization(s):  IDED 
Action Three:  Implement Iowa’s bioscience image and brand through aggressive 
marketing, public relations, and signature events. 
Rationale:  Iowa has a strong image as an agricultural powerhouse state, but it is fair to say that the 
agricultural life-science expertise of the state has not yet translated into a well-known broader bioscience 
and biotechnology image.  The IDED has been working to create a recently released brand name 
(life/changing), participate in major exhibits and events (such as BIO), and conduct outreach and 
communalization activities.  It is well recognized, however, that image building and branding is a long-
term activity that is only successful through aggressive marketing, public relations, and signature events 
supported over a decade or longer. 
Attracting talent, entrepreneurs, capital, and bioscience businesses to the state requires that Iowa be 
perceived as a dynamic bioscience hub—a place with many bioscience job opportunities, a constant flow 
of investable innovation, and a supportive bioscience business environment.  The implementation of a 
believable and sustainable image needs to be focused upon real strengths.  Therefore, it is recommended 
that the marketing activities emphasize the core bioscience technology platforms. 
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Action Specifics: The state needs to implement a bioscience image and brand campaign through 
aggressive marketing, public relations, and signature events.  Focus groups, use of volunteer public 
relations firms, and other efforts should be undertaken to formulate a marketing plan focused first in state 
and then in targeted external markets in the United States and abroad.   
Resource Requirements: The State of Iowa currently has a $20 million marketing budget over 3 years 
for bioscience marketing, including $3 million for advertisements and trade shows.  IDED should work 
with a marketing agency to develop a marketing strategy around the core platforms, reallocating the 
current marketing budget as required to cover these changes. 
Time Frame:  Immediate 
Lead Organization(s):  IDED in collaboration with the new Iowa Bioscience Alliance and the regent 
universities 
Action Four:  Review and make necessary changes to state incentives (including the Iowa 
Values Fund), tax policies, and legal code to be responsive to the needs of growing 
bioscience firms.   
Rationale:  The attraction and growth of bioscience and biotechnology business enterprises are highly 
competitive fields.  As other states and regions have come to recognize the pre-eminent importance of the 
innovation economy and its key constituent components such as the biosciences, they have focused 
efforts to ensure that their incentive programs, tax code, legal code, and other government-controlled 
factors are supportive of technology and bioscience sector growth.  For Iowa to be a competitive location 
for attracting and retaining the bioscience industry, it must ensure that its government policies, regula-
tions, and codes are encouraging rather than discouraging Iowa investment.  Furthermore, incentives, 
policies, procedures, and laws should be evaluated to assess their positive or negative impact on entrepre-
neurship, the start-up of businesses, and the spin-off of technologies from the state’s universities. 
Action Specifics: The Alliance (see above) should convene a task force of volunteers from business 
service providers (accountants, lawyers, etc.) to undertake the above-mentioned comprehensive review.  
Limited loaned staff should be provided by the Department of Revenue.  The Alliance should make 
public its review and recommendations after a 6-month investigation.  The review should include an 
analysis of the Iowa Values Fund, in particular how to extend full, 7-year, funding support.  In addition, 
the review should examine the technology transfer credit to make it a more useful and functional 
economic development tool for bioscience development.   
Resource Requirements:  $100,000 in one-time funds will be needed to cover expenses  
Time Frame:  Short-term 
Lead Organization(s):  Bioscience Alliance, IDED, Iowa Department of Revenue 
Action Five:  Conduct an economic impact study to measure the projected returns to the 
state and its regions that are estimated to result from proposed bioscience investments.  
The study should pay special attention to geographic equity and the diffusion of innovation 
benefits throughout the state. 
Rationale:  Iowa is a state characterized by egalitarian attitudes.  Given the need for early and intensive 
support from the state for the bioscience development initiatives outlined in this strategy, it will be 
necessary to provide persuasive arguments for the diffusion of economic benefits from these investments 
throughout Iowa.  An economic impact study should be conducted to provide projections of the tax, 
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employment, business volume, and other benefits that may be realized in geographic regions of the state 
attributable to the projected growth of the bioscience clusters.  The impact study should suggest specific 
actions to help ensure diffusion and equitable distribution of economic benefits to the extent possible and 
practicable.   
Action Specifics:  A projections-based economic impact study for the core elements of this bioscience 
development strategy should be developed.  Being a projective model, it will largely require scenario-
based impact modeling using examples of specific projects to illustrate diffusion benefits.  Input/output 
analysis techniques will facilitate the measurement of geographic effects induced by a specific bioscience 
industry.  For example, the location of a biorefinery operation in County A can be modeled using input/ 
output analysis to show the monetary and employment effects of its input purchases (such as corn or 
soybeans) from other counties in Iowa. 
Resource Requirements:  It is estimated that $100,000 would be required in one-time funds for a 
professionally produced impact analysis using input/output modeling and case study scenarios. 
Time Frame:  Short-term 
Lead Organization(s):  IDED 
Action Six: Develop a training program for state and local economic development 
professionals that would include information on university bioscience technology platforms 
and technical capabilities, the specialized needs of bioscience companies, and programs and 
incentives that can be used to assist new bioscience ventures and expanding and/or 
relocating firms. 
Rationale:  It should come as no surprise that the specialized needs of bioscience companies present 
some unique challenges for economic developers.  As bioscience development becomes a key emphasis 
for the state, it will be important that local economic development entities and others providing economic 
development services be educated in sector drivers, relevant industry needs, and the programs and 
initiatives available through the state, federal, and other entities to facilitate bio-business growth. 
Action Specifics:  The University of Northern Iowa’s Business and Community Services Division and 
the Institute for Decision Making (IDM) have a significant track record in coordinating and delivering 
technical assistance related to business and community development.  IDM, for example, has worked with 
more than 400 communities and regions statewide in the provision of community-based, strategic 
economic development services.  The IDED should contract with UNI’s IDM to develop a bioscience 
business development training course for Iowa’s community economic development agencies.  The 
course will work to provide a consistent message and suite of tools for use in promoting and sustaining 
bioscience economic development in the state.  In addition, UNI should serve as a central repository of 
programs, initiatives, bioscience firm successes, etc., occurring at the local level across Iowa to ensure 
that all activity is captured and recorded for reporting progress to the Legislature and also to benchmark 
best-practice activities and successes for incorporating into training and diffusion across agencies in the 
state. 
Resource Requirements:  UNI’s IDM has experienced funding cuts in excess of 65 percent over the past 
3 years.  The state needs to reinvest funds into IDM to secure the provision of high-quality bioscience 
economic development services, training programs, and progress-tracking services.  This reinvestment is 
estimated at $750,000 annually to support UNI’s IDM.  UNI’s IDM currently receives $280,000, 
necessitating an increase in annual funding of $470,000 that would be phased in over a 5-year period. 
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Time Frame:  Mid-term 
Lead Organization(s):  University of Northern Iowa 
STRATEGY FOUR:  INVEST IN AND DEVELOP IOWA’S BIOSCIENCE TALENT POOL.  
In the 21st century, economists such as Lester Thurow21 of MIT are noting that human capital will likely 
be the key differentiator between winning regions and losing ones. Without skilled people, technology 
innovation cannot occur and advanced technologies cannot be deployed.  Without skilled technical and 
managerial personnel, capital also is extremely difficult, if not impossible, to secure. In terms of natural 
resources, the 20th century proved that, while they can be important contributors to wealth, they are not 
the ultimate determinants of it.  Countries such as Japan, Taiwan, Singapore, and South Korea grew to 
become major international economic forces despite having relatively poor natural resources.  Equally, 
Russia and the former Soviet republics have tremendous natural resources but very low standards of 
living and economic performance, as do many oil-rich states.  Thurow’s research suggests that, for the 
most part, natural resources have ceased to be important sources of economic advancement.  It is the 
talent of people that drives economic success and is the fuel of the innovation and knowledge economy.  
In Workforce Education, authors Gray and Herr22 note the following: 
Among all the riches a nation may possess, its people—its human resources, its human capital—
is the most important.  The value of this human resource depends not on size, however, but on the 
occupational and intellectual skills its members possess.  At least in this regard history is clear: a 
large “unskilled” population is a detriment to national economic growth and to a high standard 
of living. 
The root cause of economic progress, higher wages, and higher standards of living in modern western 
society can be found in high levels of workforce productivity—gained in part by technology, but mostly 
through the skills and ingenuity of the people who use and maintain that technology.  Only through 
increasing levels of productivity can standards of living grow; and it is the nations, regions, communities, 
and individual firms that have the highest-skilled workforce, other factors held constant, that will be the 
most productive, produce the best products or services at the lowest costs, earn the highest profits, and 
dominate markets.   
The lesson to be learned is a simple but profound one—developed nations, states, and regions cannot 
compete on the basis of low wages but must, instead, seek to create a high-skills workforce that will 
enable firms to be innovative, efficient, pay high wages, and still be price competitive.  The strategy for a 
state like Iowa is to make the state’s workforce so productive that they can produce more than those in 
competing locations—thereby attracting the growth of industry in the state and raising the overall 
standard of living.  This must be accomplished for the bioscience sector, as it must be in all focus sectors 
of the Iowa economy. 
Much has been written about the rise of “knowledge” as the driver of the U.S. economy.  This rise is an 
accepted fact, but there is much misunderstanding of who those with “knowledge” are.  Some have 
interpreted this to mean that a 4-year college-degreed elite is the route to economic success, but the fact is 
                                                 
21 Thurow, L.  Head to Head: The Coming Economic Battle Among Japan, Europe and America.  New York: 
Morrow and Company. 1992. 
22 Gray, Kenneth C., and Edwin L. Herr.  Workforce Education.  Massachusetts: Allyn and Bacon.  1998. 
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that skills and knowledge are increasingly required across the total workforce.  The creative elite 
(scientists, engineers, clinicians, etc.) may be a critically important driver of invention and new products 
and services, but this can encompass only a small proportion of a state’s labor force.  The rest of the 
workforce must produce the output of creativity and innovation in volume and do so at a higher level of 
productivity than can be achieved elsewhere.  Gray and Herr note as follows: 
If the route to success is inventing new products, the education of the smartest 25 percent of the 
labor force is critical.  If the route to success is being the cheapest and best producer of products, 
new or old, the education of the bottom 50 percent of the population moves to center stage.  This 
part of the population must staff those new processes.  If the bottom 50 percent cannot learn what 
must be learned, new high-tech processes cannot be employed.  If the education of the bottom half 
moves to center stage, so too must workforce education, which we have defined as education and 
training below the baccalaureate level. 
The implication for Iowa is critically important for all involved in economic development to grasp.  It is 
that, in a 21st century economy driven by high productivity and increasingly skilled processes, an 
unskilled workforce is no resource at all.  It is only a “potential” resource, and that potential can be 
realized only through workforce education and skills development. 
It also must be noted that technology and productive processes are being improved or supplanted at a 
rapid pace—especially in revolutionary fields such as the biosciences.  In such a fast-paced, change-
oriented working environment, a workforce has to be equipped with the personal learning skills and 
adaptability traits required to keep pace.  Life-long learning is becoming a necessity because most 
workers cannot expect their jobs to continue to be done as they are now, or even to exist at all in a 
recognizable form a decade from now.  In this economic environment, Iowa cannot afford to produce a 
workforce output that has low levels of academic literacy, skills attainment, and adaptability. 
Skilled people drive the knowledge economy; therefore, skilled people drive the bioscience economy.  
The bioscience degree offerings provided at both the regent universities and the private universities found 
across Iowa position the state quite well in terms of higher educational degree opportunities (Figure 16).  
Overall, the 4-year higher education system in Iowa has a distinct track record of innovation and talent 
development in key bioscience, science, and engineering disciplines.  In addition, the breadth of services 
offered by ISU Extension serve to reinforce education and workforce development in the state, not only in 
agricultural production and processing but also in nonagriculture-related manufacturing and industry 
through Manufacturing Extension and CIRAS.  In addition, Iowa is blessed with a comparatively high-
performance K-12 education system and a large and well-resourced network of community colleges.   
Therefore, fundamental building blocks for high-performance talent development are in place, but 
refinement is necessary to fully meet the challenges of a bioscience-based knowledge economy.  Iowa 
also has been experiencing a talent drain, as its talented graduates are recruited to out-of-state 
employment centers by the promise of higher wages, a quality for life perceived to be more dynamic or 
exciting, or a broader cadre of technology businesses in which to build and advance their careers. 
Retaining talent and attracting talent are as important to Iowa’s future as growing talent at home. 
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Figure 16: Bioscience Degrees from Iowa Institutions, Academic Year 2002 
 
Tactics 
• Supporting a growing bioscience industry base will require an increased flow of talent at all skill 
levels that have the basic training required for success in the bioscience positions they pursue.  As a 
primary tactic, Iowa must work to assure that the K-12 and higher education sectors are teaching the 
skills and knowledge for a high-productivity bioscience workforce. 
• Four-year and graduate degrees are important; but, to realize a complete bioscience value chain, the 
bioscience production sector will require entry-level workers with strong basic skills and semiskilled 
and skilled production and technical workforce with appropriate vocational training.  A key tactic for 
Iowa will be the development of bioscience career academies, 2+2 programs between schools and the 
community colleges, and other innovative workforce training programs. 
• In an environment requiring life-time learning and reskilling, it is important to ensure that the skills 
and credits earned in one form of education transfer to programs teaching the next order of skills and 
educational attainment.  Articulation across education levels and educational institutions thus 
becomes a key tactic. 
• In addition to developing home-grown talent, Iowa must jump-start its bioscience entrepreneurial, 
technical, and managerial workforce through attracting such experienced personnel to live and work 
in Iowa. 
Actions for Strategy Four:  
Action One:  Improve K-12 scientific education by focusing on stimulating interest among Iowa’s 
children in science, thereby preparing them for careers in Iowa’s growing bioscience sectors. 
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Action Two:  Develop a bioscience vocational career education program and ensure seamless delivery 
between secondary and community college programs that serve Iowa’s growing concentration of 
bioscience employers. 
Action Three:  Streamline bioscience articulation agreements within and between community colleges 
and Iowa’s regent universities to allow students to transfer credits between academic institutions. 
Action Four:  Leverage alumni associations and the state’s Human Resources Recruitment Consortium to 
attract to Iowa bioscience professionals, including experienced bioscience managers. 
Action One:  Improve K-12 scientific education by focusing on stimulating interest among 
Iowa’s children in science, thereby preparing them for careers in Iowa’s growing 
bioscience sectors. 
Rationale:  Too few American youths choose math, science, and engineering and associated technical 
disciplines as their education path.  At a time when technical education is necessary to drive the 
innovation economy, the number of Americans entering scientific and technical education programs has 
declined dramatically.23  Between 1985 and 1997, the number of B.S. degrees in engineering in the 
United States fell 16 percent; computer science and math degrees fell 29 percent.  Only 12 percent of all 
degrees awarded in the United States are in technical areas.  Forty-eight percent of all Ph.D. graduates in 
technical fields in the United States are foreigners, and increasingly these foreign graduates are not 
retained in the United States; they are attracted home by the opportunities brought by increasing 
globalization. These trends are echoed at the pre-baccalaureate level, with declining enrollments in 
technical 2-year programs.  This trend has led the Pennsylvania Economy League to conclude that “a 
region that does not have a growing percentage of its ‘non-professional’ workforce trained at the post-
secondary pre-baccalaureate level will face increasing difficulty attracting and keeping high value added 
employment.”24 
States are producing technology, but they are not getting the model right to produce a solid flow of value-
added production from their innovation.  Iowa, with its traditional strengths in education, has a distinct 
opportunity to leverage this tradition to produce enhanced levels of students with high-school education 
and 2-year technical and B.S./M.S./Ph.D. degrees in the biosciences and related technical and scientific 
disciplines.  Building a world-class technical workforce will provide a major advantage for Iowa in 
attracting, building, and retaining skilled talent for bioscience cluster and economic growth.  Doing so 
requires that Iowa’s students and youths be introduced to the biosciences as a clear, high-value career 
path for the future and that demand be generated among students for scientific and technical training at all 
levels. 
Action Specifics: If Iowa is to compete in today’s knowledge-based economy, the state must commit to 
engaging students in scientific or technological careers.  It is recognized that a child should be introduced 
at an early age to mathematics and the sciences; otherwise, he or she will quickly fall behind and be 
unprepared to study collegiate engineering or scientific curricula.   
                                                 
23 Gray, Kenneth, and Edwin Herr.  Other Ways to Win: Creating Alternatives for High School Graduates.  
Thousand Oaks, California: Corwin Press, 2000. 
24 Pennsylvania Economy League.  Building a World-Class Technical Workforce.  Philadelphia. 1996. 
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Recommendations for potential initiatives to improve scientific education and engage additional students 
include the following:   
• Aligning standards, curricula, assessments, and accountability.  Through a standard-based 
approach, significant strides can be made to increase student achievement and meet the expectations 
of the 21st century.  Standards, including English/language arts, mathematics, science, and tech-
nology standards, are an essential foundation for the state’s workforce.  In addition, an entrepreneurial 
curriculum can be “extracted” from Iowa’s academic and technical standards.  Project-based 
experiences and senior capstones bridging both sets of standards provide students an entrepreneurial 
environment.  Other promising practices and professional development must focus on the entre-
preneurial “spirit” and the need to integrate mathematics, science, and technology in the elementary 
and high schools. 
• Supporting specialty high schools.  New school designs and deliveries (science and technology 
academies/magnet schools, small learning communities, and technology cluster programs) support 
Iowa’s economic development vision and are an asset for the state.  Programs such as this call for a 
connected and comprehensive educational system.  However, it is important to recognize that, 
without the needed scholarships to support students who achieve excellence in quality secondary 
programs, Iowa will lose its best and brightest.  Other states have successful strategies, such as loan 
forgiveness programs in New Jersey, Georgia, and Pennsylvania, which encourage students to enroll 
and remain in higher education as well as stay in the state.   
• Developing programs and initiatives designed to interest students and parents in technology. It 
is generally agreed that students choose early in their educational careers to take the necessary math 
and science classes to prepare them for advanced work in technological fields.  Therefore, it is very 
important that technology careers are promoted so that students can see the benefits of pursuing a 
scientific course of study.  All schools also should have “invention” laboratories supporting broad 
career exploration, authentic strategies for academic instruction, and opportunity for student creativity 
in solving problems. Student experiences (technology competitions, technology mentors, higher 
education summer enrichments, etc.) contribute to a climate of high expectations and opportunities.  
In addition, funding should be made available to support middle, junior, and high school student and 
teacher experiences in technological fields. 
• Using distance education technology to bring high-quality math and science instruction to 
students in all parts of Iowa. While it may be unrealistic for every community in Iowa to provide 
advanced science and math courses, students should be given the opportunity to take such courses via 
distance learning technology. 
• Instituting a differential pay scale or incentive system that allows science and math teachers to 
be more highly compensated.  In today’s market, it is extremely difficult to recruit math and science 
teachers given the opportunities available to people with scientific and technical degrees.  Yet, 
improving math and science education will require the ability to recruit teachers with math and 
science credentials.  Consideration should be given to providing a salary differential or other financial 
incentives for math and science teachers. 
Resource Requirements: To be determined based on discussions with the educational community 
Time Frame:  Mid-term 
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Lead Organization(s):  Iowa Department of Education in collaboration with community colleges and 
regent universities 
Action Two:  Develop a bioscience vocational career education program and ensure 
seamless delivery between secondary and community college programs that serve Iowa’s 
growing concentration of bioscience employers. 
Rationale:  As noted above, knowledge creation usually requires a pool of talent educated beyond the 
baccalaureate level; but, true economic growth and sustainability comes from producing the output of that 
knowledge in a high-productivity, high-wage environment—and that requires solid bioscience and 
technical skills at the pre-baccalaureate level.  In areas of Iowa where clusters of bioscience employers 
are located, it will be particularly important to sustain the growth of these businesses by developing 
production-level talent and technicians.   Iowa’s strengths in community college education and in 
developing career academies and other linkages between K-12 and community college programs provide 
a distinct advantage to leverage in this arena.  For instance, Indian Hills Community College (IHCC) has 
recently been awarded a $775,000 grant from the U.S. Department of Labor to serve as a Biotechnology 
Center of Excellence.  IHCC will work to develop skill standards and workforce data for the bio-
technology industry.  This resource should be leveraged as Iowa develops its bioscience workforce 
development programs. 
Action Specifics: As Iowa’s economy changes, so too must the delivery of its educational system.  The 
ability of students to move seamlessly and smoothly from one level of education to the next in their 
chosen field of study to obtain their ultimate educational goal—an associate’s degree, bachelor’s degree, 
or advanced degree—is critical.  This seamless integration is achieved through enhancing real partner-
ships among all educational institutions in Iowa that result in students achieving their long-term learning 
goals.  However, Iowa’s current system is often fragmented, and students cannot easily transfer their 
technical courses from high school to community college or university.  State articulation agreements 
(secondary to postsecondary as well as postsecondary to postsecondary) are necessary to provide a 
seamless pathway for students, minimize duplication, maximize resources, and offer a common resource 
to industry. 
An example of a model that Iowa could implement is Ohio’s College Tech Prep Program, which is a very 
viable means of expanding an articulated curricular pathway from vocational school through college for 
high-tech careers. Beginning in the junior year of high school, College Tech Prep students begin a 
seamless, nonduplicative pathway with rigorous academic preparation aligned with advanced technical 
skills, culminating in at least an associate’s degree at a community or technical college with articulation 
provided through the baccalaureate degree. The product of the College Tech Prep Program is a highly 
skilled technology worker ready for a career in business and industry. Preparation is focused on high-
skill, high-tech occupations. The most recently developed curricula are in information technology and 
biotechnology. 
Iowa should institute a similar program between its vocational/high school programs and its community 
colleges.  In addition, articulation programs need to be expanded to include all the various levels of the 
educational system.   
Resource Requirements:  $500,000 initially to develop the curriculum 
Time Frame:  Mid-term 
Lead Organization(s):  Iowa community colleges 
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Action Three:  Streamline bioscience articulation agreements within and between the 
community colleges and Iowa’s regent universities to allow students to transfer credits 
between academic institutions.   
Rationale:  If education and skills development are prerequisites to progress in the knowledge-driven 
bioscience economy, and if life-long learning is a likely component of such skills development, it is 
imperative that education credentials and coursework be portable across various levels of education 
delivery.  Just as efficiency is necessary in industry, it is also necessary in education and training 
(especially in today’s high-cost 
educational environment).  Against this 
background, it is highly important that 
Iowa’s public and private education 
system be structured to allow the vast 
majority of course credits earned at one 
level of education to be transferred to 
degree or certificate courses within the 
same level and between the next highest 
level.  At the current time, the great 
majority of community college credits 
earned in biology and other bioscience-
related disciplines will not transfer to 
bioscience degree programs at the U of I 
and ISU.  Such policies hamper education 
efficiency and drive up the cost of 
education to the state and its citizens—
they also dissuade citizens from 
continuing along a pathway of increasing 
educational attainment.  If the problem is 
that community college courses are not 
being taught in a way that makes the 
credits suitable for transfer acceptance, 
then the courses must be changed as 
appropriate.  If the problem is that the 
universities simply want to maximize 
revenues by having students retake 
coursework, then they should be 
dissuaded from such activity by the state 
and the Board of Regents.  UNI has made significant progress by developing articulation agreements with 
every community college in Iowa.  To achieve this result, the Provost appointed an industrial technology 
professor to work with each community college in Iowa.  This person focuses on articulation agreements, 
2+2 programs, distance programs, etc.  Alignment of course-taking pathways and liberal articulation 
agreements need to be the norm across Iowa’s public education institutions. 
Action Specifics:  A joint working committee should be established between the regent universities and 
the community colleges in Iowa that are providing, or intend to provide, a bioscience education track in 
their 2-year programs.  The regent universities should be clear in outlining the curriculum required for 
Maryland—Montgomery College, Montgomery Public Schools, 
and the Universities at Shady Grove:  Early Placement and 
University Partnership  
Montgomery College, the Community/Technical College for 
Montgomery County, Maryland, has developed relationships 
with the Montgomery County Public Schools and the 
universities at the Shady Grove Life Science Center to offer a 
2+2+2 program of technical education.  Beginning with the 
last 2 years of high school, the program continues with 
2 years and an associate’s degree from Montgomery College 
and offers the option of completing another 2 years for a 
bachelor’s degree. 
 
The first phase, the Montgomery County Public Schools 
Tech Prep Program, allows high school students to receive 
college credits for grades of B or better if they major in the 
corresponding program at Montgomery College.  As of the 
2001-2002 academic year, students are eligible to receive 
credit in one of 22 college programs, including biotechnology. 
The high school biotechnology program is housed at the 
Thomas Edison High School of Technology and offers 
intensive laboratory experience, interaction with scientists 
and technicians from local research facilities and firms, and 
leads for summer and college internship opportunities. 
 
Once the student completes the second phase and earns an 
associate’s degree from Montgomery College, he or she may 
choose to continue working toward a bachelor’s degree at 
the Shady Grove Center.  Eleven University of Maryland 
System institutions are involved in the partnership. 
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A growing literature on brain drain 
demonstrates that in the absence of the 
rudiments of a technology-based regional 
economy, the best and brightest most likely 
will leave.  We are convinced that 
aggressive, mission driven research 
universities can counteract that trend and 
contribute to the building of regional 
knowledge economies. 
 
Tornatzky, Louis, Paul 
Waugaman, and Denis O. 
Gray. “Innovation U.: New 
University Roles in a 
Knowledge Economy.”  
Southern Growth Policies 
Board, 2002. 
credits to be transferable into the universities’ bioscience and related curriculum.  In addition, to the 
extent possible, articulation agreements with the private universities in the state also should be pursued. 
Resource Requirements:  No direct costs should be involved.   
Time Frame:  Short-term 
Lead Organization(s):  Board of Regents, community colleges, academic colleges and departments, and 
the IDED 
Action Four:  Leverage alumni associations and the state’s Human Resources Recruitment 
Consortium to attract to Iowa bioscience professionals, including experienced bioscience 
managers. 
Rationale:  Iowa’s higher education strengths have led to Iowans being natural targets for the recruitment 
efforts of colleges, employers, and regions from outside of 
Iowa.  A substantial volume of skilled Iowans, and persons 
educated at Iowa institutions, exists throughout the United 
States.  These are people who have experienced Iowa first 
hand and who may be attracted back to the Midwestern quality 
of life enjoyed in the state.  Current talent reattraction 
initiatives and alumni engagement activities being undertaken 
by the state and its institutions should be considered high 
priorities for talent-driven economic development strategies in 
the biosciences. 
Action Specifics: Continued support needs to be provided to 
the Iowa Human Resource Recruitment Consortium, a unique 
public-private partnership created to meet Iowa’s need for 
highly skilled employees. Members include the IDED, Iowa 
Workforce Development, communities, businesses, 
educational institutions, and professional associations 
throughout the state. The Consortium is a comprehensive marketing initiative, working to increase the 
pool of qualified skilled individuals considering Iowa career opportunities and to successfully network 
these individuals with Iowa employers. The cornerstone of the campaign is SmartCareerMove.com, an 
interactive Web site that includes a job bank of professional/technical positions in Iowa and a resume 
bank and information on working, living, and playing in Iowa.  The Web site lists available jobs in the 
recruitment expertise areas at annualized salaries of $30,000 or more.  Also included is comprehensive 
information on living in Iowa, recreation in Iowa, and business in Iowa, with links to hundreds of 
communities, businesses, and cultural and recreational activities throughout the state.  The Web site has 
received more than 8 million hits since October 1998, and numbers continue to increase.   
Resource Requirements:  The Human Resources Recruitment Consortium is already funded, and this 
activity can be undertaken through priority setting within current funding. 
Time Frame:  Short-term 
Lead Organization(s):  IDED and alumni associations and alumni relations organizations within the 
regent universities 
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SUMMARY  
This section of the report proposed a vision for Iowa’s future as a leading Midwestern state with a 
comprehensive set of strengths in the animal, plant, and human sciences.  This vision is to be achieved 
through the execution of four strategies involving 20 actions, in addition to leveraging the significant 
investments Iowa has made to date through programs such as the Iowa Values Fund.  Because the private 
sector must make many of the investments critical to achieving this vision, the state government’s role is 
one of facilitator and catalyst, addressing and helping fill gaps that have not or cannot be addressed by the 
private sector alone.  These “gap-filling” actions, however, are designed to leverage significant private 
and other funds.  Many are one-time actions that, if successful, will enable the private sector to move 
forward without need for ongoing renewal of the state’s investments.  Other investments are annual and 
long term, such as building the state’s higher education R&D base.  The strategies and actions address the 
three key drivers of the state’s bioscience future—technology, capital, and talent.  The next section will 
offer guidance in implementing the strategic priorities. 
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Implementation Plan 
The previous sections of the report evaluated Iowa’s position in the biosciences by outlining Iowa’s 
current bioscience base (in terms of both industry and research bases); identifying Iowa’s core 
competencies in the biosciences; assessing the state’s competitive position and its bioscience development 
strengths, weaknesses, opportunities and threats; outlining a vision and mission for Iowa’s bioscience 
development; identifying gaps to be addressed; and proposing a four-strategy, 20-action program to 
address gaps and significantly improve Iowa’s standing in bioscience development for the next 10 years.  
This section of the report, the Implementation Plan, lays out the major actions critical to success, 
immediate priorities, resource requirements, and organization and structure for moving this roadmap 
forward. 
The implementation plan for the Iowa Bioscience Pathway is designed to catalyze public and private 
sector collaboration and public sector investment, focused on filling “market gaps” that the private sector 
cannot or will not undertake on its own.  But addressing gaps, while necessary, is not sufficient.  The 
State of Iowa will need a committed set of public and private sector leaders and champions working to 
raise funds and secure support for the specific strategies and actions outlined herein.  This commitment 
will need to be sustained over the next decade to ensure that necessary changes are made, gaps filled, and 
actions taken. 
Wherever possible, existing entities’ roles and responsibilities should be expanded to implement the 
recommended strategies and actions.  Reconstituting or using existing organizations and programs 
wherever possible in the implementation plan should be preferred.  Stakeholders should be encouraged to 
use this approach where it makes sense in terms of being efficient and, equally important, in terms of 
achieving results. 
CRITICAL ACTIONS 
To realize the full bioscience economic potential that this roadmap lays out, Iowa must successfully 
implement certain critical actions.  Specifically, the ultimate success of the strategy hinges on the forward 
movement of six activities, in essence Iowa’s bioscience critical path.  In other words, it is these six 
critical actions that are most significant to, and the underlying foundation for, the eventual success of the 
other proposed elements and initiatives of this strategy.  Therefore, when initial resource allocations are 
being determined, efforts must be made to ensure that the following critical actions receive funding 
priority:   
• Form a Strategic Technology Platform Infrastructure Fund to reinforce the core bioscience 
platforms by supporting faculty recruitment, entrepreneurial endowed chairs, and other key actions.  
The fund will be directed through academic consortia set up to develop the six bioscience platforms.  
Financed perhaps by issuing bonds and from other sources, the fund also would provide infrastructure 
and equipment funding to reinforce the platforms. 
• Develop and implement policies and procedures at the regent universities to ensure the highest 
level of encouragement and support for private-sector partnering, commercialization, and 
entrepreneurship.  
• Form a statewide intermediary for supporting, building, and sustaining development of new 
bioscience business enterprises in Iowa.  This organization will proactively assist Iowa’s bioscience 
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entrepreneurs and provide business development services to companies formed from university-based 
technology transfer and commercialization efforts and from other sources of intellectual capital. 
• Form the Iowa Bioscience Alliance to serve as a guiding force in engaging industry in the strategy 
implementation and stewardship.  Connect the Alliance to the proposed academic consortia to be 
formed around the bioscience platforms to ensure industry/university collaboration of platform R&D 
and commercialization of innovations. 
• Institute an industry-university matching grant program dedicated to the identified bioscience 
technology platforms to boost bioscience R&D collaborations between academia and industry in 
Iowa. 
• Increase funding to the regent universities to allow for sufficient staffing and resources for 
commercialization activities. 
The above actions will ensure that the strengths of the current core bioscience platforms are leveraged and 
further built; that industry and academe work together on joint R&D initiatives to develop commercial 
innovations from each platform; that funding and support are available to develop bioscience entre-
preneurs and their business ventures; and, that the regent universities are optimally leveraged for the 
bioscience-based economic development of the state. 
IMMEDIATE PRIORITIES  
Immediate work plan priorities are those steps that should be undertaken in the first 12 months of strategy 
implementation, regardless of how critical they are to the overall strategy.  Several immediate priorities 
can be implemented right away, while others will need to be planned and allocated funds before they can 
become fully operational.  The following actions should be undertaken in the first year: 
• Create and fund an Economic Development Director position on the Iowa Board of Regents to 
provide catalytic support for regent university economic development initiatives. 
• Develop and implement policies and procedures that actively encourage faculty entrepreneurship and 
commercialization activities at the regent universities. 
• Engage Iowa’s Congressional Delegation in discussions pertaining to federal funding and specific 
project support. 
• Institute an industry-university matching grant program dedicated to the identified bioscience 
technology platforms to encourage relationships between academic researchers and industry.    
• Increase funding to the regent universities to allow for sufficient staffing and resources for 
commercialization activities. 
• Form a statewide commercialization intermediary for supporting, building, and sustaining 
development of new bioscience business enterprises in Iowa.  The commercialization organization 
will work to address technology, capital, and talent issues. 
• Implement Iowa’s bioscience image and brand through aggressive marketing, public relations, and 
signature events. 
• Leverage alumni associations and the state’s Human Resources Recruitment Consortium to attract to 
Iowa bioscience professionals.  An initial emphasis should be placed on attracting individuals with 
experience in bioscience management. 
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RESOURCE REQUIREMENTS 
For each action, Table 17 indicates the priority of the action, breaks down state funding needs into two 
5-year phases, provides the estimated one-time costs, and indicates the anticipated external leverage.  
Table 18 breaks down the proposed revenue sources to be allocated from the state for this financial plan.  
Overall, costs to the state government include both general fund appropriations that would require new 
state dollars of $47.4 million over Phase I (years 1 to 5 of this effort) and bond financing for capacity 
building of $96.8 million for infrastructure, recruitment, and matching support.  In Phase II (years 6 to 
10), new state funds of $84.3 million would be required and bond financing for further capacity building 
of $73 million would be needed.  One-time costs are included in these bond financing totals of 
$169.8 million over 10 years.  External leverage to these investments are estimated over the entire 10-year 
period at more than $1.5 billion.  
 
Table 17:  Iowa Bioscience Pathway Financial Plan 
Action Priority 
Annual State 
Funding by Year: 
Years 1-5 
Annual State 
Funding by Year: 
Years 6-10 
Estimated 
One-Time 
Costs 
Leverage 
Ratio of 
Private and 
Federal 
Funds 
Capacity building 
in the key platform 
areas  
Short-term 
 
Consortia:  $1.2 M 
increasing to $2.0 M 
by year 5 
 
Matching grants:  
$1.7 M increasing to 
$3.8 M—this item 
covered under 
Infrastructure Fund 
Consortia:  $2 M per 
year rising to $5 M by 
year 10  
 
 
Matching grants:  
$3.8 M staying 
constant years 6-10 
 
$10.188 M 
annually for first 
5 years for 
platform invest-
ments, or 
$50.94 M from 
the bond-
financed 
Strategic 
Investment 
Fund (see 
below) 
9:1 federal 
funding leverage 
based on other 
state 
performance 
Entrepreneurial 
Endowed Chairs 
program  
Short-term 
 
$2 M per year for 
3 years and $1 M in 
year 4 
Second round of 
additional chairs:  
$3 M for 3 years and 
$1.5 M in year 4 
 2:1 (match to 
state funds) 
Strategic 
Technology 
Platform 
Infrastructure 
Fund 
 This Fund supports 
above actions in 
capacity building of 
platforms and 
endowed chairs as 
well as matching 
grants item below and 
one-time costs of 
these and prototype 
fund 
 $169.44 M 
capitalization via 
bonds with 
$96.76 M in 
Phase I 5-year 
period and 
$73 M in 
Phase II 5-year 
period. 
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Table 17:  Iowa Bioscience Pathway Financial Plan (continued) 
Action Priority 
Annual State 
Funding by Year: 
Years 1-5 
Annual State 
Funding by Year: 
Years 6-10 
Estimated 
One-Time 
Costs 
Leverage 
Ratio of 
Private and 
Federal 
Funds 
Engage Iowa’s 
Congressional 
Delegation for 
federal funding 
Immediate 
 
Existing resources Years 6 through 10 
rise from $3.0 M  to 
$5.0 M 
  
Industry- 
university 
matching grant 
program  
Immediate Initial year funding at 
$1.5 M rising to 
$3.0 M by year 5  
  3:1 (match to 
state funds) 
Economic 
Development 
Director position 
on the Iowa Board 
of Regents  
Immediate 
 
$150,000 per year $175,000 per year   
Policies and 
procedures that 
actively 
encourage faculty 
entrepreneurship 
and 
commercialization 
Immediate 
 
$200,000 per year $240,000 per year   
Funding to the 
regent universities 
for 
commercialization 
activities/tech 
transfer 
Immediate 
 
$2.9 M in year 1 
increasing to $9.55 M 
in year 5 
Mining:  start at 
$300,000 and 
increase to $600,000 
by year 5  
TT:  start at $1.5 M 
and increase to 
$5.8 M by year 5  
Business dev:  start at 
$300,000 and 
increase to $750,000 
by year 5  
Industry liaison:  start 
at $300,000 and 
increase to $1.2 M by 
year 5  
Marketing and 
communications:  start 
at $500,000 and 
increase to $1.2 M by 
year 5  
Increase by 10% per 
year or: 
Year 6:  $10.5 M 
Year 7: $11.55 M 
Year 8:  $12.71 M 
Year 9:  $13.98 M 
Year 10:  $15.38 M 
$1 M to be 
covered as 
infrastructure 
funds from 
Strategic Infra-
structure Fund 
6:1 leveraged 
return in 
increased 
sponsored 
research, 
licensing 
revenue, and 
equity in 
start-ups 
Establish a 
University 
Entrepreneurs 
Center 
Short-term $450,000 per year Years 6 and beyond 
increase to $600,000 
per year 
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Table 17:  Iowa Bioscience Pathway Financial Plan (continued) 
Action Priority 
Annual State 
Funding by Year: 
Years 1-5 
Annual State 
Funding by Year: 
Years 6-10 
Estimated 
One-Time 
Costs 
Leverage 
Ratio of 
Private and 
Federal 
Funds 
Form a statewide 
commercialization 
intermediary  
Immediate 
 
$1 M year 1 
$1.5 M year 2 
$2 M years 3, 4,  
and 5 
Years 6 and beyond 
increase to $2.2 M per 
year 
$3 M to $5 M 
Prototype 
Development 
Fund over first 
5 years and 
similar amount 
for years 6-10 
financed by 
Infrastructure 
Fund 
$25 M to $50 M 
initial 
capitalization for 
BioSeed Fund 
as part of Fund 
of Funds 
(nondirect state) 
and privately 
financed 
thereafter 
Leveraged 6:1 
return in private 
funds, sales, 
and other 
income 
Form the Iowa 
Bioscience 
Alliance 
Short-term 
 
$400,000  in year 1 
decreasing in year 5 
to $100,000  
Ongoing support in 
years 6 and beyond of 
$100,000 per year 
 Leverage 3:1 
private, 
university, and 
other funds 
Establish a State 
Bioscience 
Advocate position 
Short-term 
 
$125,000 in year 1 
increasing to 
$175,000 in year 5  
$200,000 in year 6 
increasing to 
$300,000 in year 10  
  
Implement Iowa’s 
bioscience image 
and brand through 
aggressive 
marketing 
Immediate 
 
As currently budgeted 
IDED 
   
Review and make 
necessary 
changes to state 
incentives, tax 
policies, and legal 
code  
Short-term 
 
  $100,000 for 
study and 
review in year 2 
 
Conduct an 
economic impact 
study for 
bioscience 
strategy 
Short-term 
 
  $100,000 for 
study and 
review in year 1 
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Table 17:  Iowa Bioscience Pathway Financial Plan (continued) 
Action Priority 
Annual State 
Funding by Year: 
Years 1-5 
Annual State 
Funding by Year: 
Years 6-10 
Estimated 
One-Time 
Costs 
Leverage 
Ratio of 
Private and 
Federal 
Funds 
Develop a 
biosciences-
development 
training program 
for state and local 
economic 
development 
professionals  
Mid-term 
 
$470,000 for UNI’s 
IDM operations 
funded (currently they 
are at $280,000) 
beginning in year 2 
through 5  
Maintain funding at 
$470,000 per year in 
years 6 through 10 
  
Improve K-12 
scientific 
education 
Mid-term 
 
To be determined    
Provide 
articulation 
agreements 
between K-12 and 
community 
colleges in 
bioscience 
education 
Mid-term 
 
  $500,000 in 
year 3 
 
Streamline 
bioscience 
articulation 
agreements within 
and between 
community 
colleges and 
universities 
Short-term 
 
Existing resources    
Leverage alumni 
associations and 
the state’s Human 
Resources 
Recruitment 
Consortium 
Immediate Existing resources    
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Table 18:  Financial Plan by Year and Proposed Sources of Revenue  
(state funds only—dollars in millions) 
Year Total State Investments Bond Financed General Fund Support 
1  21.913  16.588  5.325 
2  30.193  22.633   7.530 
3  29.878  19.738  10.140 
4  30.158  18.813  11.345 
5  32.083  18.988  13.095 
Subtotal Year 1-5   $144.225   $96.76  $47.435 
6  26.685  12.200  14.485 
7     33.930  18.350   15.580 
8  31.265   14.500   16.765 
9     32.195   14.150   18.045 
10     33.265   13.800   19.465 
Subtotal Year 6-10    $157.340  $73.000   $84.340 
Grand Total  $301.565  $169.76  $131.775 
ORGANIZATION AND STRUCTURE 
State science and technology initiatives are most effective when they are executed on a bipartisan basis, 
with strong executive and legislative branch support, involvement, and cooperation.  States such as 
Pennsylvania, New York, Maine, Maryland, and North Carolina have been successful with their science 
and technology investments because their efforts have been broad based, they have mobilized private 
sector champions behind them, and their initiatives have become institutionalized into both economic 
development and higher education at state and regional levels. 
The following deficiencies indicate that Iowa is less than optimally organized to develop its bioscience-
based economy: 
• No Science and Technology Office, Science and Technology Advisor, or Bioscience Advocate at the 
state government level.  As a result, policies are more likely to be enacted in an ad hoc fashion, rather 
than following a formal strategic plan and pathway. 
• No economic development function coordinated at the level of the Iowa Board of Regents.  Thus, the 
individual universities hold sole responsibility for setting strategy and actions. 
• Declining funds to support regent university economic development, technology transfer, and 
commercialization activities.  With budget cuts of more than 60 percent in the past 3 years, the regent 
universities have seen their organizational capacity in these key functions drastically reduced. 
• Small and comparatively under-resourced bioscience-related industry organizations (such as the IBA 
and BIOWA). Therefore, they are limited in the services and bioscience development initiatives they 
can undertake. 
• No clear bioscience-development imperative being set at the state level and then understood and 
implemented within the academic, non-profit, and industry sectors. 
• No clear organizational and assistance structure for would-be bioscience entrepreneurs to follow in 
terms of accessing business development assistance, prototype development, pre-seed/seed funding, 
management talent, expansion capital, etc. 
To help solve these organizational deficiencies, the Iowa Bioscience Pathway proposes a set of strategies 
and actions that involve multiple public and private organizations and entities.  These strategies and 
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actions have been designed to build on the base of organizational capabilities that currently do exist in 
Iowa, and to provide resources and structure for redirecting efforts for these organizations and the 
formation of new organizations for plugging critical gaps. 
Directing and administering the implementation of the Iowa Bioscience Pathway are critically important 
functions.  Given the important role that industry, academia, and government each must play, it is 
imperative that an organization be structured that will engage each of these groups in the process.  The 
logical convening entity would be the Iowa Bioscience Alliance (as shown in Figure 17).  The Alliance, 
staffed and financially supported by the Iowa Department of Economic Development, would be a formal 
collaboration between industry and academe.  Industry and academic consortia, established for each 
bioscience platform, would be the core constituent components of the Iowa Bioscience Alliance, working 
to advance applied bioscience R&D in the state.  In addition, it is proposed that the commercialization 
intermediary organization directly report to the Alliance. 
The Iowa Bioscience Alliance Board should include key public and private representatives including the 
following: 
• The State Bioscience Advocate 
• Iowa Regents Economic Development Director 
• Director of the Iowa Department of Economic Development 
• Provosts for Research from each of the Regent Universities 
• Dean of the University of Iowa College of Medicine 
• Dean of Iowa State University College of Agriculture 
• Vice Provost for Extension at Iowa State University 
• Representatives from the Community Colleges 
• A legislative representative from each caucus of the Iowa House and Iowa Senate 
• Chair of the Iowa Capital Investment Board 
• Board President of the Iowa Capital Investment Corporation 
• Industry representatives from the following businesses: 
o Biotechnology and Bioprocessing 
o Drugs and Pharmaceuticals 
o Biorenewable Fuels 
o Biorenewable Chemicals or Fiber Products 
o Food Processing 
o Agricultural Processing 
o Agricultural Production 
o Medical Devices, Sensors, and Imaging Equipment 
o Biosecurity 
o Utilities 
o Economic Development Organizations. 
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Figure 17:  Basic Organizing Structure of Iowa Bioscience Development 
 
The structure proposed for the Iowa Bioscience Alliance is similar to that of the Georgia Research 
Alliance (Figure 12).  The GRA is a nonprofit organization that focuses on building a strong research base 
in Georgia’s higher education system through endowed chairs, infrastructure and facilities improvements, 
recruiting packages, matching funds, and related programs.  Beginning in 1990, a consortium of 
Georgia’s business leaders conceived and founded the GRA to leverage the state’s research universities 
with the state’s economic development.  GRA has managed to leverage state funds many times over.  
Since 1992, the State of Georgia has invested more than $300 million and established endowments for 
37 Eminent Scholar positions.  GRA also invests in the physical infrastructure for conducting research 
and commercialization.  More than 40 research facilities and centers of research excellence have had their 
construction, renovation, modernization, expansion, or equipment needs supported by GRA investments. 
The Iowa Bioscience Alliance will focus on research excellence and technology commercialization 
around the key bioscience platforms described earlier in this report.  The independent nature of the 
Alliance, with its highly representative board, will facilitate the funding of projects of merit and potential 
economic development return for the State of Iowa. 
MEASURES OF SUCCESS AND ACCOUNTABILITY 
The following measures and performance goals, to be monitored on an ongoing basis by the Iowa 
Bioscience Alliance, should be used to determine the successful accomplishment of performance 
objectives: 
• There will be more than 130 new bioscience business start-ups in Iowa by 2014. 
• Iowa’s location quotient in all the biosciences will exceed 1.4 to 1.5 by 2008, compared with 1.24 in 
2002. 
• Iowa will increase its university R&D funding (primarily from federal sources) for bioscience-related 
research from $291 million in 2001 to $700 million by 2010 and more than $900 million by 2014. 
Iowa
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• The state will leverage at least $5 in federal and other dollars for every $1 of state support. 
• There will be substantial implementation progress on the actions outlined in this pathway—at least 
70 percent will have substantial action after 3 years and 90 percent within 5 years. 
10-YEAR ECONOMIC IMPACT 
The state’s proposed investment of $302 million in bond financing and general fund support over the 
next 10 years will leverage an estimated $1.5 billion in federal, industry, and other funds.  This level of 
investment is projected to translate into more than 5,100 private sector jobs through new and relocated 
firms, as well as from an additional 10,950 private sector jobs from an indirect multiplier impact on other 
industries and businesses, for a total projected impact of 16,050 jobs by the year 2014.  These numbers 
likely will increase substantially in a 15- to 20-year period as the exponential impact multiplies again and 
again.  Total sales in year 10 are projected at nearly $1.4 billion.   
Although it takes considerable time for state and private investments to have measurable impacts on a 
state economy, it is important to note that the overall economic impacts surely will include some that 
cannot be projected such as additional increases in direct university employment and retained private 
sector jobs with higher skills and better pay.  
 Iowa’s Bioscience Pathway for Development 
 
 115 
Conclusion 
 
Iowa has the opportunity to build its economy through the application of advanced biosciences. Indeed, 
given the state’s agricultural-bioscience expertise, its leading-edge work in biorenewables, and its distinct 
strengths in various areas of human and animal medicine, the biosciences represent the most logical path 
to a high-productivity, high-wage, 21st century economy.  Iowa already is beginning to see distinct 
progress around advanced areas of bioscience; but, a definite opportunity exists to accelerate the process 
and optimize the growth of these sectors in the state. 
This pathway for development lays out a detailed approach to accomplishing bioscience-based economic 
development in Iowa.  The strategy puts forward a bioscience agenda that effectively integrates the 
private, public, and academic sectors in Iowa into a unified driving force for development centered on 
Iowa’s bioscience platform strengths.  In addition, the pathway seeks to leverage the significant 
momentum that already has been built through the state’s investments in programs such as the Iowa 
Values Fund. 
However, for Iowa to succeed in achieving its bioscience vision, the state must take a comprehensive 
approach that addresses each of the key recommendations in this strategy.  Strengthening Iowa’s 
bioscience research infrastructure will result in jobs and income for the citizens of Iowa only if research 
findings are commercialized and new companies created based on technological innovation.  Similarly, 
for commercialization to be successful, there must be a steady pipeline of discoveries.  To retain and grow 
bioscience firms, firms must feel that Iowa supports them in its policies and regulations.  And lastly, if 
Iowa’s economy is to benefit from innovation in the biosciences, the state must have a talent pool ready to 
fill the new jobs created in bioscience companies.  A comprehensive and integrated approach is needed 
for Iowa to become a significant player in the biosciences.  
Iowa already has made great strides in agricultural biotechnology and has even greater opportunities to 
develop its economy around the biosciences in the future.  Iowa has an open window of opportunity to 
continue and expand its leadership position, or place among the leaders, in each of the core platforms 
identified. 
 
 
